The interaction between depression and autonomic dysregulation in patients undergoing cardiac surgery by Patron, Elisabetta
  
 
 
 
 
UNIVERSITÀ DEGLI STUDI DI PADOVA 
DIPARTIMENTO DI PSICOLOGIA GENERALE 
SCUOLA DI DOTTORATO DI RICERCA IN SCIENZE PSICOLOGICHE 
XXVI Ciclo 
 
THE INTERACTION BETWEEN DEPRESSION AND AUTONOMIC 
DYSREGULATION IN PATIENTS UNDERGOING CARDIAC SURGERY 
 
 
Direttore della Scuola: Prof.ssa Francesca Peressotti 
Supervisore: Prof.ssa Daniela Palomba 
 
 
Dottoranda: dott.ssa Elisabetta Patron 
 2 
  
 3 
 
 
 
Il presente lavoro di tesi è parte del progetto di dottorato, XXVI ciclo in collaborazione tra il 
Dipartimento di Psicologia Generale dell’Università degli Studi di Padova, l’Ospedale Ca’ 
Foncello di Treviso con borsa di Dottorato in Scienze Psicologiche (indirizzo in 
Psicobiologia Sperimentale e Clinica) sostenuta da Ospedale Riabilitativo di Alta 
Specializzazione (ORAS) di Motta di Livenza, per un programma triennale (2011-2013) su 
tema vincolato ―Disturbi affettivi e cognitivi nelle patologie neuro-cardiovascolari‖.  
 
 
 
  
 
 
 
 
 4 
 5 
CONTENTS 
 
 
OVERVIEW                9 
 
1. GENERAL INTRODUCTION 
1.1 Depression and cardiovascular diseases         12 
 1.1.1 Depression: consequence or predictor of cardiovascular diseases?    15 
1.2 Depression after cardiac surgery          17 
 1.2.1 Depression as a risk factor for adverse events after cardiac surgery    24 
1.2.2 Depression treatments in cardiac patients        27 
1.3 Psychophysiological factors linking depression and increased cardiac risk     34 
1.3.1 Heart rate variability (HRV) as a measure of autonomic nervous 
system activity            45 
 1.3.2 Measurements and components of HRV        48 
1.3.3 HRV alteration and cardiovascular diseases       58 
1.3.4 HRV alterations and depression         60 
1.4 Aims of the research project and outline of the studies        62 
 
 
 
 6 
2. STUDY I: Postoperative depression and reduced heart rate variability. 
2.1 Abstract              65 
2.2 Introduction             66 
2.3 Methods               68 
2.4 Results              74 
2.5 Discussion              75 
 
3. STUDY II: The mediating role of emotion regulation on the relationship  between 
depression and reduced heart rate variability. 
3.1 Depression and emotion regulation          81 
3.2 Abstract               84 
3.3 Introduction              85 
3.4 Methods               86 
3.5 Results              93 
3.6 Discussion              96 
 
4. STUDY III: Heart rate variability during emotional imagery in patients after cardiac 
surgery. 
4.1 Abstract             101 
4.2 Introduction            102 
4.3 Methods            105 
4.4 Results             111 
4.5 Discussion            115 
 
 
 7 
5. STUDY IV: Depression treatments in patients with cardiovascular diseases 
5.1 Introduction to respiratory sinus arrhythmia biofeedback     121 
5.2 Abstract            127 
5.3 Introduction            128 
5.4 Methods             131 
5.5 Results             139 
5.6 Discussion            143 
 
6. GENERAL DISCUSSION  
6.1 A summary of main findings         149 
6.2 Limitations of the research          155 
6.3 Directions for future research          158 
6.4 Conclusions            162 
 
References            164 
  
 8 
 9 
OVERVIEW 
The studies reported in this thesis are part of a wide longitudinal collaborative project 
of the Department of General Psychology (University of Padova), the Ca’ Foncello Treviso 
Hospital and the Highly Specialized Rehabilitative Hospital (ORAS, Motta di Livenza). The 
project involved a multimodal assessment in patients eligible for first time cardiac surgery, 
aimed at evaluating cognitive and affective deficits, which in turn are well known risk factors 
for postoperative adverse outcomes. Preliminary findings showed that preoperative 
depression significantly predicted depression three months after cardiac surgery; 
furthermore, preoperative depression was associated with postoperative cognitive decline at 
18 months follow-up. These findings have been particularly relevant for the present project, 
that focused on autonomic factors which mediate the relationship between depression and 
increased cardiac risk.  
Altered autonomic control on the heart [as indexed by reduced heart rate variability 
(HRV)] has been suggested as the most plausible mechanism by which depression is 
associated to increase cardiac risk. Four studies have been carried out: in the first study, the 
relationship between depression and impaired autonomic modulation on heart was 
investigated, in patients who underwent first time cardiac surgery. The findings displayed 
reduced vagal cardiac control in depressed patients, compared to nondepressed patients.  
In the second study, the relationship between depression, emotion regulation 
strategies and cardiac autonomic control was examined. The findings yielded that 
disproportionate suppression of emotion partially mediate the relationship between 
depression and reduced vagal control on the heart. 
Not only depression has been associated to reduced vagal control at rest, but also 
with abnormalities in vagal modulation during emotional stressors. Therefore, the third study 
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aimed at examining parasympathetic cardiac control during three emotional imagery tasks in 
depressed and non-depressed patients, after cardiac surgery. A direct association between 
postoperative depression and exaggerated vagal withdrawal during the imaging of the 
unpleasant script was found. 
Finally, the research was focused on possible non pharmacological treatment of 
depression in patients after cardiac surgery. The fourth study aimed at evaluating the 
effectiveness of a short cardiorespiratory biofeedback training in increasing vagal control on 
the heart and reducing depressive symptoms in patients after first time cardiac surgery. The 
rehabilitative protocol included the administration of a respiratory sinus arrhythmia (RSA) 
biofeedback training, in addition to the standard rehabilitation protocol, compared to the 
standard rehabilitation protocol only. RSA-biofeedback resulted effective in increasing vagal 
control on the heart, thus lowering an important cardiac risk factor. Moreover, the training 
resulted in a reduction of depressive symptoms, with a positive influence on mood. 
In conclusion, the present thesis confirms and extends the association between 
depression and reduced vagal control also in patients after first time cardiac surgery, thus 
supporting the role of depression as a potential risk factor for morbidity and mortality after 
cardiac surgery. In addition, it highlights the role of suppression of emotion as an affective 
trait and that of emotional reactivity to stressors in mediating the relationship between 
depression and increased cardiac risk. Finally, it provides evidence in support of the 
usefulness of an RSA-biofeedback training in patients after cardiac surgery. These findings 
provide suggestions for improving well-being and health care interventions in patients after 
cardiac surgery. 
 
Keywords: Depression; Emotion regulation; Cardiac surgery; Autonomic nervous system; 
Heart rate variability; Vagal tone; Biofeedback 
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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
 
1.1 Depression and cardiovascular diseases 
Depression and cardiovascular diseases are listed as two of the most detrimental 
diseases in developed countries by the Statistics from The Global Burden of Disease project 
(Mathers & Loncar, 2006; Murray & Lopez, 1997). 
Depression is a underdiagnosed and undertreated mood disorder, characterized by 
depressed mood, anhedonia, loss of interest, decreased energy, sense of futility, low self-
esteem and feelings of hopelessness. According to the Diagnostic and Statistical Manual 
(American Psychiatric Association, 2013) major depression is characterized by depressed 
mood, loss of interest or pleasure in daily activities that has also a relapse on social and work 
activity, concentration, and may affect appetite and sleep habits. In addition, depressive 
conditions include subclinical symptoms that are milder or briefer compared to diagnoses of 
major depression. Usually, mild and brief symptoms have small impact on a person’s life, on 
the contrary, mild and persistent symptoms may be detrimental to a person’s adjustment. In 
fact, subclinical depression has been reported to predict development of major depression 
and other emotional problems, and may result in significant impairment in affective and 
social functioning (Gotlib, Lewinsohn, & Seeley, 1995; Horwath, Johnson, Klerman, & 
Weissman, 1992; Wells et al., 1989; Zonderman, Herbst, Schmidt, Costa, & McCrae, 1993) 
Depression disorders (including major depression, moderate depressive symptoms 
and mild subclinical depressive symptoms) are highly prevalent, with a lifetime prevalence 
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reported between 8% and 17% (Andrade et al., 2003; Blazer, Kessler, McGonagle, & Swartz, 
1994; Kessler et al., 1994), and, by the year 2020, is likely to become the second most 
important cause of disease burden, right after cardiovascular diseases (Murray & Lopez, 
1997). 
Depression disorders are psychological disorders that can be said to be fatal. In fact, 
depression disorders are associated to high rates of disability and mortality due to suicide 
(Clark & Fawcett, 1992) and, importantly, depression disorders are strongly associated to 
cardiovascular diseases. Evidence from both experimental and epidemiological studies 
support the hypothesis of a bidirectional relationship between depression disorders and 
cardiovascular diseases.  
Cardiovascular diseases (CVD) are a wide group of disorders affecting the heart and 
blood vessels, and the most commonly associated with depression are hypertension, unstable 
and stable coronary heart disease (CHD) and congestive heart failure (CHF) therefore, these 
CVDs will be principally consider in this following sections. The major cause of artery 
disease is atherosclerosis, that occurs as an inflammatory response to chronic damages of the 
vessel wall. When the atherosclerotic plaque undergoes events like erosion, rupture, 
thrombosis, or spasm a major cardiac event occurs. Valve diseases may affect each heart 
valve and the most common diseases are valve stenosis and valve prolapse. Valve stenosis is 
characterized by commissural fusion, most frequently caused by rheumatic disease, while 
valve prolapse consists in an abnormal movement of the valve beyond its normal position, 
causing reversed blood flow and blood regurgitation.  
Currently CVDs are the primary cause of morbidity, disability and mortality 
worldwide, showing a continue increasing trend, and this incidence is predicted to increase to 
approximately 25 million deaths by 2020 (Dahlöf, 2010).  
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More importantly, patients who survive acute cardiovascular events are likely to 
become chronic patients, and, in turn, CVDs heavily compromise quality of life. Indeed, 
CVDs represent an important economic burden to the national health system. In 1999, the 
total sum of direct (e.g., treatment) and indirect cost (e.g., lost days of work) of CVDs in the 
United States were estimated as $ 180 billion (Keyes & Lopez, 2012). Recently, it has been 
assessed that in Italy cardiovascular drugs account for more than 25% of the pharmaceutical 
costs (Agenzia Italiana del Farmaco, 2012). 
Depression is strongly associated with CVDs, in fact, while the prevalence of 
depression in the general population is approximately 2–9% (American Psychiatric 
Association, 2000), its prevalence in patients after myocardial infarction is approximately 
45% (Schleifer et al., 1989), and might be even higher in patients with chronic 
cardiovascular conditions such as congestive heart failure (CHF) (Freedland et al., 2003). 
Recently, a large study on 1167 elders compared the prevalence of depression among cardiac 
patients (heart failure, post myocardial infarction and post CABG patients) with a reference 
group of healthy individuals. Patients in each of the cardiac groups showed a higher 
prevalence of anxiety, depression and hostility compared to that in the group of healthy 
individuals. Specifically, 63% of heart failure patients exceeded the threshold for depression 
compared to 56% of post-myocardial infarction patients, 53% of post-coronary artery bypass 
graft patients and only 33% of healthy individuals (Moser et al., 2011). Almost three-quarters 
of patients with heart failure reported experiencing symptoms of depression and the heart 
failure group had the greatest percentage of patients with depressive symptoms.  
Given the high prevalence of both depression and cardiovascular diseases and the 
thigh association between them, in the next sections this relationship will be described, and 
the need for understanding the mechanisms responsible for this link will be underscored. 
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1.1.1 Depression: consequence or predictor of cardiovascular diseases? 
Converging evidence from a large body of research highlight a strong, bidirectional, 
relationship between depression and CVDs. The role of CVDs as a relevant risk factor for 
mood disorders, particularly depression, is well known and recognized (Freedland et al, 
2003; Schleifer et al., 1989). The presence of cardiovascular disease can directly and 
indirectly influence mood disorder, including both depression and anxiety symptoms. 
Depression induced by CVDs can result from cognitive-behavioral processes (e.g., dealing 
with significant changes in lifestyle, poor health habits, worries about physical health, 
anxiety feelings, or fear for the future and contemplation of one’s mortality) or physiological 
processes (e.g., autonomic nervous system dysregulations, neurotransmitters and hormonal 
modifications). Both psychological and physiological mediators might contribute to the 
relationship between cardiovascular disease and mood changes. 
On the other side, in the last two decades many studies have highlighted the role of 
depression as an important and independent risk factor for the onset, maintenance and 
exacerbation of cardiovascular diseases (Barth, Schumacher, & Herrmann-Lingen, 2004; 
Ford et al., 1998; Glassman & Shapiro, 1998; Hemingway & Marmot, 1999). As shown in 
Figure 1.1, several lines of evidence indicate that depression predicts incidence of 
cardiovascular disease, as well as cardiac-related morbidity and mortality, in individuals with 
no prior history of cardiac pathophysiology (Anda et al., 1993; Barefoot & Schroll, 1996; 
Everson et al., 1996; Penninx et al., 2001).  
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Figure 1.1. Cardiac death and CHD death rates per 1000 person-years by depression 
status in individuals without cardiac disease (N=2397) (Penninx et al., 2001). 
 
 
For instance, Carney and colleagues, 1995 estimated that about 50% of patients who 
were depressed at the time cardiovascular disease was initially diagnosed have had at least 
one more previous depressive episodes. Wulsin and Singal (2003) reviewed studies that 
reported the association between depression and coronary heart disease (CHD), the authors 
reported that depressive symptoms were associated with roughly a 60% higher likelihood of 
developing CHD. Also, in a large cohort study of 2847 individuals, Penninx and coworkers 
(2001), found that depression increases the risk for cardiac mortality in both individuals with 
and without cardiac diseases at baseline. The relationship remained significant even after 
adjusting for demographic factors (such as age and sex), smoking, alcohol use, blood 
pressure, body mass index, and comorbidity. 
Moreover, a large body of literature have displayed that depression in patients with 
existent CVD increases the risk for morbidity and adverse cardiac events associated with 
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heart disease (Barefoot & Schroll, 1996; Carney & Freedland, 2003; Carney et al., 2005; 
Everson et al., 1996; Frasure-Smith, Lespérance, & Talajic, 1995; Frasure-Smith & 
Lespérance, 2003). A large meta-analysis on the mortality linked to depression in patients 
with coronary heart disease found that depression was associated with two times higher 
mortality risk in the two years after the initial assessment. Also, this negative prognostic 
effect persisted in the long-term (Barth et al., 2004). More recently, Lichtman and coworkers 
(2008) showed a dose-response relationship between the increasing of depression severity 
and subsequent cardiac events, with more severe depression being associated with higher risk 
of earlier and more severe cardiac events.  
The association between mood disorders and CVDs has been shown to be 
independent of traditional cardiovascular risk factors such as reduced physical activity, 
smoking, hypertension, high cholesterol, increased body mass index and diabetes (Anda et 
al., 1993; Barefoot & Schroll, 1996; Barth et al., 2004; Carney et al., 1988; Frasure-Smith & 
Lespérance, 2003; Penninx et al., 2001). 
Therefore, the majority of the studies reported data in support of depression as a risk 
factor for both the development of and the worsening of CVD. More importantly, given the 
growing evidence on depression as a risk factor for CVD, recently the American Heart 
Association (AHA) reported an advisory in which depression have been introduced as an 
officially recognized cardiac risk factor for coronary heart disease (CHD).  
 
 
1.2 Depression after cardiac surgery 
Cardiac surgery is frequently performed to treat complications of cardiovascular 
diseases, and/or to remove or reduce cardiac symptoms, like angina and pressure over the 
chest. The most common operated surgical intervention for ischemic diseases is coronary 
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artery bypass graft (CABG). Cardiac valve replacement and repair is used as a therapy for 
degenerative, infectious and congenital lesions of aortic and mitral valve. In general the 
benefits, positive outcomes of both CABG and cardiac valve surgery are well established and 
include reduction of cardiac symptoms angina and stenosis, the stabilization of ventricular 
function, increased survival rate (Eagle et al., 1999) and improvements in the quality of life 
and functional activity of daily living (Shan, Saxena, McMahon, Wilson, & Newcomb, 
2013). CABG and cardiac valve surgery differ for many factors, including patients related 
characteristics (usually patients undergoing cardiac valve surgery are older), technical 
differences and postoperative complication. Especially, CABG surgery is often associated 
with heart failure, myocardial infarction, arrhythmia, thrombosis and stroke (Hannan et al., 
2003), while cardiac valve surgery is associated with atrial fibrillation, and less frequently, 
renal failure and stroke (Mathew et al., 2004). 
Even though many CVD patients may be relieved after cardiac surgery, due to better 
physical function and overall wellbeing, undergoing cardiac surgery is a significant life 
event, with a relevant impact on the patients’ affective states. In fact, many studies have 
disclosed that a modest, still consistent, number of patients report cognitive and emotional 
disorders, such as a decline in cognitive domains, anxiety and mood disorders after CABG 
(Arrowsmith, Grocott, Reves, & Newman, 2000; Ho et al., 2004; McKenzie, Simpson, & 
Stewart, 2010). Similarly, valve surgery has been associated with increased anxiety and 
mood disorder postoperatively (Ho et al., 2005; Székely et al., 2007). 
Langosch and Schmoll-Flockerzie (1992) highlight that both patients who underwent 
CABG or valve surgery could report increased levels of global psychopathology, especially 
higher anxiety and depression symptoms. Depressive symptoms occur both immediately 
after the surgery and all over the first 3 to 6 months after hospital discharge (Gallagher, 
McKinley, & Dracup, 2004) and may persist in the long term. More importantly, 
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postoperative depression has a negative impact on recovery after cardiac surgery, resulting in 
reduced postoperative quality of life (Dickens, Cherrington, & McGowan, 2012), increased 
rehospitalization rate (Burg, 2003b), morbidity (Connerney, Shapiro, McLaughlin, Bagiella, 
& Sloan, 2001) and even increased mortality risk (Scheier, 1999). 
Given the growing relevance of depression in the cardiac surgery context, incidence 
and consequences of postoperative depression will be described. 
High rates of depression are commonly reported in patients undergoing cardiac 
surgery. Specifically, the prevalence of major depression among these patients is reported at 
around 20% (Connerney et al., 2001; Fráguas, Ramadan, Pereira, & Wajngarten, 2000) while 
depressive symptoms are commonly reported by 20% to 36% of patients before cardiac 
surgery (Figure 1.2) (Langeluddecke, Fulcher, Baird, Hughes, & Tennant, 1989; McKhann, 
Borowicz, Goldsborough, Enger, & Selnes, 1997; Pirraglia, Peterson, William-Russo, 
Gorkin, & Charlson, 1999; Rymaszewska, Kiejna, & Hadryś, 2003). McKhann and 
colleagues (1997) reported that 27% of patients had clinically significant scores on the 
Center for Epidemiological Study-Depression (CES-D) questionnaire prior to CABG 
surgery. Similarly, Ho and colleagues (2005) reported a prevalence of depressive symptoms 
of 29% before cardiac valve surgery (including aortic valve replacement, mitral valve 
replacement, and valve replacement without CABG). 
Even though cardiac surgery is usually effective in improving physical function and 
overall wellbeing, depression often persist from pre- to postoperative period. Timberlake and 
coworkers (1997) examined the modifications in depression from preoperative to 
postoperative periods in patients who underwent cardiac surgery. They found a temporary 
increase in the incidence of clinical depression immediately after the surgical procedure 
(50% of the patients showed clinical depression eight days after the surgery), with a long-
term reduction to levels below that found prior to surgery. The increased depression 
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incidence in the short period following surgery is probably associated with the great 
discomfort and pain due to the main surgery, as well as isolation from family, friends, and 
home. Nevertheless, eight weeks after the operation, 24% of patients were still significantly 
depressed, and, one year after the surgical procedure, 22% of the patients were still 
depressed. 
 
 
 
Figure 1.2. Percentage of patients without depression and with mild or moderate 
depression as measured by the Beck Depression Inventory (BDI) preoperatively, 
postoperatively and at follow up (Rymaszewska et al., 2003). 
 
 
Preoperative major depression has been found to persist after cardiac surgery in up to 
22% of patients (Vingerhoets, 1998), while, the incidence of depressive symptoms in the 
 21 
postoperative period is 32% (Burg, 2003a; Magni et al., 1987; McKhann et al., 1997). Magni 
and colleagues (1987), reported poor postoperative psychological outcome prevalence in 
25% of patients after cardiac surgery, with depression and anxiety being particularly 
prominent. Several other studies have described similar incidence of depression and anxiety 
disorders following CABG (Cay & O’Rourke, 1992; Pimm, Foole, & Feist, 1986).  
Even though depressive symptoms may show an improvement after cardiac surgery, 
at least in some patients, the majority of patients who were depressed preoperatively 
continued to display depression after cardiac surgery. More importantly, it has been shown 
that a small number of patients, without depression preoperatively, may develop depression 
after cardiac surgery (reactive depression). Pirraglia and coworkers (1999) evaluated the 
incidence of depression from preoperative period to three months follow-up after cardiac 
surgery.  
As shown in Figure 1.3, the authors reported that the majority (91%) of patients 
without preoperative depression were not depressed in the postoperative period (i.e., absent 
depression), nevertheless, a small group of patients (9%) who were not depressed prior to 
surgery developed depression after cardiac surgery (i.e., reactive depression).  
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Figure 1.3. Proportion of patients with and without depressive symptoms as 
measured by the Center for Epidemiological Study-Depression (CES-D) preoperatively and 
at 6 months follow-up. The white bars show the proportion of patients without depressive 
symptoms (CES-D score < 16); the black bars show the proportion of patients with 
depressive symptoms (CES-D score ≥ 16). Labels are reported next to the segment of the 6 
months follow-up bar that they represent. ―Absent‖ means no depression preoperatively and 
at follow-up; ―New‖ correspond to reactive depression (patients without depression 
preoperatively who showed depression at follow-up); ―Resolved‖ correspond to improved 
depression (patients with depression preoperatively and without depression at follow-up) and 
―Continued‖ means persistent depression at both the evaluations (Pirraglia et al., 1999). 
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Moreover, among patients who were depressed before surgery, roughly 50% were 
still depressed afterwards (i.e., persistent depression), whereas depression improved from the 
preoperative to postoperative period in the remaining 50% of patients (i.e., improved 
depression) (Pirraglia et al., 1999). 
Similarly, Patron and coworkers (in press) recently found that depression three 
months after cardiac surgery, as evaluated with the CES-D, was predicted by preexisting 
depression, state anxiety and higher score on the European System for Cardiac Operative 
Risk Evaluation (EuroSCORE; Nashef et al., 1999). 
More importantly, the authors reported that patients who developed postoperative 
depression (i.e., reactive depressed patients) were characterized by higher biomedical risk 
factors (i.e., greater EuroSCORE) than those without depression both in the preoperative and 
postoperative periods. More severe biomedical risk factors are very likely to interact with 
cardiac surgery effects, causing poor physical conditions and quality of life after cardiac 
surgery, that, in turn, may lead to reactive depression. More importantly, the finding that 
patients with reactive depression have higher risk of mortality than those without depression 
may be implicated as one possible mechanism underlying the relationship between 
postoperative depression and cardiac morbidity and/or mortality after surgery. Conversely, 
patients with preoperative and postoperative depression (i.e., persistent depressed patients) 
were characterized by more severe depression (i.e., greater CES-D scores) before surgery 
compared to those whose depression improved from the preoperative to postoperative period. 
the severity of preoperative depressive symptoms may account for postoperative depression 
and represent a plausible marker of depression-related postoperative risk in patients after 
surgery. 
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In conclusion, depression disorder prior to cardiac surgery significantly increased the 
likelihood of being depressed after surgery. 
 
 
1.2.1 Depression as a risk factor for adverse events after cardiac surgery 
Depression has been shown to be an independent risk factor for the development and 
persistence of CVDs, and more importantly, both pre- and postoperative depression has been 
associated with negative outcomes after cardiac surgery. First evidence that preoperative 
depressive symptoms and anxiety symptoms, were associated with adverse outcomes after 
cardiac surgery were reported in clinical works during the late 1960s (Blachly & Blachly, 
1968; Kimball, 1969) More recently, results from different studies have suggested that 
preoperative symptoms of depression significantly predict postoperative cardiac events such 
as unstable angina, myocardial infarction, repeat CABG and death (Baker, Andrew, 
Schrader, & Knight, 2001; Frasure-Smith et al., 1995; Scheier, 1999). In a longitudinal study, 
preoperative emotional distress (including symptoms of depression, asthenia and anxiety) 
was associated with increased rate of cardiac events during three years follow-up after 
CABG. In addition, higher emotional distress symptoms were significantly correlated with 
poorer quality of life one year after cardiac surgery (Perski et al., 1998). Connerney and 
coworkers (2001) evaluated the impact of both major depression and depressive symptoms in 
309 patients who underwent CABG surgery. The results displayed evidence that women had 
a higher risk of nonfatal and fatal cardiac events compared to men (see Figure 1.4). More 
importantly, major depression significantly increases the incidence of nonfatal cardiac 
events, independently from classic risk factors (such as age, left ventricular function, 
diabetes).  
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A prospective cohort study on 648 patients undergoing valve surgery found that 
preoperative depression was associated to increase six-month all-cause mortality, with a 1.9-
fold increased odds of death, even after adjusting for other clinical risk variables (Ho et al., 
2005). The findings were consistent across subgroups of patients who underwent aortic valve 
replacement, mitral valve replacement, and valve replacement without CABG. 
 
 
 
Figure 1.4. Frequency of cardiac events after CABG surgery (defined as readmission 
to the hospital for a cardiac event or death by cardiac event) by sex and presence or absence 
of major depressive disorder (Connerney et al., 2001). 
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As mentioned previously, preoperative depression frequently persists after cardiac 
surgery. Therefore, postoperative depression is associated with a higher risk of cardiac 
morbidity and fatal cardiac events (Burg, 2003a; Connerney et al., 2001; Scheier, 1999). 
Indeed, several studies reported the association between postoperative depression and a 
higher rate of cardiovascular morbidity or mortality (Ariyo et al., 2000; Blumenthal et al., 
2003a; Lespérance & Frasure-Smith, 2000; Penninx et al., 2001). Saur and coworkers (2001) 
studied depressive symptoms and medical outcomes in 416 patients scheduled for CABG. 
The authors reported that the presence of depressive symptoms both before or after surgery 
was associated to higher readmission rate for cardiac problems within 6 months after surgery. 
Blumenthal and colleagues (2003) in the largest study of depression as a risk factor for 
mortality in patients after cardiac surgery, showed that patients with persistent (i.e., before as 
well as six months after CABG) mild or moderate to severe depression had a greater 
likelihood (i.e., more than twice) of death than those who were never depressed. Goyal and 
colleagues (2005) studied the role of both preoperative and postoperative depressive 
symptoms on quality of life six months after cardiac surgery. The findings showed that both 
preoperative depressive symptoms and postoperative increases in depressive symptoms were 
associated with poor quality of life six months after cardiac surgery.  
Given this evidence, it is of particular relevance to identify those patients at higher 
risk of persistent depression or to develop reactive depression, given that either pre and 
postoperative depression are risk for cardiac morbidity and/or mortality after surgery (Ariyo 
et al., 2000; Blumenthal et al., 2003b; Lespérance & Frasure-Smith, 2000) 
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1.2.2 Depression treatments in cardiac patients 
Given that depression is an independent and important cardiac risk factor, particular 
attention must be paid to depression treatment selection, especially in depressed cardiac 
patients. Depression treatments comprehend different interventions that can be categorized in 
three main groups: pharmacological medications, psychological therapies, and biobehavioral 
trainings. In addition, in this context, cardiac rehabilitation programs are of particular 
relevance. 
Among pharmacological treatments, tricyclic antidepressants are the oldest 
antidepressant agents. Tricyclics act by elevating levels of serotonin, dopamine, and mostly 
norepinephrine (NE) in the brain and antagonizing histamine, muscarinic, and alpha-
adrenergic receptors (Stern, Rosenbaum, & Fava, 2008). Although this class of medications 
is effective in reducing depressive symptoms, tricyclics are not recommended in cardiac 
patients because they may cause vagal inhibition, conduction disturbances, and arrhythmias, 
and compared with selective serotonin reuptake inhibitors (SSRIs), tricyclics have been 
associated with more frequent adverse cardiac events (Carney, Freedland, Miller, & Jaffe, 
2002).  
Even less conventional antidepressant medication, such as monoamine oxidase 
inhibitors (MAOIs), lithium, and barbiturates, have been associated with elevated 
cardiovascular risk (Cohen, Gibson, & Alderman, 2000; Pratt et al., 1996). 
Another group of antidepressant agents is SSRIs, that act by blocking the neuronal 
reuptake of serotonin, resulting in a higher level of serotonin in the synapses. SSRIs have 
been reported to be safe and effective in patients with both unstable and stable CHD, 
(Lespérance et al., 2007; Roose et al., 1998) and they seem to increase safety profile in 
cardiac patients (Stern et al., 2008). In addition, the use of SSRIs was associated with 
improvement in depressive symptoms resulting in no risk of adverse cardiac events in 
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patients with cardiovascular diseases (CVDs) (Glassman et al., 2002; Strik et al., 2000) and 
in patients after myocardial infarction (MI) (Shapiro et al., 1999). Glassman and coworkers 
(2002) reported no significant differences between sertraline (SSRIs) and placebo on several 
cardiac outcomes (i.e., number of left premature ventricular contractions, ventricular ejection 
fraction, prolongation of QT interval, or major adverse cardiac events) in patients with CHD. 
More importantly, sertraline was associated with higher improvement in depression response 
rates. Further evidence came from the Canadian Cardiac Randomized Evaluation of 
Antidepressant and Psychotherapy Efficacy (CREATE) study, that evaluated the efficacy of 
citalopram (SSRIs) in 284 patients with stable CHD over 3 months (Lespérance et al., 2007). 
The findings showed that this medication was effective in reducing depressive symptoms, 
increasing functional status, and improving interpersonal relationships. In addition, patients 
treated with citalopram showed no difference in cardiac measures, compared with the control 
group, suggesting that citalopram was safe and tolerable for CHD patients (Lespérance et al., 
2007). Overall, these findings suggest that SSRIs are both effective in reducing depressive 
symptoms and safe for administration in patients with CVDs. Moreover, the inhibitory 
effects of SSRIs on platelets have been implicated in a decreased risk of MI and mortality 
(Serebruany, Gurbel, & O’Connor, 2001).  
Although many studies displayed the effectiveness of SSRIs in reducing depression, 
there are less data supporting the hypothesis that SSRIs may also improve cardiac outcomes 
in these patients. In fact, the studies investigating the cardiac outcomes in depressed patients 
treated with SSRIs found no significant reductions in recurrent cardiac events and mortality 
(Glassman et al., 2002; Shapiro et al., 1999; Strik et al., 2000). Therefore, SSRIs 
antidepressant treatment can be only partially recommended in patients with CVDs. 
Regarding second-generation antidepressants, such as mirtazapine, bupropion, 
venlafaxine, and duloxetine, there are fewer data about the efficacy and safety in the 
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treatment of depression in patients with CVDs. Mirtazapine, broadly classified as a centrally 
acting alpha-2 adrenergic receptor antagonist, has been found to be effective in reducing 
depressive symptoms in patients after MI without side effects on the cardiovascular system 
(Honig et al., 2007; van Melle et al., 2007) although mirtazapine intake has been often 
associated with weight gain and hyperlipidemia, that are risk factors for cardiac patients. 
The effects of venlafaxine and duloxetine, both members of the serotonin-
norepinephrine reuptake inhibitor (SNRI) class, have not been studied in CVD patients yet, 
but given that venlafaxine tends to increase blood pressure, the administration is not 
recommended in these patients. 
Therefore, a wide range of pharmacological medications, including tricyclic 
antidepressants, MAOIs, lithium, barbiturates, alpha-2 adrenergic receptor antagonists, and 
SNRIs, cannot be recommended in patients with CVDs because they can have cardiac side 
effects, that are to be avoided in these patients. Side effects may include anticholinergic 
effects (Feighner, 1999) and/or vagolytic effects (Agelink, Majewski, Andrich, & Mueck-
Weymann, 2002), yielding to reduced heart rate variability (HRV) (Schroeder et al., 2002). 
Exception must be made for the class of SSRIs that does not show significant cardiac side 
effects. However, this class of medication exerts no effect in reducing cardiac risk; therefore, 
SSRIs cannot be recommended as the only treatment in CVD patients. 
Based on these limitations, in recent years, more attention has been paid to 
nonpharmacological interventions for depression. Many studies have examined the effects of 
regimented psychotherapeutic interventions in cardiac patients with comorbid depression 
disorder. These treatments include interpersonal therapy (IPT) and cognitive behavioral 
therapy (CBT). The major focuses of IPT are improving interpersonal relationships, self-
esteem, and, of course, depressive symptoms, whereas CBT emphasizes the patients’ ability 
to recognize how their feelings, emotions, thoughts, and behaviors interact in maintaining 
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depressive symptoms (Elkin et al., 1989; Leichsenring, Hiller, Weissberg, & Leibing, 2006; 
Stern et al., 2008). In this context, both IPT and CBT are characterized by a limited duration 
(lasting typically for 12–16 sessions), and many studies have shown their effectiveness in 
reducing depressive symptoms in patients without CVDs (Elkin et al., 1989; Leichsenring et 
al., 2006; Lett et al., 2005; Stern et al., 2008). 
Lespérance and colleagues (2007) compared the effectiveness of IPT, with medical 
management as a control, in patients with stable CHD and comorbid moderate to severe 
depression. While medical management resulted to be more effective in patients with 
reduced functional ability and lower social supports, both medical management and IPT were 
associated with significant improvements in depressive symptoms (Lespérance et al., 2007). 
CBT effectiveness has been studied by Berkman and colleagues (2003) in the 
ENRICHD study. In this wide study, 2,481 patients with a diagnosis of minor or major 
depressive disorder and low perceived social support after MI were randomized to receive 
either the standard cardiac rehabilitation program or CBT for a maximum of 6 months. 
Patients who underwent CBT treatment and had low perceived social support and minor or 
major depression experienced statistically significant improvements in depressive symptoms 
and social support scores. Nevertheless, these reductions in depressive symptoms faded over 
time. No differences emerged comparing the 2 groups in terms of cardiac outcome, such as 
MI or death (Berkman et al., 2003).  
More recently, a smaller study on 123 patients who underwent CABG surgery within 
the past year and had a diagnosis of minor or major depression explored the effectiveness of 
CBT in the treatment of depression. The patients were randomized to receive CBT, 
supportive stress management, or the standard cardiac rehabilitation program. After 3 
months, the findings displayed that depressive symptoms improved in both the patients in 
CBT and in supportive stress management compared with the cardiac rehabilitation group. 
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No difference emerged between patients with minor and major depression. In addition, CBT 
treatment was associated with greater improvement in anxiety symptoms, hopelessness, 
perceived stress, and mental health–related quality of life (HRQoL) compared with usual 
care. More importantly, after 9 months, only patients in the CBT group maintained the 
results (Freedland et al., 2009). Interestingly, Carney and coworkers (2000) reported that 
CBT can also reduce resting heart rate in severely depressed patients. Since studies 
evaluating the effectiveness of psychotherapeutic interventions in reducing cardiac risk factor 
are controversial, these interventions in depressed cardiac patients should be accompanied by 
specific intervention for the reduction of cardiac risk (Lett et al., 2005). 
Furthermore, the collaborative care literature adds more evidence suggesting the 
effectiveness of psychotherapy in CVD patients. Specifically, collaborative care is a 
population-based approach in which multidisciplinary primary care teams, such as a nurse or 
social work case manager and a psychiatrist, assist the primary care provider in delivering 
the treatment. Collaborative care and care management programs should help to improve 
depression identification and treatment in patients with cardiac disease. Interventions that 
include collaborative care have been reported to be effective in reducing depressive and 
anxiety symptoms and in improving mental health–related quality of life and functional 
status (Davidson, Rieckmann, Clemow, Schwartz, & Shimbo, 2010; Huffman et al., 2011; 
Rollman & Belnap, 2011). In particular, collaborative care programs focused on depression 
treatment have been found to be effective in different primary care patients (Katon et al., 
1999), the elderly (Chang-Quan et al., 2009), and those with diabetes mellitus (Katon et al., 
2004), arthritis (Chang-Quan et al., 2009), or cancer (Ell et al., 2008). Recently, a telephone-
based study evaluated the effectiveness of collaborative care therapy in patients after an 
acute cardiac event (such as MI, unstable angina, coronary heart failure exacerbation, or 
arrhythmia). Depressed patients were contacted by a social work care manager who, together 
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with the patients, considered the symptoms and treatment options. Results showed reductions 
in depressive and anxiety symptoms, improvements in mental health–related quality of life, 
and further decreases in depression symptoms at 6 and 12 months of follow-up (Huffman et 
al., 2011). 
Most of the interventions mentioned above are commonly included in cardiac 
rehabilitation programs. Cardiac rehabilitation programs consist of interventions designed to 
improve the physical, the psychological, and the social functioning of the patients with 
CVDs and of the patients who underwent cardiac surgery. Usually, these programs include 
an assessment of the patient’s baseline status, counseling on the appropriate use of 
cardioprotective drugs, nutritional counseling, interventions aimed at reducing classic risk 
factors such as smoking cessation and weight management, physical activity and exercise 
training, psychosocial counseling, and stress reduction intervention. Cardiac rehabilitation 
programs have been consistently reported to reduce depressive symptoms in CVD patients 
following major cardiac events (Blumenthal et al., 2005; Lavie & Milani, 2006, 2004). A 
recent study showed that the cardiac rehabilitation program was associated with a marked 
reduction in the prevalence of depressive symptoms, that, in turn, resulted in a significant 
improvement in survival rate after a major coronary event (Milani & Lavie, 2007). Stress 
reduction intervention or relaxation training are usually part of cardiac rehabilitation 
programs. Relaxation training allows to teach the individual to reduce his or her tension or 
stress, accumulated due to acute or chronic stressful experiences, without using external 
means (van Dixhoorn & Duivenvoorden, 1999).  
Relaxation training usually focuses on attention, mental representations such as 
images and words (meditation/mindfulness, autogenic training, and hypnosis), muscle 
contraction and relaxation (progressive muscle relaxation), and breathing instructions. 
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Relaxation techniques have been consistently reported to be effective in depressive 
symptoms reduction (Gonzales, 2001) and in lowering distress, blood pressure, and 
cholesterol levels, that, in turn, leads to reduced mortality and cardiac adverse events 
(Linden, Stossel, & Maurice, 1996). Recently, a review reported that a wide group of 
relaxation therapies—such as stress management, progressive muscle relaxation, hypnosis, 
autogenic training, meditation, and biofeedback—were effective in enhancing recovery after 
a cardiac ischemic event when added to standard cardiac rehabilitation. More importantly, 
relaxation therapies were associated with improved mood and decreased anxiety, with a 
reduction in resting heart rate and in the frequency of angina pectoris, and with increased 
return to work and a higher survival rate (van Dixhoorn & White, 2005).  
Among relaxation techniques, there has been growing interest in the application of 
cardio-respiratory biofeedback, which stimulate differential systems involved in 
cardioregulatory phenomenon.  
Depression treatment in cardiac patients is a challenge; antidepressant medications 
are often contraindicated in these patients because of vagolytic effects and cardiac side 
effects. Among pharmacological medications, only SSRIs have been shown to be safe in 
cardiac patients. Nevertheless, they cannot be recommended as the only treatment in 
depressed patients with CVDs because SSRIs are not associated with reduced cardiac risk. 
Psychotherapeutic intervention (IPT and CBT) and collaborative care management have been 
reported to be effective in improving mood and reducing depressive symptoms in cardiac 
patients. However, they cannot be recommended as the only intervention because there is no 
proof of their effectiveness in reducing cardiac risk. Finally, cardiac rehabilitation programs, 
including psychosocial intervention such as relaxation training, have been reported to 
influence depression symptoms, stress feelings, and classic biomedical risk factors. 
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More importantly, a few studies have displayed the efficacy of cardio-respiratory 
biofeedback in increasing vagal control on the heart (thus reducing cardiac risk) (Cowan, 
Kogan, Burr, Hendershot, & Buchanan, 1990; Del Pozo, Gevirtz, Scher, & Guarneri, 2004) 
and improving perceived stress and depressive symptoms in CVD patients (Nolan et al., 
2005). Therefore cardio-respiratory biofeedback may be a useful interventions aimed at 
reducing depressive symptoms and their psychophysiological correlates, which, in turn, are 
considered risk factors for cardiac morbidity and mortality in patients with cardiovascular 
diseases. Cardio-respiratory biofeedback training details will be further described in the next 
sections. 
 
 
1.3 Psychophysiological factors linking depression to increased cardiac risk 
Despite the evidence that depression is strongly associated with CVDs, the 
pathophysiological mechanisms underlying this relationship remains unclear. Stressful 
events and, most importantly, prolonged or excessive in amplitude responses to stress are 
thought to influence the pathogenesis of both depression (Griffiths, Ravindran, Merali, & 
Anisman, 2000) and CVDs (Schwartz et al., 2003) by exerting negative effects on behavioral 
and biological processes that influence disease risk. 
A stress response occurs when an individual perceives that environmental demands 
exceed his or her ability to face the situation and can be associated with dysphoria and 
emotional disease. 
The acute stress response to sudden stress, also known as the fight-or-flight response, 
is characterized by modifications that help the body to mobilize the necessary resources to 
deal with the stressor. Usually, stress response results in increased cognitive alertness, 
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cardiovascular modifications such as rapid increases in heart rate and blood pressure, 
respiration rate, and muscle tension and in decreased gastrointestinal activity (Cacioppo, 
1994).  
The stress response is controlled centrally by the hypothalamus and the brain stem. 
Acute and chronic stress responses are characterized by the activation of the hypothalamic-
pituitary-adrenal (HPA) axis and sympathetic nervous system. Initially, the hypothalamic 
neurons increase the synthesis of corticotropin-releasing factor (CRF), that, in turn, leads to 
the release of adrenocorticotropic hormone (ACTH) from the anterior pituitary gland. Then 
the ACTH hormone induces the release of glucocorticoids (mainly cortisol) from the adrenal 
cortex (Figure 1.5). Glucocorticoids are involved in the control of both body homeostasis and 
stress response, and more importantly, they produce an inhibitory feedback on the 
hypothalamus neurons involved in ACTH secretion to limit the duration of the exposure to 
glucocorticoids, thus minimizing the negative effects (i.e., immunosuppression) of these 
hormones. 
The activation of the sympathetic branch of the autonomic nervous system (ANS) not 
only provides rapid responses of the cardiovascular, respiratory, gastrointestinal, and renal 
systems but also increases in epinephrine and NE circulation from the adrenal medulla. In 
addition, the HPA axis and sympathetic nervous system activation lead to an increase in the 
aldosterone level (Kubzansky & Adler, 2010). 
Usually, stress response is limited to the duration of the stressor, but when the 
stressor or the individual perception of a stressful situation persists, it produces a chronic 
hyperactivation and the continuous release of neurotransmitters and hormones, increasing the 
risk for depression disorders and cardiac diseases (Björntorp, Holm, & Rosmond, 1999). 
Stress response affects a number of behavioral mechanisms, that, in turn, have been 
reported to be involved in the relationship between depression and CVDs. Several studies 
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reported that depressed patients are less likely to engage in health-promoting behaviors, such 
as initiating and maintaining a healthy diet (Everson-Rose et al., 2004; Ziegelstein, 2000) and 
regular physical exercise (Mendes de Leon, 1998; Whooley et al., 2008; Ziegelstein, 2000), 
reducing or avoiding smoking and alcohol consumption (Everson-Rose et al., 2004; Fenton 
& Stover, 2006), adhering to medical treatments and regimens (Bollini, Pampallona, 
Kupelnick, Tibaldi, & Munizza, 2006; Fenton & Stover, 2006; May et al., 2010; Rieckmann 
et al., 2006; Ziegelstein, 2000), adhering to cardiac rehabilitation protocols (Casey, Hughes, 
Waechter, Josephson, & Rosneck, 2008; McGrady, McGinnis, Badenhop, Bentle, & Rajput, 
2009) and engaging in stress reduction behaviors (Ziegelstein, 2000). Therefore, depressed 
patients may show higher cardiac risk because they are less likely to adhere to lifestyle 
changes and medical treatments and regimens that are required to improve cardiovascular 
health and to reduce cardiac risk. 
Among lifestyle-related risk factors, environmental stressors, stress at work and in 
family life (including work overload and high psychological demands at work), lack of social 
support, marital conflicts, health problems, or long-term stressful conditions in the family 
have all been strongly associated with mood disorder onset. More importantly, stress at work 
and within the family have been found to increase CVD risk 2.7- to 4.0-fold (Eaker, Sullivan, 
Kelly-Hayes, D’Agostino, & Benjamin, 2007; Orth-gome, Wamala, Horsten, Schneiderman, 
& Mittleman, 2000), while social isolation and low social support result in 1.5- to 3.0-fold 
increased risk of CVDs (Lett et al., 2005; Mookadam & Arthur, 2004). In addition, mood 
disorders and depressive symptoms have been frequently associated with excessive fatigue 
and vital exhaustion (including loss of vitality and libido, listlessness, tiredness, and 
increased irritability), that, in turn, have been shown to be a risk factor for MI and sudden 
cardiac death (Appels & Mulder, 1988; Kop, 1999). Moreover, exhaustion results are 
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predictive of future myocardial infarction independent of age, cholesterol, blood pressure, 
antihypertensive medications, and smoking (Appels & Mulder, 1988). 
Among emotional risk factors, anxiety disorders have been found to be frequently 
comorbid with depression disorder. Hence, anxiety has been investigated as a mechanism 
involved in the relationship between depression and cardiovascular diseases. Some studies 
have reported the effect of anxiety disorders—such as panic attack, generalized anxiety, and 
phobic anxiety—in increasing risk for CVDs by 1.01- to 4.2-fold (Chen, Tsai, Lee, & Lin, 
2009; Shibeshi, Young-Xu, & Blatt, 2007). Conversely, many studies have been 
inconclusive, finding little or no influence of anxiety on CVD risk (Meyer, Buss, & 
Herrmann-Lingen, 2010; Roest, Martens, de Jonge, & Denollet, 2010; Roest, Martens, 
Denollet, & de Jonge, 2010). Therefore, anxiety is unlikely to be a major contributor to the 
relationship between depression and CVDs. 
In conclusion, despite the reported relationship between behavioral, lifestyle-related, 
and psychological mechanisms linking depression to increased cardiac risk, current findings 
on these mechanisms are still far from being conclusive. 
 
Inflammatory response 
As mentioned above, the stress response may lead to an inflammatory response, and 
this association is supported by the fact that some neuropeptides, such as CRF, mediate both 
the responses. In addition, several lines of evidence suggest that depression is associated with 
the dysregulation of the immune system and activation of the inflammatory response 
(Dantzer, 2006; Dunn, Swiergiel, & de Beaurepaire, 2005; Hawkley, Bosch, & Engeland, 
2007). The inflammatory response in depressed patients has been demonstrated by the 
increased secretion of proinflammatory cytokines such as interleukin (IL-1, IL-2, and IL-6), 
interferon (IFN)-γ, and tumor necrosis factor (TNF)-α (Empana et al., 2005; Miller, Stetler, 
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Carney, Freedland, & Banks, 2002; Penninx et al., 2003; Zorrilla et al., 2001). More 
importantly, inflammation response may contribute to the development of depressive 
symptoms. In fact, the high secretion of proinflammatory cytokines has been shown to 
induce neurohormonal modifications (resulting in HPA hyperactivation) and changes in the 
activity of monoamines, such as serotonin, dopamine, and NE, that are believed to contribute 
to depression (Anisman, Hayley, Turrin, & Merali, 2002). 
Recent studies have reported that depressed individuals, both with and without a 
history of CVD, have increased levels of proinflammatory cytokines, particularly C-reactive 
protein (CRP), IL-1, and IL-6 (Howren, Lamkin, & Suls, 2009; Kop et al., 2010; Miller, 
Maletic, & Raison, 2009). Immune system activation and inflammation response have been 
directly associated with cardiovascular disorders. Specifically, proinflammatory cytokine 
activity has been linked to atherosclerotic plaque formation, progression, and rupture 
(Moyer, Sajuthi, Tulli, & Williams, 1991; Ross, 1999). Furthermore, it has been found that 
during acute myocardial infarction, some proinflammatory cytokines such as TNF-α, IL-1β, 
and IL-6 are released into the systemic circulation (Das, 2000). 
A study on 559 women examined the relationship between depression, cardiac 
ischemia, and inflammatory response. Interestingly, the findings showed a predictive role of 
depression on cardiac ischemia, and even after controlling for proinflammatory factors such 
as CRP and IL-6, depression continued to be the most predictive factor. Inflammatory factors 
reduced the association between depression and cardiovascular events by 20%, suggesting a 
small yet still significant contribution of proinflammatory factors (Vaccarino et al., 2007).  
Inflammatory response seems to play a role, although small, in the relationship 
between depression and cardiac outcomes. 
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Renin-angiotensin aldosterone system activation 
Stress response is associated with renin-angiotensin-aldosterone system (RAAS) 
activation; in fact, both HPA axis and sympathetic adrenomedullary system activation lead to 
an increase in the aldosterone level (Kubzansky & Adler, 2010). Some studies have reported 
a hyperactivation of the RAAS in individuals exposed to high stress, in patients suffering 
from mood disorders (Connor & Leonard, 1998; Pollak & Yirmiya, 2002) and in CVD 
patients (Felder et al., 2001). Emanuele and colleagues (2005) found high levels of 
circulating aldosterone and a high trend in plasma renin levels in a sample of depressed 
patients who met the criteria for major or minor depression (Association American 
Psychiatric, 1994), compared with controls matched for age and gender (Emanuele et al., 
2005). More importantly, a higher level of circulating aldosterone may be involved in 
depression disorder development by promoting inflammation response and by stimulating 
catecholamine release (Murck, Schüssler, & Steiger, 2012). In addition, hyperaldosteronism 
is associated with cardiac arrhythmias, vascular injury, myocardial necrosis, and heart failure 
(Felder et al., 2001; Stier, Chander, & Rocha, 2002).  
Hence, it is feasible that hyperaldosteronism is involved in the relationship between 
depression and cardiac risk. 
 
Endothelial dysfunctions 
There are evidences that endothelial dysfunctions play a role in the relationship 
between depression and cardiac risk. Endothelial dysfunctions have been found to be linked 
to depression disorder (Cooper et al., 2010; Pizzi, Manzoli, Mancini, & Costa, 2008). One of 
the mechanisms that have been proposed to link endothelial dysfunction to depression 
postulates that inflammation reactivity may play a role in the endothelial damage of the 
cerebral vasculature and thus contribute to the development of depression disorder. 
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Mainly, endothelial dysfunctions are involved in the process leading to coronary 
thrombosis (Miyata et al., 2000) and in the development of ischemic coronary heart disease 
(Skop & Brown, 1996). Furthermore, endothelial dysfunctions have been reported in 
depressed patients with established CVDs (Sherwood, Hinderliter, Watkins, Waugh, & 
Blumenthal, 2005). Recently, Pizzi and colleagues (2009) found that the treatment of 
depression with SSRIs improved endothelial function in patients with coexisting depression 
and established CHD. 
Therefore, there is some evidence, although far from conclusive, that endothelial 
dysfunctions may be involved in the relationship between depression and cardiac outcomes. 
 
Platelets Activation 
Platelets may be activated through several pathways mediated by platelet surface 
receptors. In particular, serotonin can activate the platelets by binding to specific 
serotoninergic receptors on their surface. When the platelets are activated, they release 
substances that induce irreversible platelets aggregation and thrombus formation. Serotonin 
is not only involved in platelets aggregation, but it is well recognized that serotonin is 
implicated in depression pathogenesis. Both serotoninergic dysfunction (Shrestha et al., 
2012) and increased platelet reactivity to serotonin (Shimbo et al., 2002) have been found in 
patients with minor or major depression. More importantly, increased platelet reactivity to 
serotonin may lead to increase the risk for thrombus formation (Shimbo et al., 2002). 
Furthermore, SSRIs have been shown to decrease platelet reactivity both in vitro and in 
patients with CHD. Specifically, SSRIs act by inhibiting serotonin reuptake by the 
serotoninergic receptors, blocking the process of platelet activation (Serebruany et al., 2001; 
Serebruany et al., 2005). Excessive platelet reactivity possibly mediates the increased cardiac 
risk in patients with depressive disorder. 
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Autonomic nervous system disorders 
Most of the above-mentioned factors are associated with ANS dysregulation, which 
has been consistently reported to mediate the relationship between depression and cardiac 
disorders. 
The ANS mediates completely, or in part, the cardiac reflex mechanisms, that are 
essential in regulating the cardiovascular function. The ANS consists of 2 branches that 
regulate the function of the heart, namely, the sympathetic and the parasympathetic systems. 
The interplay between the sympathetic and the parasympathetic activity causes constant 
modifications in the heart activity. These regular modifications allow to maintain a dynamic 
homeostasis and to respond to stressors and situational factors. Hence, disturbances of 
cardiac reflexes may be crucial in the relationship between depression and CVDs. The 
normal cardiac rhythm is controlled by the electrical activity of the cardiac sinoatrial node, 
innervated from both the branches (sympathetic and parasympathetic) of the ANS. (Randall, 
1994). Specifically, postganglionic parasympathetic terminals release acetylcholine on the 
sinoatrial node, resulting in a reduction in the rate of depolarization and in a lower heart rate. 
In contrast, sympathetic terminals on the sinoatrial node release NE, that increases the 
sinoatrial node rhythm by means of a cascade of second messenger intracellular signals that 
mediate beta1 receptors. In addition, HR can be modulated by the effect of different 
neuropeptides (e.g., neuropeptide Y) (Hill, Wallick, Martin, & Levy, 1995). Thus, ANS 
modifications have a high impact on the heart rate at rest. In fact, resting heart rate is 
heightened as a result of sympathetic nervous system activation combined to vagal 
withdrawal. 
Many studies have reported the association between depression and autonomic 
cardiac dysregulation, such as vagal control withdrawal, hyperactivation of the sympathetic 
nervous system, and as a consequence, elevations in heart rate, decrease in HRV, and 
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alteration of the baroreceptor reflexes (Barton et al., 2007; Carney et al., 1995; Murray Esler, 
1982; Hausberg, Hillebrand, & Kisters, 2007; Krittayaphong et al., 1997; Pitzalis et al., 2001; 
Rechlin, Claus, & Weis, 1994; Rechlin, 1994; Watkins, Grossman, Krishnan, & Blumenthal, 
1999).  
During the past decades, advances in psychobiology and biological psychiatry have 
contributed to the discoveries of numerous neurochemical, neuroendocrine, and 
neuroanatomical alterations associated with ANS dysregulation in depression. Many studies 
have reported the hyperactivation of the HPA axis in nonmedicated depressed patients. 
Specifically, heightened CRF concentration, blunting of the ACTH response to CRF 
administration, hypercortisolemia, pituitary and adrenal gland enlargement, and evidence of 
increased numbers of hypothalamic CRF neurons in the postmortem tissue were reported in 
patients with major depression (Asnis et al., 1987; Barton et al., 2007; Maes, De Ruyter, 
Claes, & Suy, 1998; Weber, Lewicka, Deuschle, Colla, & Heuser, 2000). 
The hypersecretion of NE has also been displayed in unipolar depression. Peripheral 
plasma NE concentrations are produced by the rate of release from sympathetic nervous 
system nerve terminals. Therefore, increased sympathetic activity leads to elevated plasma 
NE concentration. 
Some studies showed that depressed patients, compared with nondepressed subjects, 
displayed higher plasma NE concentration at rest and greater elevation in plasma NE in 
response to the orthostatic challenge test (Gold et al., 2005). This means that the sympathetic 
activity is both tonically elevated and more reactive to stress in depressed patients. 
Furthermore, depressed patients who show no response to a dexamethasone test reveal a 
higher basal level of plasmatic NE compared with depressed patients who show a suppressor 
response to dexamethasone. These results suggest an elevated sympathetic activity in 
depressed patients resistant to dexamethasone (Barnes et al., 1983). Interestingly, Gold and 
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colleagues (2005) found no differences in the concentration level of plasma catecholamines 
between patients with mild, moderate, or severe depression, although only unmedicated 
patients with severe depression displayed an association between high levels of plasma NE 
and increased cardiac mortality. 
Many studies have shown a relationship between depression, CVDs, and heightened 
basal heart rate. In fact, a high heart rate at rest has been reported in depressed patients both 
with and without CVDs (Carney et al., 1988; Forbes & Chaney, 1980). Similarly, depressed 
patients with (Carney et al., 1988) or without CVDs (Lechin et al., 1995) have been found to 
display higher heart rates compared with individuals without depression. In addition, 
depressed patients with comorbid CVDs exhibit higher heart rates than nondepressed patients 
with CVDs (Carney, Freedland, Rich, Smith, & Jaffe, 1993). The mechanism resulting in 
heightened basal heart rate in depressed patients may involve the effect of NE and 
epinephrine on cardiac β-adrenergic receptors at the sinoatrial node level or imply an 
increased sensitivity of myocardial β-adrenergic receptors (Kannel, Anderson, McGee, 
Degatano, & Stampfer, 1987). However, a few studies failed to find an association between 
depression and a higher heart rate at rest (Barton et al., 2007; Dawood et al., 2007), although 
it is acknowledged that a fast heart rate at rest is a prognostic factor for morbidity and 
mortality related to heart disease (Ferrari, Censi, Mestrorilli, & Boraso, 2003).  
Furthermore, the literature on disrupted autonomic balance suggests that increased 
sympathetic and/or decreased parasympathetic tone may predispose both patients with 
(Podrid, 1990; Pruvot et al., 2000) and without CVDs to ventricular fibrillation, ventricular 
tachycardia, and sudden cardiac death (Kleiger, Miller, Bigger, & Moss, 1987; Lown & 
Verrier, 1976). Alterations of the ANS activity have been found to be associated with 
cardiovascular risk factors such as increased body mass index, heightened blood glucose, and 
hypertension; in addition, similar autonomic changes are noticed in acute and chronic CVDs, 
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including arrhythmias, atherosclerosis, heart failure, and myocardial ischemia (Billman, 
Schwartz, & Stone, 1982; Carney et al., 1993; Dyer et al., 1980; Esler & Kaye, 2000; Kannel 
et al., 1987; Kristal-Boneh, Raifel, Froom, & Ribak, 1995; La Rovere, Bigger, Marcus, 
Mortara, & Schwartz, 1998; Palatini & Julius, 1997; Schwartz et al., 1988). 
 
 
 
Figure 1.5. Diagram of the psychobiological and neuroendocrine mechanisms 
involved in the stress response. Autonomic nervous system innervation of the heart via 
parasympathetic vagus (X) and sympathetic nerves (postganglionic efferent from cervical 
and upper thoracic paravertebral ganglia) are shown. CRF = corticotropin-releasing factor; 
ACTH = corticotropin; TNF-alpha = tumor necrosis factor; IL-1 = interleukin 1; IL-6 = 
interleukin 6; HRV = heart rate variability; HPA = hypotalamic-pituitary-adrennocortical 
axis (Musselman, Evans, & Nemeroff, 1998) 
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In summary, a large body of literature supports the hypothesis of altered ANS 
activity as a mechanism underlying the link between depression and increased cardiac risk. 
ANS activity, and specifically the balance between sympathetic and parasympathetic activity 
on the heart, can be easily detected by means of HRV. Therefore, in the next sections, HRV 
and its measures will be described. 
 
 
1.3.1 Heart rate variability (HRV) as a measure of autonomic nervous system activity 
Cardiac rhythm is easily determined by means of electrocardiogram (ECG). Heart 
rate (HR) is controlled by reciprocal influences of acceleratory sympathetic nervous system 
activity and decelerator parasympathetic nervous system activity. The constant interplay 
between the two systems results in a rhythmic oscillation, also known as heart rate variability 
(HRV). Specifically, HRV is the physiological phenomenon of oscillation in the interval 
between consecutive heartbeats or the fluctuation between consecutive instantaneous heart 
rates (see Figure 1.6).  
 
 
 
Figure 1.6. Variations in the interval between consecutive heartbeats (Watkins, 
2011). 
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Analysis of HRV is an accurate method of measuring neural autonomic nervous 
system influences on cardiac function.  
As mentioned above, the cardiac neural control is mediated mainly via the interaction 
between sympathetic and parasympathetic branches, that are strongly interconnected from 
central nervous system to postganglionic endings. Given the opposite effect of sympathetic 
or parasympathetic branches on heart function, the activation of either sympathetic or 
parasympathetic system is commonly associated with the inhibition of the other one, 
suggesting the presence of balance between the two systems, namely, the sympathovagal 
balance (Malliani, 2000). Yet, sympathetic and parasympathetic activity on heart can be 
simultaneously activated or inhibited. 
Commonly, the autonomic sympathovagal balance swings from rest, characterized by 
a predominance of homeostatic negative feedback reflexes, that allow to maintain a slow 
heart rate and reduced metabolic rate, to excitatory states (i.e., physical or emotional stress), 
characterized by central mechanisms activation (i.e., the perception of a threatening 
stimulus), that through positive feedback enhance cardiac performance (Malliani, Pagani, 
Lombardi, & Cerutti, 1991). This continual excitatory-inhibitory interaction leads to dynamic 
heart rate oscillations, namely heart rate variability. Thus, HRV reflects complex processes 
of cardiac neural chronotropic control (Calkovska and Javorka, 2008). 
HRV analysis represents a noninvasive method to obtain information about cardiac 
autonomic regulation and provides important indications on central-peripheral interaction 
(Carney et al., 2001; Carney et al., 2002; Krittayaphong et al., 1997; Task Forcey, 1996).  
In general, it is assumed that high variability is an index of better system functioning 
and is associated to better health and adaptability. According to assumptions based on 
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complexity theories, to maintain stability and flexibility of the organism a dynamic 
relationship among system elements is needed (Thayer & Lane, 2000). In fact, stable and 
adaptable biological systems are characterized by complex patterns of oscillation, which 
represent the self-regulatory reflexes of the body (Giardino, Lehrer, & Feldman, 2000). 
Complex oscillation patterns in the human body include slow circadian rhythms such as the 
sleep-wake cycle, and temperature modifications, and faster oscillation patterns, such as the 
baroreflex activity and HRV. A well regulated and healthy flexible body is characterized by 
complex and relatively high amplitude oscillations patterns. Therefore, reduction in 
amplitude or complexity is an index that body self-regulatory systems are not functional and 
unable to deal with obstacles such as stress, diseases or injuries. Patterns of variability that 
are organized (not random variability), rather than static levels, reflect better adaptability and 
the ability to face the environmental demands that are constantly changing. Thus, higher 
variability in the oscillation patterns of the system leads to optimal system functioning, 
whereas scarce variability, or rigid regularity, causes morbidity, diseases and mortality (Ellis 
& Thayer, 2010).  
As HRV reflects general health and adaptability, it correlates negatively with age 
(Liao et al., 1995) and positively with aerobic capacity in the adult population (Hedelin, 
Wiklund, Bjerle, & Henriksson-Larsén, 2000; Pardo et al., 2000). Diminished HRV, on the 
contrary, is a sign of vulnerability to stress, whether the decrease arises from psychological 
or physical stress. More importantly, decreased HRV has been recognized as an important 
marker of impaired cardiovascular regulation. In fact, low HRV has been associated with 
excessive sympathetic modulation and/or inadequate vagal control (Task Force, 1996). 
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1.3.2 Measurement and components of HRV 
To obtain heart rate variability (HRV) inter beat intervals (IBIs) must be measured 
from time series of electrocardiography (ECG). In addition, photoplethysmography (PPG) 
has been recently used as a noninvasive yet reliable method to obtain HR and IBIs. ECG 
produces waveforms that peak due to the ventricular depolarization phase of the cardiac 
cycle, namely, the R wave. Conversely, PPG is mainly used to monitors arterial oxygen 
saturation on a continuous basis. Arterial oxygen saturation is directly associated to arterial 
blood flow, that reflect the mechanical pump function of the heart. Given that mechanical 
heart activity is coupled to its electrical activity, arterial blood flood, recorded by means of 
PPG, reflects the cardiac rhythm. This characteristic forms the basis for comparison of ECG-
derived HRV and PPG-derived HRV. Recently, some studies have demonstrated that 
parameters of HRV calculated from PPG are highly correlated with the parameters of HRV 
obtained from ECG (see Figure 1.7). Thus, HRV obtained from PPG could be reliably used 
as an alternative measurement of HRV (Bolanos, Nazeran, & Haltiwanger, 2006; Lu et al., 
2008; Selvaraj, Jaryal, Santhosh, Deepak, & Anand, 2008). 
After ECG or PPG is obtained, the signal is digitalized by a computer and a series of 
R-R (distance in time between two consecutive R waves) or a series of P-P (peak to peak 
interval on the PPG waves) intervals is derived.  
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Figure 1.7. Simultaneous recording of photoplethysmographyc signal and 
electrocardiographyc signals. R-R = R to R interval; PTT = Pulse Transit Time; P-P = Pulse 
to Pulse interval; ECG = electrocardiography; PPG = photoplethysmography (modified from 
Liu et al., 2010). 
 
 
Methods for quantifying HRV are categorized as: (a) time domain which are global 
descriptive statistics to characterize the distribution of heart periods (e.g., standard deviation, 
and variance) (see Table 1.1) and (b) frequency domain which consist of power spectral 
analysis of the IBIs series, in order to extract specific frequency components of variance that 
have been related to functional processes or physiological mechanisms (see Table 1.2). 
Among time domain HRV indexes, standard deviation of the normal IBIs, or NN 
intervals (SDNN) is the simplest variable to calculate (Formula 1).  
 
√
 
 
∑ (      ̅̅ ̅̅ )
 
          (1) 
 
Specifically, SDNN reflects the whole cyclic components responsible for variability 
in the period of recording. Some other statistical variables are calculated from specific 
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segments of the total period, among which, rMSSD, NN50 and pNN50. rMSSD consist in 
the square root of the mean squared differences of successive NN intervals (Formula 2). 
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NN50, correspond to the number of successive NN intervals differences greater than 
50 ms (Formula 3). 
 
∑ *|         |      +
 
        (3) 
 
pNN50 correspond to the proportion of NN50 on the total number of NN intervals 
(Formula 4). 
 
    
 
           (4) 
 
All three rMSSD, NN50 and pNN50 are strongly correlated index of short-term 
variation, and, are estimate of high frequency variations in heart rate. Thus all of these 
indexes highly correlate with indexes of vagal activity on heart. 
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Table 1.1. Time domain indexes of HRV 
Time domain indexes Units Description 
SDNN ms Standard deviation of the inter beat intervals. Estimate of overall 
HRV. 
rMSSD ms Square root of the mean squared differences of successive inter 
beat intervals. Cardiac vagal control on the heart. 
NN50  Number of successive NN intervals differences greater than 50 ms 
pNN50  proportion of NN50 on the total number of NN intervals 
 
 
Regarding spectral or frequency domain indexes, the power spectrum of the whole 
IBIs series is conventionally divided in three bands, each corresponding to different 
physiological processes: very low frequency (VLF), low frequency (LF), and high frequency 
(HF) components (see Figure 1.8). 
The VLF component (range 0.005–0.05 Hz) can be influenced by several different 
systems, such as the renin-angiotensin, thermoregulatory, and peripheral vasomotor systems 
(Akselrod et al., 1981; Kamath et al., 1987; Taylor, Carr, Myers, & Eckberg, 1998). Thus, 
the attribution of a specific physiological process to these heart period changes might be 
questioned.  
The attribution of an autonomic processes to LF component (range 0.05–0.15 Hz) is 
controversial. Some studies proposed that the LF range reflect mainly sympathetic outflow 
(Malliani, Lombardi, & Pagani, 1994; Malliani et al., 1991) while most investigators report 
that LF range seems to be influenced by both the sympathetic and parasympathetic systems 
and is specifically associated with baroreflex function (Kamath et al., 1987). Moreover, this 
component is influenced by body position, in particular, there is evidence that in supine 
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position, the sympathetic system contributes only minimally to LF (Myers, Cohen, Eckberg, 
& Taylor, 2001; Eckberg, 2000). 
There is more agreement on HF range (0.15-0.40 Hz) interpretation, that is mainly 
reported as an index of parasympathetic activity (Task Force, 1996). Specifically, during 
normal breathing (9-24 breath per minute) HF is reported as an index of vagal control on the 
heart and respiratory sinus arrhythmia (Berntson et al., 1997; Paul Grossman & Taylor, 
2007). 
 
 
 
 
 
Figure 1.8. Power spectrum of one hour recording IBIs series divided in three bands, 
red (range 0.005–0.05 Hz) correspond to very low frequency (VLF); blue (range 0.05–0.15 
Hz) correspond to low frequency(LF); yellow (range 0.15-0.40 Hz) correspond to high 
frequency (HF) components. 
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While the measurement of VLF, LF and HF power components is usually reported in 
absolute values of power (ms2), LF (Formula 5) and HF (Formula 6) can also be transformed 
in normalized units (n.u.), which is calculated dividing the relative value of each power 
component by the total power minus the VLF component.  
 
  
(               )
         (5) 
 
  
(               )
          (6) 
 
LF and HF transformation in n.u. specifically emphasizes the influence and balance 
of the two branches of the autonomic nervous system (Task Force, 1996). In addition, the 
normalization process reduce the effect of the changes in total power on the values of LF and 
HF bands. Nevertheless, absolute values of the LF and HF power should always be reported 
together with the normalized units in order to describe the whole distribution of power in 
spectral components. Finally, LF/HF ratio (Formula 7) is widely used as a measure of 
autonomic balance (Task Force, 1996). 
 
 
  ,   -
  ,   -⁄       (7) 
 
Higher LF/HF ratio reflect higher influence of the sympathetic activity and/or 
reduced influence of the parasympathetic control on the heart. 
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Table 1.2. Frequency domain indexes of HRV 
Frequency domain 
indexes 
Units Description Frequency 
Range 
VLF ms
2 Very low frequency. VLF reflect many 
systems activities, among which renin-
angiotensin, thermoregulatory, and peripheral 
vasomotor systems. 
0.005-0.05 Hz 
LF ms
2 Low frequency. LF reflect sympatethic and 
parasympatethic control of the heart, and 
baroreflex influences. 
0.05-0.15 Hz 
HF ms
2 High frequency. HF reflect cardiac vagal 
control and respiratory sinus arrhythmia. 
0.15-0.40 Hz 
LF n.u.  LF power in normalized units.  
HF n.u.  HF power in normalized units.  
LF/HF  Sympathovagal balance.  
 
 
Respiratory sinus arrhythmia 
Respiratory sinus arrhythmia is an additional cardiorespiratory index that is strongly 
associated with HRV indexes. Specifically, RSA is a physiological cardiorespiratory 
phenomenon characterized by rhythmical fluctuation in heart periods, or R-R interval, that 
are in phase relationship with respiration. In fact, normally, HR accelerates during inspiration 
and slows down during expiration (Figure 1.9).  
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Figure 1.9. Schematic representation of electrocardiogram during respiration. The 
RR intervals decreases during inhalation and increases during exhalation reflecting 
respiratory sinus arrhythmia (Thaler, 2010). 
 
 
Over the last decades, several studies have supported the hypothesis that RSA is 
mainly mediated by the vagal nerve, at least within the normal physiological range of 
respiration rate (9-24 breath per minute). RSA is the result of the effects of both peripheral 
afferent and central respiratory mechanisms (Berntson, Cacioppo, & Quigley, 1993). During 
inhalation, a reflex inhibition on vagal nerve outflow is produced by thoracic stretch 
receptors, resulting in an increase in HR. During exhalation the absence of thoracic stretch 
receptors inhibitory effect result in vagal nerve excitation that cause a reduction in HR (see 
Figure 1.10).  
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Figure 1.10. Schematic illustration of the interaction between primary determinants 
of RSA, either central and peripheral, as a function of respiration phase. Solid lines illustrate 
excitatory influence; dashed lines illustrate inhibitory influences (Berntson et al., 1993). 
 
 
Therefore, cardiac acceleration during inspiration reflect parasimpathetic inhibitory 
influences upon the sinoatrial node. On the contrary, cardiac deceleration during expiration 
mirrors vagal excitatory influences upon the heart via the sinoatrial node.  
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Since the respiratory frequency band range in the human adult from about 9 to 24 
breath per minute (corresponding to 0.15 - 0.4 Hz), RSA is often matched with HF 
component. Thus, RSA is thought to be mediated predominately by fluctuations of vagal-
cardiac nerve activity and can provide a reliable index of vagal activity (Eckberg, 2003; 
Hedman, Tahvanainen, Hartikainen, & Hakumäki, 1995; Berntson et al., 1997; Grossman & 
Taylor, 2007). In addition, some studies have reported that RSA reflect rhythmic waxing and 
waning of the parasympathetic efferent on the sinoatrial node (Eckberg, 2003; Hedman et al., 
1995).  
More specifically, RSA arises from a complex interaction of central and peripheral 
factors. In fact, several factors possibly contribute to RSA, including , cardiac and pulmonary 
stretch reflexes, central cardiorespiratory rhythm generators and tonic and phasic 
baroreceptor (Saul, 1990; Spyer, 1990). In particular, the two predominant sources of the 
respiratory modulation of vagal outflow are a) the phasic modulation (both excitatory and 
inhibitory) of vagal motor neurons operated by the central respiratory nuclei and b) the 
influence of pulmonary stretch receptors which determines phasic excitatory inputs on the 
vagal nerve. These two mechanisms are functionally linked via the diaphragmatic control of 
respiration, and, the balance between these two mechanisms may be altered by specific 
respiratory maneuvers and chemoreceptor actions on the respiratory generator. Anrep and 
coworkers (1936) suggested that both central and peripheral mechanisms contribute 
approximately equivalently to RSA. 
Respiratory and cardiovascular system react to a wide variety of environmental 
demand that requires elevated metabolic responses, but also to psychological and behavioral 
variations, as well as physiological state, including modification in the levels of alertness, 
different types of emotion, mental activity and arousal.  
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Given that different processes may interfere and modify the relationship between 
respiration process and vagal control, the RSA-vagal control association is not always direct, 
thus, desuming vagal regulation from RSA is complicated. In fact, the exact phase 
relationship between respiratory oscillation and HR fluctuation depend on the respiration rate 
(Eckberg, 1983). Furthermore, even when autonomic tone is stable, the amplitude of HR 
fluctuations depend upon both respiratory frequency and depth of ventilation (i.e. tidal 
volume; Hirsch & Bishop, 1981). In addition, people breathe at different frequencies and 
RSA sometimes is decoupled from the vagal influence on HR (Sargunaraj et al., 1996; 
Yasuma, 2004). Furthermore, even acetylcholine metabolism may affect RSA. In fact, the 
vagal nerve determine the releasing of acetylcholine during exhalation (resulting in HR 
increases), nevertheless acetylcholine may be metabolized more completely during slow 
respiration, compared to fast respiration, thus causing a reduction in the effect of the vagal 
nerve activity on HRV (Eckberg & Eckberg, 1982) and thus decouple amplitude of RSA 
from quantity of vagus nerve traffic. In addition, sympathetic activity may affect HF of HRV 
under some circumstances (Taylor, Myers, Halliwill, Seidel, & Eckberg, 2001).  
Hence, it is important to consider respiration rate while evaluating HRV indexes, 
both HF and/or RSA as a measure of autonomic parasympathetic function.  
 
 
1.3.3 HRV alterations and cardiovascular diseases 
Reduced HRV is associated with a wide variety of cardiovascular disorders including 
hypertension, particularly when accompanied by left ventricular hypertrophy (Mancia, 
Ludbrook, Ferrari, Gregorini, & Zanchetti, 1978), sudden cardiac death (Goldberger, Rigney, 
Mietus, Antman, & Greenwald, 1988; Goldberger, 1991), mainly from arrhythmic events 
 59 
after myocardial infarction (Bigger, Fleiss, Rolnitzky, & Steinman, 1993; Farrell et al., 
1991), ventricular arrhythmia (Matveev & Prokopova, 2002), presence and severity of 
ischemic heart disease (Huikuri & Mäkikallio, 2001); and risk of rejection after heart 
transplant (Izrailtyan et al., 2000). 
Several lines of evidence have documented that reduced RSA may represent an index 
of poor vagal control, that, in turn, is a marker of cardiovascular risk both in patients with 
and without CVDs (Bigger et al., 1992; Hayano et al., 1990).  
The unbalance of the autonomic nervous system plays an important role in a wide 
range of visceral-somatic and mental diseases. As mentioned before, the balance between 
sympathetic and parasympathetic branches is associated to healthy, adaptable and flexible 
physiological system. Reduced parasympathetic activity and/or excessive sympathetic 
reactivity is frequently reported as associated with several maladaptive conditions, and with 
the increased risk of cardiovascular adverse outcomes (Friedman, 2007; Porges, 2007; 
Thayer & Sternberg, 2006). Specifically, a constant reduced parasympathetic activity on the 
heart may lead to accelerated heart rate at rest, reduced HRV and longer recovery time after a 
stressor occurs. Moreover, elevated sympathetic reactivity may cause disproportionate 
increment of heart rate in response to a stressor. Therefore, the correct functioning of the 
ANS and a dynamic balance between sympathetic and parasympathetic systems both during 
rest and in response to different internal/external stressors is important in order to maintain 
flexibility, adaptability and health. Decreased HRV have been related to onset and 
exacerbation of CVDs, such as hypertension, coronary heart disease, and congestive heart 
failure. In fact, CVD patients display a reduced HRV (Kristal-Boneh et al., 1995), and 
diminished variability in heart rate have been shown to be a risk factor negative outcomes in 
myocardial infarction and CHF (Kleiger et al., 1987; Tapanainen et al., 2002; Wolk, 
 60 
Kulakowski, & Ceremuzynski, 1996). Many studies reported that a reduced HRV represents 
an independent risk factor for cardiovascular mortality in patients with stable CHD (Rich et 
al., 1988) and after a myocardial infarction (Glassman, Roose, & Bigger, 1993; Kleiger et al., 
1987).  
Furthermore, although few negative findings have been reported on the relationship 
between depression and HRV in CHD patients (Gehi, Mangano, Pipkin, Browner, & 
Whooley, 2005), there is abundant evidence that depressed patients with CHD or acute 
myocardial infarction are characterized by a reduced HRV compared to individuals without 
depression (Carney et al., 2001, 2002; Krittayaphong et al., 1997; Stein, Domitrovich, 
Kleiger, Schechtman, & Rottman, 2000). 
 
 
1.3.4 HRV alterations and depression 
Reduced amplitude and complexity of HRV is associated with a wide range of 
psychological dysfunctions, including anxiety and depression (Agelink, Boz, Ullrich, & 
Andrich, 2002; Gorman & Sloan, 2000; Kawachi, Sparrow, Vokonas, & Weiss, 1995; 
Yeragani, Balon, Pohl, & Ramesh, 1995). Reduced HRV has been found in depressed 
patients with and without CVDs, compared to individuals without depression (Carney et al., 
1995; Pitzalis et al., 2001; Rechlin et al., 1994; Rechlin, 1994). Some studies reported 
reduced cardiac vagal control in adult patients with depression (Kikuchi et al., 2009; Udupa 
et al., 2007). Krittayaphong and colleagues (1997) found that patients with higher depressive 
symptoms on the Minnesota Multiphasic Personality Inventory-Depression (MMPI-D; 
Hathaway & McKinley, 1967) compared to patients with lower scores had significantly 
lower HRV. In addition, cross-sectional and longitudinal studies have displayed that reduced 
levels of RSA are linked to depression and/or depressive symptoms in nonsurgical 
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populations (Balogh, Fitzpatrick, Hendricks, & Paige, 1993; Carney, Freedland, Rich, & 
Jaffe, 1995). In addition, a few studies have demonstrated that baroreceptor reflex 
(baroreflex) sensitivity may be reduced in patients with depression (Watkins et al., 1999). A 
reduction in baroreflex sensitivity has been reported to differentiate high- from low-risk 
patients recovering from myocardial infarction and CHF (Mortara et al., 1997).  
However, discrepant findings have also been reported regarding the relationship 
between RSA and depression (Carney et al., 1988; Khaykin et al., 1998) and between 
reduced HRV and depression (Yeragani et al., 1991; Dawood et al., 2007). Possible reasons 
for these inconsistent findings involve the heterogeneity of individuals diagnosed with 
depression (Gotlib & Hammen, 1992), small sample sizes, and the quantification of RSA 
without controlling for possible confounds such as respiratory rate and depth (Grossman & 
Taylor, 2007).  
Pharmacological data suggest that one possible mechanism underlying the 
relationship between depression and reduced HRV may involve central serotonergic 
regulation (Khaykin et al., 1998). In fact, recently, Barton and colleagues (2007) showed the 
efficacy of pharmacological treatment with selective serotoninergic reuptake inhibitors 
(SSRIs) in depressed patients in reducing sympathetic activation, as shown by a 
norepinephrine spillover reduction. However, a few studies have reported adverse effects in 
patients with depression treated with SSRIs (Dawood et al., 2007), while some studies have 
reported no significant cardiovascular changes (neither positive nor negative) (Nemeroff, 
Musselman, & Evans, 1998; Roose & Miyazaki, 1998; Roose et al., 1998). 
In conclusion, reduced ANS control of the heart, characterized by imbalance between 
sympathetic and parasympathetic modulation, is likely a central mechanism contributing to 
the increased cardiac risk associated with depression disorder (for reviews, Brown, Barton, & 
Lambert, 2009; Carney & Freedland, 2009). 
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1.4 Aims of the research project and outline of the studies  
With the goal of increasing our understanding of depression as a cardiac risk factor, 
this thesis investigates the psychophysiological mechanisms underlying the relationship 
between depression and increased cardiac risk in patients after first time cardiac surgery, and, 
secondarily, it explores the effectiveness of a biofeedback training in reducing cardiac risk in 
these patients.  
Accordingly, the primary aim of the first study was to investigate whether the 
association between depression symptoms and reduced heart rate variability can be extended 
to patients after first time cardiac surgery, independently of anxiety symptoms, and 
specifically if depression would be related to reduced vagal control after cardiac surgery. The 
experiment reported in chapter two examined the relationship between postoperative 
depressive symptoms and reduced vagal control on the heart, as measured by HRV indexes, 
controlling for anxiety symptoms. It is hoped that this will lead to a better understanding of 
the psychophysiological mechanism linking depression to increased cardiac risk.  
The current thesis also aims to examine the role of emotion regulation in the 
relationship between depression and HRV. The experiment in chapter three aimed to 
investigate whether patients with depressive symptoms after first time cardiac surgery use 
altered emotion regulation strategies when compared to nondepressed patients. Moreover, it 
was examined whether excessive use of expressive suppression strategy would mediate the 
relationship between depression and reduced HRV. Excessive use of expressive suppression 
was hypothesized to increase cardiac risk, further decreasing HRV. The understanding of the 
role of altered emotion regulation strategies can lead researchers to better comprehension of 
the emotional factors in the relationship between depression and the sympathovagal 
imbalance. 
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The current thesis also aims to observe vagal modulation during a stressful emotional 
situation in depressed patients after cardiac surgery. The experiment reported in chapter four 
examined vagal activity, as measured by HF index of HRV, during three emotional stressors 
in depressed and non-depressed patients after cardiac surgery. It was hypothesized that 
depression would be associated with greater stress response, characterized by vagal 
withdrawal during unpleasant situation rather than neutral and pleasant ones. The 
understanding of the relationship between postoperative depressive symptoms and 
sympathovagal balance during emotional stressors can lead researchers to develop easy-to-
use protocols in order to improve the diagnosis and treatment of depressed patients. 
Given the relevant role played by depression as a risk factor for postoperative 
adverse outcomes, and the lack of completely effective and reliable treatment for depressive 
symptoms in cardiac patients the research was finally focused on possible non 
pharmacological treatment of depression in patients after cardiac surgery. The experiment in 
chapter five was designed to examine the effectiveness of a short training with RSA-
biofeedback. Specifically, the current experiment was carried out to investigate whether the 
biofeedback intervention would be effective in increasing vagal control of heart rate (as 
measured by RSA) at rest. Secondarily, it examined whether the RSA-biofeedback training 
would also be associated with a reduction in depressive symptoms, thus contributing to 
lowering risk factors linked to depressive symptoms after cardiac surgery, which may 
influence clinical outcomes in these patients. 
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CHAPTER 2 
 
Postoperative depression and reduced heart rate variability 1 
 
 
2.1 Abstract 
Objective: Depression is a risk factor for cardiovascular diseases. Reduced heart rate 
variability (HRV), which reflects altered autonomic nervous system activity, has been 
suggested as one of the mechanisms linking depression to cardiovascular diseases. However, 
the relationship between depression and HRV has not yet been investigated in patients 
undergone cardiac surgery. Therefore, the main aim of this study was to examine whether 
postoperative depression could be related to reduced HRV. 
Methods: Eleven patients with depression and 22 patients without depression, who had 
undergone cardiac surgery, were enrolled postoperatively. In all patients, HRV was derived 
from a four-minute blood volume pulse recording at rest. Analyses of covariance and partial 
correlations, while controlling for anxiety, were used to examine the associations between 
postoperative depression and each HRV parameter. 
Results: Compared to non-depressed patients, patients with depression showed significantly 
lower standard deviation of N-to-N intervals (SDNN) (p = .02), root mean square successive 
difference of N-to-N intervals (rMSSD) (p = .001), and high frequency power (p = .002). 
Partial correlation analyses showed that depression was inversely related to SDNN (r = -.49, 
p = .005), rMSSD (r = -.58, p = .001), and high frequency power (r = -.41, p = .02), whereas 
it was unrelated to other HRV parameters (p’s > .09). 
                                                 
1 Results from this study have been partially published in: Patron, E., Messerotti Benvenuti, S., Favretto, 
G., Valfrè, C., Bonfà, C., & Palomba, D. (2012). Association between Depression and Heart Rate 
Variability in Patients after Cardiac Surgery: A Pilot Study. Journal of Psychosomatic Research, 73, 42-6. 
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Conclusions: The current findings extend the depression-reduced HRV relationship to the 
patients after cardiac surgery. Also, our study suggests that postoperative depression is more 
likely to be associated with reduced vagal modulation on the heart than with excessive 
sympathetic activity. 
 
Keywords: autonomic nervous system; cardiac surgery; depression; heart rate variability 
 
 
2.2 Introduction 
Several lines of evidence suggest that depression is a relevant and independent risk 
factor for cardiovascular diseases onset (Carney et al., 2005). Specifically, Wulsin and Singal 
(2003) reported that depressive symptoms were associated with roughly a 60% greater 
likelihood of developing coronary heart disease (CHD). Also, Lichtman and coworkers 
(2008) found a dose-response relationship between the increasing of depression severity and 
subsequent cardiac events, with more severe depression being associated with greater risk of 
earlier and more severe cardiac events. The physiological mechanisms underlying depression 
as risk factor for developing cardiovascular diseases are still debated (Carney et al., 2005, 
2002). The strongest evidence implicates an altered autonomic tone as a possible link 
between depression and cardiovascular morbidity or even mortality (Carney et al., 2005, 
2002). Indeed, it is well-established that depression is associated to dysregulation of the 
hypothalamic pituitary-adrenal axis, as well as increased sympathetic nervous system activity 
(Siever & Davis, 1985; Veith, 1994). Decreased parasympathetic and/or increased 
sympathetic nervous system activity, in turn, may predispose patients with cardiovascular 
diseases to ventricular fibrillation, ventricular tachycardia, and sudden cardiac death (Podrid, 
Fuchs, & Candinas, 1990; Pruvot et al., 2000). 
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Heart rate variability (HRV) has been widely used to assess cardiac autonomic 
modulation since it reflects the influence of both sympathetic and parasympathetic nervous 
system effects on the heart (Carney et al., 2001; Carney et al., 2002; Krittayaphong et al., 
1997; Task Force, 1996). A reduced HRV is associated with sympathovagal imbalance, in 
particular, excessive sympathetic modulation and/or inadequate vagal control (Task Force, 
1996). Specifically, it has been reported that a reduced HRV is an independent risk factor for 
cardiac mortality after a myocardial infarction (Bigger et al., 1993; Kleiger et al., 1987) and 
in patients with stable CHD (Rich et al., 1988). Moreover, although few negative findings 
have been reported on the relationship between depression and HRV in CHD patients (Gehi 
et al., 2005), there is large evidence that depressed patients with CHD or acute myocardial 
infarction have a reduced HRV compared to individuals without depression (Carney et al., 
2001; Carney et al., 2002; Krittayaphong et al., 1997; Task Force, 1996). 
Cardiovascular diseases such as heart valve diseases, coronary heart disease, or 
aneurysms of the ascending aorta can be surgically treated. Nevertheless, high rates of 
depression are commonly reported in 25% to 30% of patients undergoing cardiac surgery 
(Langeluddecke et al., 1989; McKhann et al., 1997; Pirraglia et al., 1999). Langeluddecke 
and coworkers (1989) found that 36% of patients had clinically significant scores on the 
Center for Epidemiological Study of Depression scale (CES-D) prior to coronary artery 
bypass graft (CABG) surgery. Similarly, McKhann and colleagues (1997) using the same 
scale (i.e., CES-D) reported that the incidence of preoperative depression in patients 
undergoing a CABG was 27%. Preoperative depression may persist after cardiac surgery in 
up to 20% of the patients (Vingerhoets, 1998) and 32% of the patients had clinically 
significant depression at least once in their postoperative period (Burg, 2003b; McKhann et 
al., 1997). More importantly, patients with postoperative depression are at higher risk of 
cardiac morbidity and fatal cardiac events (Burg, 2003a; Connerney et al., 2001; Scheier, 
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1999). Indeed, several studies reported the association between postoperative depression and 
a higher incidence of cardiovascular morbidity or mortality (Ariyo et al., 2000; Blumenthal 
et al., 2003b; Penninx et al., 2001). 
Despite several studies on the association between depression and a reduced HRV in 
patients with cardiovascular diseases, to our knowledge, this potential relationship has not 
yet been investigated in patients after cardiac surgery. Accordingly, the main aim of the 
current pilot study was to examine whether depression would be related to reduced HRV in 
patients who had undergone first-time cardiac surgery. Specifically, it was hypothesized that 
patients with depression had a reduced HRV at rest compared to those without depression 
after cardiac surgery. 
 
 
2.3 Methods 
 
Participants 
After receiving the local ethics committee’s approval, 33 patients (mean age = 60.7, 
SD = 8.1) who underwent first-time cardiac surgery were sequentially enrolled in this study 
after their written informed consent was obtained. All patients underwent cardiac surgery at a 
regional specialized hospital and were admitted for rehabilitation in a highly specialized 
hospital between November 2010 and July 2011. Patients underwent heart valve surgery (N 
= 8), coronary artery bypass graft surgery (CABG) (N = 15), and combined surgery (heart 
valve plus CABG surgery) (N = 10). Each patient had the same protocol of cardioplegia and 
a mild hypothermic cardiopulmonary bypass. Ages greater than 75, inability to read or 
understand Italian, visual or auditory impairments, use of psychotropic drugs, other life-
threatening medical illness, and prior cerebrovascular and/or neurological diseases were the 
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exclusion criteria. All patients were treated in the hospital with beta-blockers and/or 
angiotensin-converting enzyme inhibitors. Based on the presence of clinically significant 
depression (i.e., scoring greater than 16 on the Center for Epidemiological Study-Depression, 
CES-D) (Fava, 1982; Radloff, 1977), the patients were classified into one of two groups: 
with depression (N = 11) or without depression (N = 22). The descriptive statistics for each 
group are reported in Table 2.1. 
 
Psychological evaluation 
The psychological evaluation included a short clinical interview and three self-
reporting questionnaires aimed at assessing depression and anxiety symptoms. The anxiety 
and depression questionnaires were selected according to their sensitivity, specificity and 
reliability and consisted of:  
Center for Epidemiological Study-Depression (CES-D; Fava, 1982; Radloff, 1977); 
that is a 20-item, self-reporting questionnaire designed to measure the presence of common 
symptoms of depression over the previous week. It includes six components: depressed 
mood; feelings of guilt and worthlessness; feelings of helplessness and hopelessness; 
psychomotor retardation; loss of appetite; and sleep disturbance. Respondents indicate how 
often within the last week they experienced the symptoms on a four-point Likert scale and 
scores range from 0 to 60, with the higher scores indicating greater depressive symptoms. 
Scores equal or greater than 16 are indicative of clinically significant depression. Reliability 
and validity of the scale have been tested in either general and clinical populations (Radloff, 
1977), yielding very good internal consistency with an alpha of 0.85 for the general 
population and 0.90 for a psychiatric population. Moreover, construct validity was supported 
by differences between the psychiatric in- patients and the general population. 
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Table 2.1. Demographic, Biomedical, and Surgical Characteristics of Patients with 
Depression and without Depression 
Notes: Data are M (SD) of continuous and N (%) of categorical variables. CABG = coronary 
artery bypass graft; PTCA = percutaneous transluminal coronary angioplasty; HR = heart 
rate; STAI Y1, STAI Y2 = state-trait anxiety inventory form Y1 and Y2. 
 
 
Self-reported anxiety symptoms were assessed by means of the two subscales of the 
State-Trait Anxiety Inventory (STAI-Y1 and STAI-Y2; Spielberger, Gorsuch, & Lushene, 
Variable 
Group with Depression 
(N = 11) 
Group without Depression 
(N = 22) 
p 
Age (years) 62.5 (10.2) 59.8 (6.7) .36 
Education (years) 8.7 (3.8) 11.0 (3.1) .08 
Male Sex (N, %) 8 (73) 20 (91) .30 
Surgical Procedure   .90 
   CABG (N, %) 5 (46) 10 (46)  
   Heart Valve (N, %) 2 (18) 6 (27)  
   Combined (N, %) 
 
4 (36) 6 (27)  
Diabetes (N, %) 3 (27) 3 (14) .39 
Hypertension (N, %) 7 (64) 10 (46) .47 
Myocardial Infarction (N, %) 3 (27) 1 (5) .11 
Dyslipidemia (N, %) 4 (36) 11 (50) .47 
PTCA (N, %) 0 (0) 4 (18) .27 
Smoking   .48 
   Actual (N, %) 1 (9) 6 (27)  
   Past (N, %) 4 (36) 4 (18)  
   No (N, %) 6 (55) 12 (55)  
HR (bpm) 75.3 (7.4) 74.1 (9.6) .72 
STAI Y1 39.9 (6.3) 31.4 (8.7) .007 
STAI Y2 37.4 (7.0) 31.3 (6.6) .02 
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1970; Spielberger, 1996). The STAI-Y form 1 and 2 is a 40-item questionnaire rated by 
patients and divided into two equal and separate parts; the first part measures the state 
anxiety presented by the subject in the exact moment of compilation (STAI-Y1) while the 
second part concerns the usual tendency for the subject to be anxious (STAI-Y2). Each item 
is rated from 1 to 4 depending on the intensity of the symptoms. This scale has been 
frequently used in psychiatric research and in the evaluation of emotional modifications in a 
surgical context. 
 
Physiological recordings 
Blood volume pulse (BVP) was recorded by means of a photoplethysmographic 
detection sensor attached to the left ring finger, and heart rate (HR) was obtained. 
Photoplethysmography is a simple, non-invasive technique used to detect blood volume 
changes. As electrical and mechanical activities of heart are coupled, photoplethysmography 
can be used for determining the normal-to-normal (NN) intervals (or inter-beat intervals), 
and HR corresponds to the reciprocal of the N-to-N intervals. The HR signal derived from 
the analog output of the BVP amplifier was processed via a 12-bit analog-to-digital 
converter, with a sampling rate of 256 Hz and stored sequentially for spectral analysis. All 
HR data were exported in Kubios-HRV 2.0 software (University of Kuopio, Kuopio, 
Finland) and artifacts were corrected with a piecewise cubic spline interpolation method that 
generates missing or corrupted values into the normal-to-normal (NN) intervals. Time 
domain indexes are measures of the total variation of heart rate and were calculated as 
follows:  
 
1) Standard deviation of NN intervals (SDNN) expressed in ms; 
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2) Root mean square successive difference of N-to-N intervals (rMSSD) expressed 
in ms. 
Fast Fourier spectral analysis was then applied on the N-N series to compute 
frequency domain indexes, that, in turn, were calculated as follows: 
1) Very low frequency (VLF) power (0 to 0.04 Hz) in ms2. 
2) Low frequency (LF) power (0.04 to 0,15 Hz) in ms2. 
3) High frequency (HF) power (0.15 to 0.40 Hz) in ms2. 
All frequency domain indexes were logarithmically transformed to normalize their 
distribution. In addition, the LF/HF ratio was computed as the ratio of LF(ms2)/HF(ms2) as a 
measure of sympathovagal balance (Malliani, Lombardi, & Pagani, 1994; Task Force, 1996). 
 
Procedure 
After their admission for rehabilitation, all patients underwent the assessment 
protocol, about two weeks (range 10-14 days) after cardiac surgery. The assessment protocol 
consisted of psychological evaluation aimed at assessing depression and anxiety symptoms, 
and a physiological recording in resting conditions. All self-reporting questionnaires 
assessing depression and anxiety were administered individually by a trained psychologist 
blind to the physiological assessment. After the psychological evaluation HR was recorded at 
rest over a four-minute period for each patient. NN intervals were then used to compute 
HRV. Given that photoplethysmography is subject to movement artifacts, each patient was 
instructed to stay still and not to talk during the HRV recordings. All physiological 
recordings were taken with the patients seated on a semireclined armchair after adaptation to 
the laboratory. In order to avoid possible confounder effect of circadian variations on cardiac 
activity, each physiological measurement was taken in a quiet and isolated laboratory during 
morning hours (from 10:00 to 12:00). 
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Statistical analysis 
Analysis of variance (ANOVA), with Group (patients with depression, patients 
without depression) as the between-subjects factor, was used to compare age, education, 
STAI Y1 and Y2 scores, and HR, in the two groups. Fisher’s exact test or chi-square 
analyses were conducted to compare the two groups in terms of demographic, biomedical, 
and behavioral variables.  
These preliminary analyses showed greater state and trait anxiety scores on STAI Y1 
and Y2, respectively, in patients with depression than those without depression (see Results). 
Given that anxiety may influence HRV (Watkins, Grossman, Krishnan, & Sherwood, 1998) 
and is strongly related to depressive symptoms (Gorman, 1997), STAI Y1 and STAI Y2 
scores were used as covariates in the subsequent analyses to control for state and trait 
anxiety. Separate analyses of covariance (ANCOVAs), with Group (patients with depression, 
patients without depression) as the between-subjects factor, and STAI Y1 and Y2 scores as 
covariates, were conducted on SDNN, rMSSD (i.e., time domain measures of HRV) as well 
as logVLF, logLF, logHF, and LF/HF (i.e., frequency domain measures of HRV). Partial eta-
squared (ηp
2) was reported as a measure of the effect size. The ηp
2 values considered to 
represent small, medium, and large effects are .01, .06, and .14, respectively (Cohen, 1988). 
To evaluate the relationship between CES-D scores and each HRV parameter, partial 
correlations were calculated, adjusting for possible effects of state and trait anxiety (i.e., 
scores on STAI Y1 and Y2, respectively). A p value of < .05 was considered statistically 
significant. All statistical analyses were performed using STATISTICA 6.1 (StatSoft Inc., 
Tulsa, OK, USA). 
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2.4 Results 
Characteristics of Patients with Depression and without Depression 
Fisher’s exact test or chi-square analysis revealed no group differences for gender (p 
= .30), surgical procedures (p = .90), hypertension (p = .47), diabetes (p = .39), dyslipidemia 
(p = .47), previous myocardial infarction (p = .11), previous percutaneous transluminal 
coronary angioplasty (p = .27), and smoking (p = .48). Similarly, ANOVA yielded no group 
differences for age (F(1, 31) = 0.86, p = .36, ηp
2 = .03), or education (F(1, 31) = 3.27, p = .08, ηp
2 
= .10), HR (F(1, 31) = 0.13, p = .72, ηp
2 = .004). In contrast, ANOVA showed group 
differences for STAI Y1 (F(1, 31) = 8.29, p = .007, ηp
2 = .21), and STAI Y2 (F(1, 31) = 5.88, p = 
.02, ηp
2 = .16). STAI Y1 and Y2 scores were significantly greater in patients with depression 
than those without depression.  
 
Relationship between Depression and Heart Rate Variability 
ANCOVA yielded a significant main effect for Group on both time domain 
measures, i.e., SDNN (F(1, 29) = 6.08, p = .02, ηp
2 = .17), and rMSSD (F(1, 29) = 13.48, p = 
.001, ηp
2 = .32). SDNN and rMSSD values were significantly lower in patients with 
depression than those without depression. Also, ANCOVA yielded a significant main effect 
for Group on logHF (F(1, 29) = 12.09, p = .002, ηp
2 = .29), and LF/HF ratio (F(1, 29) = 8.25, p = 
.008, ηp
2 = .22). LogHF values were significantly lower in patients with depression that those 
without depression and vice versa for LF/HF ratio. In contrast, no significant main effects for 
Group were found on logVLF (F(1, 29) = 2.77, p = .11, ηp
2 = .09), and logLF (F(1, 29) = 0.06, p 
= .81, ηp
2 = .002). All means (SD) of each HRV parameter are reported in Table 2.2. 
Partial correlation analyses, adjusting for STAI Y1 and Y2 scores, revealed 
significant inverse associations between CES-D scores and SDNN (r = -.49, p = .005), 
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rMSSD (r = -.58, p = .001), and logHF (r = -.41, p = .02), whereas CES-D scores were 
unrelated to logVLF (r = .30, p = .10), logLF (r = -.04, p = .82), and LF/HF (r = .31, p = .09). 
 
 
Table 2.2. Relationship between Depression and Heart Rate Variability Parameters 
Notes: Results are reported as M (SD). HRV = heart rate variability; SDNN = standard 
deviation of all NN intervals in ms; rMSSD = the square root of the mean of the sum of the 
squares of differences between adjacent NN intervals in ms; logVLF = logarithm 
transformation of very-low-frequency power (0.0033 to 0.04 Hz) in ms²; logLF = logarithm 
transformation of low-frequency power (0.04 to 0.15 Hz) in ms²; logHF = logarithm 
transformation of high-frequency power (0.15 to 0.40 Hz) in ms²; LF/HF = the Ratio LF 
[ms²]/HF [ms²]. 
 
 
2.5 Discussion 
The current study examined the association between depression and HRV in patients 
who underwent cardiac surgery. Patients with depression showed a more reduced HRV, as 
measured by SDNN, than those without depression. Also, compared to non-depressed 
patients, depressed patients were characterized by lower rMSSD and HF power (i.e., time 
HRV Index 
Group with 
Depression 
(N = 11) 
Group without 
Depression 
(N = 22) 
 
p ηp
2 
SDNN (ms) 17.5 (9.8) 36.7 (25.2) .02 .17 
rMSSD (ms) 8.1 (3.2) 43.3 (32.9) .001 .32 
logVLF (ms²) 
 
2.0 (0.6) 1.7 (0.7) .11 .09 
logLF (ms²) 1.6 (0.5) 1.7 (0.6) .81 .002 
logHF (ms²) 1.2 (0.4) 2.2 (0.7) .002 .29 
LF/HF 3.6 (4.2) 0.9 (1.5) .008 .22 
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and frequency domain HRV measures, respectively), indicative of reduced cardiac vagal 
modulation. A sympathovagal imbalance, as indexed by the increased LF/HF ratio, was also 
observed in patients with depression compared to those without depression. Moreover, 
correlation analyses yielded that CES-D scores were inversely related to SDNN, rMSSD, and 
HF power. More importantly, the associations between depression and time and frequency 
HRV domains were independent of state or trait anxiety, as assessed by STAI Y1 and Y2. In 
contrast, CES-D scores were unrelated to VLF and LF powers, that reflect both sympathetic 
and parasympathetic activities, and LF/HF ratio, that reflects also a sympathetic influence on 
the heart (Malliani et al., 1994; Task Force, 1996). 
These novel findings add to the literature on physiological mechanisms underlying 
the association between depression and cardiovascular disease by showing that a depression-
reduced HRV relationship extends to patients after cardiac surgery. These preliminary 
findings complement a large body of studies that have documented reduced HRV in 
depressed individuals with cardiovascular diseases (Carney et al., 2002) as well as after a 
myocardial infarction (Carney et al., 2001; Stein et al., 2000). 
Although it is well-established that increased sympathetic and/or reduced 
parasympathetic cardiac control can represent the physiological mechanisms linking 
depression to cardiovascular diseases, the relative contribution of the sympathetic and 
parasympathetic nervous systems to depression as a risk factor for cardiovascular diseases is 
still debated (Carney et al., 2001; Carney et al., 2005). The current pilot study provides the 
evidence for the relationship between depression and reduced vagal cardiac modulation 
rather than increased sympathetic cardiac modulation. Indeed, a selective association was 
found between CES-D scores and reduced rMSSD and HF power, that, in turn, are 
considered to be largely influenced by parasympathetic activity of the heart (Taylor et al., 
1998). In contrast, VLF and LF powers, that mostly reflect sympathetic and parasympathetic 
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effects on the heart, were unrelated to CES-D scores. Therefore, our findings suggest that 
postoperative depression is more likely to be associated with reduced vagal rather than 
excessive sympathetic modulation of the heart. 
Along with depression, anxiety has been frequently linked to reduced HRV. 
Specifically, low HRV has been reported in patients with high levels of anxiety after a 
myocardial infarction (Martens, Nyklícek, Szabó, & Kupper, 2008; Watkins, Blumenthal, & 
Carney, 2002). Therefore, it is noteworthy that our pilot study showed an association 
between depression and reduced HRV, even after controlling for anxiety as measured by 
STAI Y1 and Y2. 
It is important to consider the clinical benefits of the current findings. Several lines of 
evidence indicate that postoperative depression represents a relevant and independent risk 
factor for adverse patient outcomes after cardiac surgery (Blumenthal et al., 2003; Connerney 
et al., 2001; Scheier, 1999). Specifically, Scheier (1999) observed a two-fold increase in the 
odds of having a cardiac event within six months after surgery in patients with depressive 
symptoms. Moreover, Connerney and coworkers (2001) reported that a major depressive 
disorder was an independent predictor of cardiac events in the 12 months after a CABG, even 
after controlling for other biomedical risk factors. Blumenthal and colleagues (2003b) 
showed that depressed patients after cardiac surgery with persistent (i.e., before as well as six 
months after a CABG) mild or moderate to severe depression had more than twice the risk of 
cardiac death compared to patients without depression. Our findings suggest that reduced 
HRV, especially a reduced vagal control, is a potential mechanism underlying the 
relationship between postoperative depression and subsequent cardiac events or mortality 
after surgery. 
The current findings should be interpreted in light of a number of possible 
methodological limitations. First, this study used a relatively small sample size and, 
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therefore, should be considered as a pilot study. Nonetheless, the effect size, which indicates 
the proportion of the variance in the dependent variable that is related to the independent 
variable(s), showed a large main effect for the group on SDNN, rMSSD and log HF (ηp
2 > 
.17). Second, all patients were treated in a hospital with beta-blocker and/or angiotensin-
converting enzyme inhibitor medication, that, in turn, influenced cardiovascular physiology 
and, therefore, blood pressure, HR, and HRV values. Nevertheless, the pharmacological 
treatment was part of these cardiac patients’ standard clinical care in this post-surgical 
context and was the same between individuals with depression and those without depression. 
Third, the current pilot study did not take into account respiration rate and respiratory sinus 
arrhythmia, even though HRV indexes may be confounded and exaggerated by respiration 
without reflecting completely the influence of vagal regulation on the HR (Soares, Moreno, 
Cravo, & Nóbrega, 2005). Fourth, we employed photoplethysmography, an easier-to-use 
technique than electrocardiography, that, in turn, is the gold-standard method to measure HR 
and to determine HRV. Nonetheless, several studies have reported that 
photoplethysmographic variability highly correlates with a HRV extracted from an 
electrocardiogram (Association American Psychiatric, 1994; Demirel, Akkaya, Oflaz, Tükek, 
& Erk, 2002). Finally, we did not conduct follow-up evaluations and, therefore, we do not 
know whether the current results can predict long-term clinical outcomes in patients who 
underwent cardiac surgery. Clearly, future research is warranted to replicate and extend the 
present preliminary findings by conducting short- and long-term clinical follow-ups. 
In conclusion, the current study investigate the relationship between depression and 
time and frequency domain measures of HRV in patients who underwent cardiac surgery. 
HRV indexes, that are known to be associated with cardiac morbidity and mortality, were 
significantly lower in patients with depression than those without depression. Moreover, our 
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findings suggest that depression may be selectively related to impaired parasympathetic 
activity as revealed by reduced rMSSD and HF power.  
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CHAPTER 3 
 
The mediating role of emotion regulation on the relationship between depression and 
reduced heart rate variability 2 
 
 
3.1 Depression and emotion regulation 
Depression is progressively being conceptualized as a disorder of emotion (Gross & 
Muñoz, 1995). In fact, the core symptoms of depression disorder include persistent and 
excessive negative mood and emotions and loss of interest or pleasure in daily activities, 
suggesting that impaired regulation of emotion may play an important role in their 
development or maintenance (Campbell-Sills, Barlow, Brown, & Hofmann, 2006b).  
Emotions mirror the individual perception of relevant environmental stimuli, 
including not only the perception of challenges and threats, but also the perceived ability to 
deal with them (Frijda, 1988). Affective system, including emotion regulation processes, is 
efficient when it promotes flexible adaptation to changing environmental demands.  
More importantly, both altered emotion regulation as a trait and altered emotion 
regulation in response to stressors have been proposed as pathophysiological mechanisms 
involved in the development of depression disorders. For example, many studies reported 
that higher HRV levels are associated with the ability to produce emotional responses 
appropriate to the context, specifically, during emotion modulated startle responses, fear-
potentiated startle responses, and phasic heart rate responses, in addition to behavioral and 
                                                 
2 Results from this study have been partially published in: Patron, E., Messerotti Benvenuti, S., Favretto, 
G., Gasparotto, R., & Palomba, D. (2014). Depression and reduced heart rate variability after cardiac 
surgery: The mediating role of emotion regulation. Autonomic Neuroscience: Basic and Clinical, 180:53-
58. 
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self reported emotional responses (Melzig, Weike, Hamm, & Thayer, 2009; Ruiz-Padial, 
Sollers, Vila, & Thayer, 2003; Julian F Thayer & Brosschot, 2005). Thus, emotion regulation 
strategies are involved in the process of selection of the optimal response, from a large 
behavioral repertoire. In addition, emotion regulation strategies help the inhibition of 
responses that are dysfunctional. In this context, HRV may be considered a useful resource 
that modulate and support this regulatory function (Julian F Thayer & Lane, 2009). Recently, 
Butler and coworkers (2006) found that, during situations requiring emotional regulation, 
phasic increases of HRV can facilitate effective emotional regulation processes and are 
associated with flexible and efficient use of emotional regulation strategies. 
Literature has mainly focused on two strategies of emotion regulation, that is, 
cognitive reappraisal and suppression of emotion-expressive behavior (Gross, 2002). The 
former, cognitive reappraisal, which comes early in the emotion-generative process, is 
described as construing a potentially emotion-provoking situation in a neutral, nonemotional 
one and therefore is a type of cognitive change. The latter, suppression of emotion-
expressive behavior, which appears later in the emotion-generative process, is defined as 
inhibiting ongoing emotion-expressive behavior and therefore is a type of response 
modulation. There is evidence that whereas cognitive reappraisal is effective for reducing 
both expression and experience of emotion without side effects on memory or physiology, 
emotion suppression reduces emotion expression, but fails to reduce the feeling of emotion 
and is associated with memory and physiological responding impairment (Gross & 
Levenson, 1997; Gross, 1998). It has been shown, indeed, that cognitive reappraisal is 
associated with greater positive emotion experience and expression, and reduced negative 
emotion experience and expression. The habitual use of emotion suppression strategy, by 
contrast, has been related to a wide range of negative outcomes, including, higher levels of 
psychopathology, negative mood, worse social adjustment, and reduced well-being (Gross & 
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John, 2003; Moore, Zoellner, & Mollenholt, 2008). More interestingly, there is consistent 
evidence that suppression of emotion-expressive behavior, but not cognitive reappraisal, 
increases sympathetic cardiovascular activity, as indexed by decreases in finger temperature, 
finger pulse, and pulse transit times to the finger and ear (Gross & Levenson, 1997; Harris, 
2001), and electrodermal system activity (Gross, 1998).  
Therefore, depression disorder is characterized by altered emotion regulation 
strategies, which, in turn, may increase cardiac risk in these patients.  
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3.2 Abstract 
Background: Heart rate variability (HRV), as an index of autonomic nervous system (ANS) 
functioning, is reduced by depression after cardiac surgery, but the underlying mechanisms 
of this relationship are poorly understood. Poor emotion regulation as a core symptom of 
depression has also been associated with altered ANS functioning. The present study aimed 
to examine whether emotion dysregulation could be a mediator of the depression-reduced 
HRV relationship observed after cardiac surgery. 
Methods: Self-reported emotion regulation and four-minute HRV were measured in 25 
depressed and 43 nondepressed patients after cardiac surgery. Mediation analysis was 
conducted to evaluate emotion regulation as a mediator of the depression-reduced HRV 
relationship. 
Results: Compared to nondepressed patients, those with depression showed lower standard 
deviation of normal-to-normal (NN) intervals (p < .05), root mean square successive 
difference of NN intervals (p < .004), and number of interval differences of successive NN 
intervals greater than 50 ms (NN50) (p < .05). Increased low frequency (LF) in normalized 
units (n.u.) and reduced high frequency (HF) n.u. were also found in depressed compared to 
nondepressed patients (p’s < .01). Mediation analysis revealed that suppression of emotion-
expressive behavior partially mediated the effect of depression on LF n.u. and HF n.u. 
Conclusions: Results confirmed previous findings showing that depression is associated with 
reduced HRV, especially a reduced vagal control and a sympathovagal imbalance, after 
cardiac surgery. This study also provides preliminary evidence that increased trait levels of 
suppression of emotion-expressive behavior may mediate the depression-related 
sympathovagal imbalance after cardiac surgery. 
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3.3 Introduction 
There is consistent evidence that depression is an important and independent risk 
factor for the onset, the adverse course and outcomes in patients with coronary heart disease 
(CHD) (Carney et al., 2005; Wulsin & Singal, 2003). Specifically, it has been reported that 
depressive symptoms are associated with roughly a 60% greater likelihood of exhibiting 
CHD (Wulsin & Singal, 2003). Moreover, patients with depression are at greater risk to have 
a major cardiac event within 12 months of the diagnosis of CHD (Carney et al., 1988), and 
they are significantly more likely to die in the years following the diagnosis (Barefoot & 
Schroll, 1996). It has also been documented that depression is a risk factor for cardiac 
morbidity and/or mortality in patients who had undergone cardiac surgery (Blumenthal et al., 
2003; Lespérance & Frasure-Smith, 2000). 
It has been recently shown that depression is associated with reduced heart rate 
variability (HRV), a measure that reflects both sympathetic and parasympathetic activity 
(Task Force, 1996), in patients who underwent cardiac surgery (Patron et al., 2012). As 
mentioned above (see Chapter 2) patients with depression had significantly lower HRV, 
especially a reduced cardiac vagal control, at discharge from the hospital compared to 
nondepressed patients. This depression-related cardiac autonomic dysfunction is likely to 
increase the risk for adverse clinical outcomes in patients after surgery because it may lead to 
direct electrical instability of myocytes and increase the occurrence of ischemic events 
(Soares et al., 2005). Reduced HRV has been therefore suggested as one of the 
pathophysiological mechanisms underlying the strong role of postoperative depression as a 
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risk factor for subsequent cardiac events and/or mortality that has been reported in patients 
after cardiac surgery (Blumenthal et al., 2003; Lespérance & Frasure-Smith, 2000). 
In recent years, depression has been directly associated with poor emotion regulation 
(Gross & Muñoz, 1995), especially excessive emotion suppression(Ehring, Tuschen-Caffier, 
Schnülle, Fischer, & Gross, 2010), and type D personality, that, in turn, have been linked to 
increased risk of cardiac morbidity and/or mortality (Mols, Martens, & Denollet, 2010). 
However, research has yet to investigate the relationship between depression and emotion 
regulation strategies in patients after cardiac surgery. More importantly, whether emotion 
regulation strategies could mediate the association between depression and ANS 
abnormalities after cardiac surgery has yet to be examined. In light of these considerations, 
the primary purpose of this study was to formally evaluate whether emotion dysregulation 
would mediate the effects of depression on HRV in patients who underwent cardiac surgery. 
Specifically, emotion suppression strategy was expected to mediate the effects of depression 
on HRV, especially on HRV indices reflecting increased sympathovagal imbalance. It was 
also hypothesized that, compared to nondepressed patients, those with depression would 
have significant lower HRV, greater emotion suppression and/or reduced cognitive 
reappraisal postoperatively. 
 
 
3.4. Methods 
Participants 
After receiving the local ethics committee's approval, 68 patients (mean age = 58.5, 
SD = 8.5) who had undergone first-time cardiac surgery were enrolled in this study after their 
written informed consent was obtained. Given the difficulty of recruiting patients in the early 
postoperative period after cardiac surgery and in order to increase the sample size, 
 87 
maintaining the homogeneity of the sample, 33 patients from a previous report (see Patron et 
al., 2012) were included in the present study. All patients had undergone cardiac surgery at 
the same regional hospital and were admitted for rehabilitation in the same specialized 
hospital between November 2010 and December 2012. The same surgical techniques, 
surgical team and α-stat moderately hypothermic cardiopulmonary bypass strategy were used 
for each patient. Ages greater than 75, use of psychotropic drugs, other life-threatening 
medical illness, and prior cerebrovascular and/or neurological diseases were the exclusion 
criteria. Patients were treated in the hospital with beta-blockers, angiotensin-converting 
enzyme inhibitors, anticoagulants, and/or antiarrhythmics. Based on the presence of 
clinically significant depression [i.e., scoring equal or greater than 16 on the Center for 
Epidemiological Studies of Depression scale (CES-D)] (Fava, 1982; Radloff, 1977), the 
patients were classified into one of two groups: with depression (N = 43) or without 
depression (N = 25). The descriptive statistics for each group are reported in Table 3.1. 
 
Psychological evaluation 
The psychological evaluation included a short clinical interview and two self-
reporting questionnaires aimed at assessing depression and emotion regulation. The 
questionnaire to assess depression consisted of CES-D (Fava, 1982; Radloff, 1977), and 
Emotion regulation was assessed using the Emotion Regulation Questionnaire (ERQ) 
(Balzarotti, John, & Gross, 2010; Gross & John, 2003), which is composed by a 10-item 
scale that measures individual differences in habitual use of the emotion regulation strategies 
of cognitive reappraisal (i.e., ERQ-Reappraisal) and suppression of emotion-expressive 
behavior (i.e., ERQ-Suppression). The questionnaire includes six items for cognitive 
reappraisal and four items for emotion suppression. Scores range from 6 to 42 for reappraisal 
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scale and from 4 to 28 for suppression scale, with higher scores indicating higher reappraisal 
and suppression, respectively. 
Table 3.1 Demographic, Biomedical, Surgical, and Emotion Regulation 
Characteristics by Depression Status 
Notes: Data are M (SD) of continuous and percentage (%) of categorical variables. ACE = 
angiotensin-converting enzyme; PTCA = percutaneous transluminal coronary angioplasty; 
HR = heart rate; CABG = coronary artery bypass graft; ERQ = emotion regulation 
questionnaire. 
 
 
Variable 
Depressed 
(N = 25) 
Not Depressed 
(N = 43) 
p 
Age (years) 59.3 (9.5) 58.0 (8.0) .55 
Male Gender (%) 80 86 .51 
Beta-blockers (%) 80 88 .35 
ACE inhibitors (%) 56 54 .84 
Anticoaugulant (%) 76 88 .18 
Antiarrhythmics (%) 36 12 .02 
Diabetes (%) 12 14 .99 
Hypertension (%) 56 44 .35 
Dyslipidemia (%) 48 44 .76 
Myocardial Infarction (%) 12 9 .70 
PTCA (%) 12 16 .74 
Smoking   .43 
   Actual (%) 12 18  
   Past (%) 48 33  
   No (%) 40 49  
HR (bpm) 74.8 (10.9) 73.0 (10.5) .50 
Surgical Procedure   .06 
   CABG (%) 44 37  
   Heart Valve Replacement (%) 20 47  
   Combined (%) 36 16  
ERQ-Reappraisal 29.5 (6.2) 29.3 (7.2) .93 
ERQ-Suppression 17.0 (4.6) 13.8 (6.2) .03 
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Physiological recordings 
Physiological measures were recorded in a standardized fashion using a 
computerized recording system (ProComp Infiniti, Thought Technology;Montreal, Canada). 
Photoplethysmography and electrocardiogram (ECG) were used to measure heart rate (HR) 
and HRV in 33 and 35 patients, respectively. A detailed description of 
photoplethysmographic method has been previously reported (see Chapter 2). Given that 
electrical and mechanical activities of the heart are coupled, there is large and consistent 
evidence that photoplethysmographic variability highly correlates with HRV extracted from 
an ECG (Lu et al., 2008; Selvaraj et al., 2008); photoplethysmography and ECG, therefore, 
can be used reliably and interchangeably to assess HRV. ECG signal was obtained from 
three disposable Ag⁄AgCl electrodes that were positioned on the patient’s chest in a modified 
lead II configuration. Each ECG signal was amplified, band-pass filtered (1–100 Hz), and 
sampled at 256 Hz. A digital trigger detecting R-waves was applied to ECG signal to obtain 
inter-beat intervals. All ECG data were visually inspected and artifacts were corrected with a 
piecewise cubic spline interpolation method that generates missing or corrupted values into 
the normal-to-normal (NN) intervals (or inter-beat intervals). Then, time domain and 
frequency domain indices of HRV were calculated by Kubios HRV Analysis Software 2.0 
(Matlab, Kuopio, Finland). Time domain indices, which are measures of the total variation of 
heart rate, were calculated as follows: 
1) Standard deviation of NN intervals (SDNN) expressed in ms. 
2) Root mean square successive difference of NN intervals (rMSSD) expressed in ms. 
3) Number of interval differences of successive NN intervals greater than 50 ms in the 
entire recording (NN50), expressed in ms. 
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Among time domain HRV indices, SDNN, rMSSD, and NN50 were calculated as the 
most appropriate HRV measures for short-term recordings (Task Force, 1996) and as the 
most frequently used measures in literature (Kleiger et al., 1987). 
Given that the correlation between time and frequency domain HRV indices is less 
consistent for short-term HRV recordings compared to those recorded over longer periods 
(i.e., traditionally 24 h) (Task Force, 1996), fast Fourier spectral analysis was then applied on 
the NN series to compute frequency domain indices, which, in turn, were calculated as 
follows: 
1) Very low frequency (VLF) power (0 to 0.04 Hz) in ms2. 
2) Low frequency (LF) power (0.04 to 0.15 Hz) in ms2. 
3) High frequency (HF) power (0.15 to 0.40 Hz) in ms2. 
All frequency domain indices were logarithmically transformed to normalize their 
distribution. In addition, LF and HF components were expressed in normalized units (n.u.), 
which represent the relative value of each power component in proportion to the total power 
minus the VLF component and range from 0 to 100%. The relation between LF and HF 
components in n.u. emphasizes the controlled and balanced behavior of the two branches of 
the ANS, thus reflecting more accurately the sympathovagal balance (Malliani et al., 1994; 
Task Force, 1996). Moreover, the normalization has the advantage to minimize the effect of 
the changes in total power on the values of LF and HF components (Task Force, 1996). 
 
Procedure 
All patients completed the assessment protocol after their admission for 
rehabilitation, approximately two weeks (range 10-14 days) after cardiac surgery. The 
assessment protocol consisted of affective evaluation to assess depression and the habitual 
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use of emotion regulation strategies, and physiological recording to assess HRV in resting 
condition. All self-reporting questionnaires were administered individually by a trained 
psychologist blind to the physiological assessment. After the affective evaluation, ECG was 
recorded at rest over 4-min period for each patient. A 4-min period of ECG recording has 
been previously shown to be an adequate procedure to measure short-term time (i.e., SDNN, 
rMSSD, and NN50) and frequency (i.e., LF, HF, and VLF) domain HRV indices examined 
in the present study (Task Force, 1996). In order to avoid movement artifacts, each patient 
was instructed to stay still and not to talk during the ECG recordings. All ECG recordings 
were taken with the patients seated on a semireclined armchair after adaptation to the 
laboratory. Each physiological measurement was taken in a quiet and isolated laboratory 
during morning hours (from 10:00 to 12:00), in order to avoid possible confounder effect of 
circadian variations on cardiac activity. 
 
Statistical analysis 
As our first step, Fisher's exact test or chi-square analyses were conducted to 
compare the two groups in terms of gender, cardiac drugs, biomedical variables, smoking 
habits, and types of cardiac surgery. Then, separate analyses of variance (ANOVAs), with 
Group (patients with depression, patients without depression) as the between-subjects factor, 
were used to compare age, emotion regulation strategies, HR, and time and frequency 
domain indices of HRV in the two groups. 
As our final step, we chose the analysis of covariance (ANCOVA) approach to assess 
mediation given that it is recommended for experimental designs where the sample size is 
low (Hoyle & Robinson, 2004). ANOVA and ANCOVA produce identical results to and are 
conceptually equivalent to regression analyses (Cohen, Cohen, West, & Aiken, 2003). 
Mediation analyses were used to examine whether suppression of emotion-expressive 
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behavior mediated postoperative cardiac autonomic dysfunctions, indicated by lower values 
of HRV indices in patients with depression compared to those without depression. Mediation 
is established when four criteria are satisfied. First, the independent variable must affect the 
dependent variable. The main effect of depression on HRV indices, that is, SDNN, rMSSD, 
NN50, LF n.u, and HF n.u. satisfied this criterion (see Results). Second, the independent 
variable must affect the mediator. This was established by the significant effect of depression 
on ERQ-Suppression scores (see Results). Third, the mediator must affect the dependent 
variable, and, fourth, the effect of the independent variable on the dependent variable must 
be reduced in the presence of the mediator. The amount of change of partial eta-squared 
(η2p), a measure of the effect size, associated with depression when emotion suppression is 
used as covariate reflects the importance of emotion suppression in explaining the effects of 
depression on HRV indices. Thus, the greater the change in the effect size for the depression 
condition factor, when ERQ-Suppression scores are used as a covariate, the greater the 
importance of emotion suppression in explaining these effects. Separate ANCOVAs, with 
ERQ-Suppression as the covariate, and depression as a between-subjects factor were 
conducted to simultaneously test whether the third and the fourth criteria were met. 
The η2p values considered to represent small, medium, and large effects are .01, .06, 
and .14, respectively (Cohen, 1977). All statistical analyses were performed using 
STATISTICA 6.1 (StatSoft Inc., Tulsa, OK, USA). A p value of < .05 was considered 
statistically significant. 
 
 
 
 
 
 93 
3.5 Results 
 
Characteristics of patients with depression and without depression 
Fisher's exact test or chi-square analysis revealed no group differences for gender 
χ2(1) = 0.43, p = .51, beta-blockers χ2(1) = 0.88, p = .35, angiotensin-converting enzyme 
inhibitors χ2(1) = 0.04, p = .84, anticoagulants χ2(1) = 1.79, p = .18, diabetes (p = .99), 
hypertension χ2(1) = 0.88, p = .35, dyslipidemia χ2(1) = 0.09, p = .76, previous myocardial 
infarction (p = .70), previous percutaneous transluminal coronary angioplasty (p =.74), 
smoking χ2(2) = 1.68, p = .43, and surgical procedures χ2(2) = 5.82, p = .06. A significant 
group difference for antiarrhythmics χ2(1) = 5.74, p < .03 was noted. Specifically, 36% of 
patients with depression were administered antiarrhythmics compared to 12% of 
nondepressed individuals. Similarly, separate ANOVAs yielded no group differences for age 
(F(1,66) = 0.36, p =.55, η2p = .01), and HR (F(1,66) = 0.45, p =.50, η
2
p = .01).  
 
Depression, emotion regulation, and HRV 
As far as emotion regulation strategies are concerned, while ERQ-Reappraisal scores 
did not differ between groups (F(1,66) = 0.01, p =.93, η2p = .00), ANOVA yielded significant 
group differences for ERQ-Suppression scores (F(1,66) = 5.10, p < .04, η2p = .07). 
Specifically, ERQ-Suppression scores were significantly greater in patients with depression 
than those without depression (see Table 3.1). 
Separate ANOVAs yielded a significant main effect for Group on each time domain 
measure, i.e., SDNN (F(1,66) = 4.54, p < .05, η2p = .06), rMSSD (F(1,66) = 9.56, p < .004, 
η2p = .13), and NN50 (F(1,66) = 4.12, p < .05, η
2
p = .06). SDNN, rMSSD, and NN50 values 
were significantly lower in patients with depression than those without depression. Also, 
ANOVAs yielded a significant main effect for Group on LF n.u. (F(1,66) = 7.36, p < .01, η2p 
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= .10), and HF n.u. (F(1,66) = 7.36, p < .01, η2p = .10)
3. LF n.u. values were significantly 
greater in patients with depression than those without depression and vice versa for HF n.u., 
as shown in Figure 1. In contrast, no significant main effects for Group were found on 
logVLF (F(1,66) = 0.24, p = .62, η2p = .00), logLF (F(1,66) = 0.01, p = .91, η
2
p = .00), and 
logHF (F(1,66) = 2.58, p = .11, η2p = .04). All means (SD) of each HRV index are reported 
in Table 3.2. 
 
Emotion suppression as a mediator of sympathovagal imbalance 
The original analyses indicated that 6% of the variance in SDNN, 13% in rMSSD, 
6% in NN50, 10% in LF n.u. and 10% HF n.u. could be attributed to depression; these 
correspond to medium-size (i.e., rMSSD, LF n.u., and HF n.u.) or a small-to-medium (i.e., 
SDNN, and NN50) effect for depression on HRV indices. The effect of depression survived 
the covariate adjustment for emotion suppression on SDNN (F(1,65) = 5.31, p < .03, η2p = 
.08, Δη2p = .02), rMSSD (F(1,65) = 8.08, p < .007, η
2
p = .11, Δη
2
p = -.02), and NN50 
(F(1,65) = 4.71, p < .04, η2p = .07, Δη
2
p = .01). In contrast, the covariate adjustment for 
emotion suppression partially mediated the effect of depression on LF n.u (F(1,65) = 4.65, p 
< .04, η2p = .07, Δη
2
p = -.03) and HF n.u. (F(1,65) = 4.65, p < .04, η
2
p = .07, Δη
2
p = -.03). 
This latter mediation was partial as a small-to-medium effect size remained. 
 
 
 
 
 
                                                 
3
 All significant effects on each HRV index survived the covariate adjustment for 
antiarrhythmics (p’s < .05) 
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Table 3.2 HRV in Patients With and Without Depression 
Notes: Results are reported as M (SD). HRV = heart rate variability; SDNN = standard 
deviation of all NN intervals in ms; rMSSD = the square root of the mean of the sum of the 
squares of differences between adjacent NN intervals in ms; NN50 = number of pairs of 
adjacent NN intervals differing by more than 50 ms in the entire recording; logVLF = 
logarithm transformation of very-low-frequency power; logLF = logarithm transformation of 
low-frequency power; logHF = logarithm transformation of high-frequency power; LF n.u. = 
low frequency power expressed in normalized units [LF/(total power-VLF)*100]; HF n.u. = 
high frequency power expressed in normalized units [HF/(total power-VLF)*100]. 
 
 
 
 
Variable 
Depressed 
(N = 25) 
Not Depressed 
(N = 43) 
p ηp
2 
Time domain indices     
   SDNN (ms) 20.4 (16.9) 33.8 (28.8) .04 .06 
   rMSSD (ms) 14.8 (15.8) 32.9 (26.7) .003 .13 
   NN50 count 3.5 (14.3) 23.4 (47.6) .05 .06 
Frequency domain indices     
   logVLF (ms²) 2.0 (0.7) 1.9 (1.0) .62 .00 
   logLF (ms²) 1.7 (0.8) 1.6 (1.0) .91 .00 
   logHF (ms²) 1.5 (0.7) 1.8 (0.9) .11 .04 
   LF n.u. (%) 55.3 (20.3) 40.1 (23.3) .009 .10 
   HF n.u. (%) 44.7 (20.3) 59.9 (23.3) .009 .10 
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3.6 Discussion 
The current study examined the association between depression, emotion regulation 
strategies and HRV in patients who underwent first time cardiac surgery. The finding showed 
that, as expected, compared to nondepressed patients, those with postoperative depression 
were characterized by lower SDNN, rMSSD, and NN50 indices, indicative of reduced HRV 
and cardiac vagal control. A more pronounced sympathovagal imbalance, as reflected by 
increased LF n.u. and reduced HF n.u., was also observed in patients with depression as 
compared to those without depression after cardiac surgery. As far as the relationship 
between depression and emotion regulation strategies is concerned, we found that depressed 
patients reported using significantly more emotion suppression but not cognitive reappraisal 
strategies than nondepressed individuals. More interestingly, mediation analyses revealed 
that the increased trait levels of emotion suppression were in part responsible for the 
observed sympathovagal imbalance in patients who underwent cardiac surgery. Specifically, 
mediation analyses showed that one-third of the LF n.u. and HF n.u. variance explained by 
depression was accounted for by increased suppression of emotion-expressive behavior. On 
the contrary, the trait levels of emotion suppression strategy did not mediate the reduction in 
SDNN and in indices of HRV mediated by the vagal control on the heart, that is, the rMSSD, 
and NN50, observed in depressed patients as compared to those without depression. 
Our main hypothesis that sympathovagal balance would be impaired by depression 
and that the trait level of suppression to down-regulate emotion-expressive behavior would 
mediate depression-related sympathovagal imbalance was supported. Our findings add to the 
literature showing that increased suppression of emotion-expressive behavior is selectively 
associated with increased sympathetic activation of the cardiovascular and electrodermal 
systems (Gross, 2002). Specifically, Gross, 1998 reported that, compared to participants in 
the cognitive reappraisal group, individuals who were instructed to suppress emotions 
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elicited by a disgust-inducing film showed increased sympathetic activation, as indexed by 
greater increases in skin conductance as well as greater decreases in finger temperature and 
in finger pulse amplitude. In a companion study, Gross and Levenson (1997) found that 
participants in the suppression group had increased sympathetic activation of the 
cardiovascular system, as reflected by decreases in finger temperature, finger pulse 
amplitude, and pulse transit times to the finger and ear, than those who were not instructed to 
suppress emotion elicited by negative and positive emotional films. Similarly, Harris (2001) 
has reported that, compared to non-suppression group, individuals who were told to suppress 
emotion elicited by an embarrassing video had pronounced effects on cardiovascular 
reactivity, that is, an increase of 67% and 38% in systolic and diastolic blood pressure, 
respectively, which continued even when the video had stopped. 
As far as the association between depression and emotion dysregulation is concerned, 
our findings suggest that maladaptive emotion regulation could be a major symptom of 
depression (Gross & Muñoz, 1995). Specifically, our study showed that depressed 
individuals report using more frequently maladaptive emotion regulation strategies (i.e., 
suppression of emotion-expressive behavior), which have been found to be associated with 
dysfunctional outcomes (Gross & John, 2003). Our results are also in line with emerging 
evidence suggesting that emotion dysregulation is not confined to acute episode of 
depression but may be considered as a stable trait of depression (Ehring et al., 2010). 
Moreover, consistent with previous studies, no differences between depressed patients and 
healthy controls regarding cognitive reappraisal were noted (Campbell-Sills, Barlow, Brown, 
& Hofmann, 2006a; Ehring et al., 2010). 
The present findings are in line with a large number of studies that have 
demonstrated cardiac autonomic dysfunction, as reflected by reduced HRV, in depressed 
patients with CHD (Carney et al., 1995; Stein et al., 2000) as well as in those after a 
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myocardial infarction (Carney et al., 2001) or after cardiac surgery (Patron et al., 2012). Our 
study also suggests that reduced HRV may be considered as a plausible marker for the 
depression-related increased risk of cardiac morbidity and/or mortality that has been 
documented in patients who underwent cardiac surgery (Carney et al., 2002; Lespérance & 
Frasure-Smith, 2000). 
Although the relative contribution of the sympathetic and parasympathetic nervous 
systems to depression as a risk factor for cardiovascular diseases is still debated (Carney et 
al., 2005, 2002), the current findings suggest that depression is more likely to be associated 
with reduced cardiac vagal modulation and sympathovagal imbalance rather than excessive 
sympathetic activity on heart. Indeed, a selective association was found between depression 
and HRV indices that have been shown to be largely influenced by cardiac vagal control (i.e., 
rMSSD, and NN50) (Taylor et al., 1998) and by sympathovagal imbalance (i.e., LF n.u. and 
HF n.u.) (Malliani et al., 1994; Task Force, 1996). VLF and LF power components, by 
contrast, which are the mirror of both sympathetic and vagal influences on cardiac activity 
(Task Force, 1996), were unrelated to depression. 
The current findings should be interpreted in light of a number of possible 
methodological limitations. First, although HRV, especially HF power, may be confounded 
and exaggerated by respiration without reflecting the influence of cardiac vagal control on 
the heart, we did not record respiration rate and respiratory sinus arrhythmia. However, there 
is consistent and abundant evidence that even uncontrolled HRV recordings have been found 
to predict adverse outcomes in patients with CHD (Bigger et al., 1993; Kleiger et al., 1987) 
or after myocardial infarction (Rich et al., 1988) and/or to show reduced HRV in depressed 
patients with CHD (Carney et al., 1995; Stein et al., 2000) or after myocardial infarction 
(Carney et al., 2001) compared to nondepressed individuals. Finally, given that it is well-
established that HRV is reduced in patients who underwent recent cardiac surgery and then 
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gradually recovers over several months (Soares et al., 2005), HRV indices may not be stable 
in patients in the early postoperative periods. Clearly, future research is warranted to include 
long-term clinical follow-ups in order to examine the time course of depression and that of 
emotion dysregulation in relation to the alterations in temporal patterns of HRV after cardiac 
surgery. 
The current study, examine the relationship among depression, emotion regulation, 
and HRV, as an index of cardiac autonomic functioning, in patients who had undergone 
cardiac surgery. In particular, the present findings add to the recent evidence that depression 
is associated with reduced HRV postoperatively (Patron et al., 2012) by showing that the 
increased trait levels of emotion suppression may partially and selectively mediate the effect 
of depression on sympathovagal imbalance in patients after cardiac surgery.  
 
  
 100
  
 101 
CHAPTER 4 
 
Heart rate variability during emotional imagery in patients after cardiac surgery 
 
4.1 Abstract 
Objective: The main aim of the present study was to examine the influence of depression on 
heart rate and heart rate variability (HRV) reactivity during an emotional stressor task in 
patients after cardiac surgery. 
Methods: Based on the scores of the Center for Epidemiological Studies of Depression 
(CES-D) scale, 28 patients after cardiac surgery were assigned either to the group with 
depression (CES-D scores ≥ 16; N = 14) or the one without depression (CES-D scores < 16; 
N = 14). Each patient completed a baseline and an emotional imagery task including 
pleasant, neutral and unpleasant scripts. Inter-beat intervals (IBIs) and HRV parameters were 
measured during the entire protocol. 
Results: Compared to nondepressed patients, those with depression had greater reductions in 
HF expressed in normalized units (HF n.u.) during the imaging of the unpleasant script (p < 
.01, Cohen’s d = 1.34). Moreover, HF n.u. were reduced during the imaging of unpleasant 
script than pleasant one in depressed patients only (p < .03, Cohen’s d = 0.55). CES-D scores 
were also inversely correlated with changes in IBIs (r = -.38; p < .05) and HF n.u.(r = -.49; p 
< .01) from baseline to imaging of unpleasant script. 
Conclusions: These findings add to the literature of depression-related exaggerated 
cardiovascular reactivity by showing that a depression-increased vagal withdrawal 
relationship extends to patients after cardiac surgery. The present study suggests that 
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increased vagal withdrawal to unpleasant emotions in patients after cardiac surgery may 
mediate the conferral of cardiac risk by depression. 
 
Keywords: cardiac surgery; cardiovascular reactivity; depression; heart rate variability; 
imagery; mood 
 
 
4.2 Introduction 
Depression is an important and independent risk factor for the onset, the adverse 
course and outcomes in patients with CHD (Carney et al., 2005; Wulsin & Singal, 2003). 
Specifically, there is evidence that depression is associated with a 60% greater likelihood of 
having CHD (Wulsin & Singal, 2003). Patients with depression are also more likely to have 
a major cardiac event within a year of the diagnosis of CHD (Carney et al., 2005) and/or to 
die in the years following the diagnosis (Barefoot & Schroll, 1996). Moreover, it has been 
consistently reported that depression is a risk factor for cardiac morbidity and/or mortality in 
patients who had undergone cardiac surgery (Blumenthal et al., 2003; Lespérance & Frasure-
Smith, 2000). 
The autonomic nervous system (ANS) has been identified as a pivotal site of 
dysregulation, with reduced parasympathetic and increased sympathetic nervous system 
activity leading to arrhythmias and sudden cardiac death (Musselman et al., 1998; Podrid et 
al., 1990). Given that depression itself is associated with reduced parasympathetic and/or 
increased sympathetic activity (Kemp et al., 2010), the presence of depression may potentiate 
the impaired parasympathetic control and increased sympathetic activity observed in patients 
with CHD. In turn, these depression-related ANS abnormalities, especially a reduced cardiac 
vagal control, may further predispose depressed patients with CHD to ventricular 
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tachycardia, ventricular fibrillation, myocardial ischemia, and sudden cardiac death (Carney 
et al., 2005, 2002). 
In line with these findings, it has been reported that low heart rate variability (HRV), 
which reflects the balance between the sympathetic and parasympathetic nervous system 
effects on heart (Task Force, 1996), represents an independent risk factor for cardiovascular 
mortality in patients with recent myocardial infarction (Bigger et al., 1993; Kleiger et al., 
1987) or stable CHD (Rich et al., 1988). More interestingly, there is abundant and 
converging evidence that, compared to nondepressed individuals, depressed patients with 
CHD have reduced HRV, which is associated with excessive sympathetic modulation and/or 
inadequate cardiac vagal control (Carney et al., 2001; Carney et al., 2005). In light of these 
findings, reduced HRV has been implicated as a plausible marker for the depression-related 
increased risk of cardiac morbidity and/or mortality in patients after myocardial infarction 
(Carney et al., 2001) or with CHD (Carney et al., 1995; Carney et al., 2005, 2002). 
Intriguingly, it has been recently shown that a depression-reduced HRV association 
extends to patients who underwent cardiac surgery (Patron et al., 2012). In particular, Patron 
et al. (2012) observed that, compared to patients without depression, those with depression 
have reduced HRV, especially a lowered cardiac vagal control, at discharge from the 
hospital, thus suggesting an association between postoperative depression and cardiac vagal 
dysfunctions after cardiac surgery. Based on this finding, reduced HRV has been also 
suggested as one possible pathophysiological marker of depression-related ANS 
dysregulation that has been implicated as a risk factor for cardiac morbidity and/or mortality 
in patients after cardiac surgery (Blumenthal et al., 2003; Lespérance & Frasure-Smith, 
2000). 
In addition to the depression-ANS dysregulation relationship at rest, two studies have 
shown depression-related abnormalities in vagal reactivity during speech and cold pressor 
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tasks, indicating a reduced ability to regulate cardiac activity to meet the task demands 
(Appelhans & Luecken, 2006; Hughes & Stoney, 2000; Sheffield et al., 1998). Specifically, 
Sheffield et al. (1999) found that, compared to individuals without depression, depressed 
patients with CHD showed greater decreases in vagal activity, as reflected by reduced high 
frequency (HF) power of HRV, during speech task – a stressor that generally elicits 
reduction in HF power (Berntson et al., 1994). Hughes and Stoney (2000) extended this 
previous evidence by showing that depressed mood in healthy individuals elicited increased 
vagal withdrawal during speech task compared to individuals without depressed mood. In 
line with this finding, the same authors reported that depressed mood was associated with 
reduced increases in HF power during the forehead cold pressor task – a stressor that 
generally elicits increase in HF power (Durel et al., 1993; Khurana, Watabiki, Hebel, Toro, 
& Nelson, 1980). Consistent with these studies, a recent meta-analysis reported that 
depression is associated with increased heart rate reactivity, especially in those patients with 
cardiovascular diseases (Kibler & Ma, 2004). In particular, Kibler and Ma (2004) suggested 
that the depression-related autonomic imbalance may predispose depressed patients with 
cardiovascular diseases to exaggerated physiological stress reactions and therefore increase 
cardiac risk in these individuals. In other words, the autonomic dysregulation typically found 
in depressed patients with cardiovascular diseases is likely to be associated with exaggerated 
cardiac (i.e., heart rate and/or HRV) reactivity, which, in turn, increases the risk of cardiac 
morbidity and/or mortality. 
However, it should be noted that the effect sizes of the relationship between 
depression and exaggerated cardiovascular reactivity in patients were only small to moderate 
(Kibler & Ma, 2004). This may be due to the fact that the vast majority of studies examining 
whether and how vagal reactivity could be modulated by depression used non-emotional 
tasks (e.g., mental arithmetic, cold pressor or Stroop tasks) (for a review, see Kibler & Ma, 
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2004). Conversely, the number of studies that investigated the influence of depression on 
vagal reactivity during emotional stressors is much more limited. This is particularly 
surprising given that it is well-established that depression is characterized by a bias toward 
negative affect or emotion, namely the mood-congruent bias (Eizenman et al., 2003; 
Erickson et al., 2005; Mogg & Bradley, 1998; Murphy et al., 1999), which, in turn, has been 
found to potentiate emotional and physiological reactivity to negative stimuli or context 
(Golin, Hartman, Klatt, Munz, & Wolfgang, 1977; Lewinsohn, Lobitz, & Wilson, 1973). In 
addition, despite the growing knowledge on the depression-related ANS dysregulation 
underlying exaggerated cardiovascular reactivity in patients with CHD, the influence of 
depression on vagal reactivity during stressors in patients who underwent cardiac surgery has 
yet to be investigated. 
Based on these considerations, the present study was designed to examine whether 
postoperative depression would be associated with increased vagal withdrawal during an 
emotional imagery task in patients after cardiac surgery. It was hypothesized that, compared 
to patients without depression after surgery, those with postoperative depression would show 
greater vagal withdrawal, as reflected by lower HF power of HRV, during the imaging of 
unpleasant script rather than neutral and pleasant ones. 
 
 
4.3. Methods 
 
Participants 
After receiving the local ethics committee's approval, 28 patients who had undergone 
first-time cardiac surgery were enrolled in this study after their written informed consent was 
obtained. Based on the presence of clinically significant depression [i.e., scoring greater than 
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16 on the Center for Epidemiologic Studies of Depression (CES-D) scale] (Fava, 1982; 
Radloff, 1977), the patients were classified into one of two groups: with depression (N = 14) 
or without depression (N = 14). All patients had undergone cardiac surgery at a regional 
specialized hospital and were admitted for rehabilitation in a highly specialized hospital 
between July 2012 and December 2012. Patients underwent heart valve surgery (N = 12), 
coronary artery bypass graft surgery (CABG) (N = 12), and combined surgery (heart valve 
plus CABG surgery) (N = 4). Each patient had the same protocol of cardioplegia and a mild 
hypothermic cardiopulmonary bypass. Ages greater than 75, use of psychotropic drugs, other 
life-threatening medical illness, and prior cerebrovascular and/or neurological diseases were 
the exclusion criteria. Patients were treated in the hospital with beta-blockers, angiotensin-
converting enzyme inhibitors, antiarrhythmics, and/or anticoagulants. The descriptive 
statistics for each group are reported in Table 4.1. 
 
Imagery task 
Three narratives, selected from the Affective Norms of English Text (ANET) (34) 
based on standardized ratings of pleasure and arousal, were categorized as pleasant (narrative 
n. 8500: Pleasure, M = 8.5 SD = 1.5; Arousal, M = 8.2, SD = 1.7), neutral (narrative n. 2610: 
Pleasure, M = 5.4, SD = 1.3; Arousal, M = 3.1, SD = 1.7) or unpleasant (narrative n. 6020: 
Pleasure, M = 1.9, SD = 1.2; Arousal, M = 8.2, SD = 1.5). All patients were instructed to 
listen to the scripts read by the experimenter and upon offset vividly imagine the events 
described. The experimenter read the scripts slowly (for a total duration of 30-second each), 
in order for the patients to fully understand each script. Each imagery trial consisted of a 2 
minutes of imagery followed by 2 minutes of rest. The order of the presentation of the three 
narratives was counterbalanced across participants. Afterwards, pleasantness and arousal of 
the current affective were rated using the Self-Assessment Manikin (Bradley & Lang, 2007). 
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Table 4.1. Demographic and biomedical characteristics by depression status 
Variable 
Group with depression 
(N = 14) 
Group without depression 
(N = 14) 
p 
Age (years) 56.6 (8.4) 57.0 (8.4) .89 
Male Sex (N, %) 11 (79) 13 (93) .60 
Diabetes (N, %) 1 (7) 2 (14) .99 
Beta-blockers (N, %) 11 (79) 12 (86) .99 
ACE inhibitors (N, %) 7 (50) 5 (36) .70 
Antiarrhythmics (N, %) 4 (29) 2 (14) .65 
Anticoagulants (N, %) 13 (93) 14 (100) .99 
Hypertension (N, %) 8 (57) 5 (36) .45 
Myocardial infarction (N, %) 0 (0) 2 (14) .48 
Dyslipidemia (N, %) 7 (50) 5 (36) .70 
Smoking   .14 
   Actual (N, %) 2 (14) 0 (0)  
   Past (N, %) 9 (64) 7 (50)  
   No (N, %) 3 (22) 7 (50)  
Notes: Data are M (SD) of continuous and N (%) of categorical variables. ACE = 
angiotensinconverting enzyme. 
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Physiological recordings 
HRV was recorded in a standardized fashion using a computerized recording system 
(ProComp Infiniti, Thought Technology; Montreal, Canada). ECG signal was obtained from 
three disposable Ag⁄AgCl electrodes that were positioned on the patient’s chest in a modified 
lead II configuration. Each ECG signal was amplified, band-pass filtered (1–100 Hz), and 
sampled at 256 Hz. A digital trigger detecting R-waves was applied to ECG signal to obtain 
inter-beat intervals (IBIs). All ECG data were visually inspected and artifacts were corrected 
with a piecewise cubic spline interpolation method that generates missing or corrupted values 
into the normal-to-normal (NN) intervals (or inter-beat intervals). Fast Fourier spectral 
analysis was then applied on the NN series to compute frequency domain indices, which, in 
turn, were calculated by Kubios HRV Analysis Software 2.0 (Matlab, Kuopio, Finland) as 
follows: 
1) Low frequency (LF) power (0.04 to 0.15 Hz) in ms2. 
2) High frequency (HF) power (0.15 to 0.40 Hz) in ms2. 
All frequency domain indices were logarithmically transformed to normalize their 
distribution. In addition, LF and HF components were expressed in normalized units (n.u.) 
(Task Force, 1996). Given that LF and HF n.u. are algebraically redundant we reported only 
the HF n.u. in the Results section. 
 
Procedure 
All patients completed the experimental protocol after their admission for 
rehabilitation, approximately two weeks (range 10-14 days) after cardiac surgery. Upon 
arrival for the session, the patients completed the Questionnaire upon Mental Imagery (QMI) 
(Sheehan, 1967), a 35-item self-report questionnaire that measures individual differences in 
imagery skills. QMI requires participants to indicate on 7-point scales how lively and vividly 
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they can imagine each item; scores range from 35 to 245, with lower scores reflecting better 
imagery ability. Then, after skin preparation, surface electrodes were placed over the right 
subclavicular space and a left intercostal space for measurement of ECG. After the electrodes 
were attached, patients rested for 5-min and then completed the imagery task. ECG was 
recorded during both the 5-min resting period (i.e., baseline) and the imagery task.  
In order to avoid movement artifacts, each patient was instructed to stay still and not 
to talk during the ECG recordings. All ECG recordings were taken with the patients seated 
on a semireclined armchair after adaptation to the laboratory. Each physiological 
measurement was taken in a quiet and isolated laboratory during morning hours (from 10:00 
to 12:00), in order to avoid possible confounder effect of circadian variations on cardiac 
activity. The light was dimmed to provide a relaxing atmosphere and the temperature in the 
room was approximately 21°C. After imagery task was completed, the sensors were removed 
and patients were debriefed and thanked for their participation. 
 
Statistical analysis 
As our first step, analysis of variance (ANOVA), with Group (with depression, 
without depression) as the between-subjects factor, was used to compare the age of the two 
groups. Chi-square or Fisher’s exact test analysis was conducted to compare the two groups 
in terms of gender, smoking, biomedical risk factors (e.g., the presence of hypertension, 
diabetes, dyslipidemia, previous myocardial infarction), and cardiac drugs (i.e., beta-
blockers, angiotensin-converting enzyme inhibitors, antiarrhythmics, and anticoagulants). 
As our second step, mixed ANOVAs, with Group (with depression, without 
depression) as the between-subjects factor, and emotional Condition (Pleasant, Neutral, 
Unpleasant scripts) as a within-subjects factor, were conducted on self-reported evaluations 
of pleasantness and arousal. 
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As our third step, mixed analyses of covariance (ANCOVAs) with Group (with 
depression, without depression) as the between-subjects factor, emotional Condition 
(Baseline without script, Pleasant, Neutral, Unpleasant scripts) as a within-subjects factor, 
and QMI scores as covariate were conducted on HRV parameters (IBIs, ln LF, lnHF, and HF 
n.u.) collected during the imagery task. QMI score was entered as covariate given that 
depressed patients had higher QMI scores (i.e., worse imagery ability; M = 93.1; SD = 34.2) 
than those without depression (M = 72.9; SD = 42.6). Indeed, although we did not find an 
effect of group, when we considered the effect size of the mean difference between groups in 
QMI scores, we found a medium effect size (Cohen’s d = 0.52). The significance of main 
effects and interactions was adjusted where appropriate using the Greenhouse–Geisser 
method to correct for violations of sphericity. In the results, the corrected p levels and 
epsilon (ε) are reported together with the uncorrected degrees of freedom. The Fisher’s LSD 
test was used for post hoc analyses. Cohen’s d was calculated as a measure of the effect size. 
The Cohen’s d values considered to represent small, medium, and large effects are 0.20, 
0.50, and 0.80 (Cohen, 1988). 
Pearson’s correlation coefficients were calculated between CES-D scores and 
residualized changes for IBIs and HRV parameters from baseline to pleasant, neutral and 
unpleasant imagery conditions. Residualized change scores were calculated by regressing 
IBIs and HRV parameters during baseline on their values during the imaging of pleasant, 
neutral and unpleasant scripts and calculating the residual of the resultant regression (40-43). 
Therefore, residualized change is an index of change that takes into account the patient's IBIs 
and HRV parameters during baseline. A p value of < .05 was considered to be statistically 
significant. 
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4.4 Results 
 
Characteristics of patients with depression and without depression 
Fisher's exact test or chi-square analysis revealed no group differences for gender (p 
= .60), smoking (χ2[2] = 3.85, p = .14), beta-blockers (p = .99), angiotensin-converting 
enzyme inhibitors (χ2[1] = 0.58, p = .70), antiarrhythmics (p = .65), and anticoagulants (p = 
.99), hypertension (χ2[1] = 1.29, p = .45), diabetes (p = .99), dyslipidemia (χ2[1] = 0.58, p = 
.70), and previous myocardial infarction (p = .48). Similarly, ANOVA yielded no group 
differences for age (F[1, 26] = 0.02, p = .89 , η2p = .00).  
 
Emotional self-reports 
Mixed ANOVAs on self-reported pleasantness of each script yielded a significant 
effect for Condition (F[2, 52] = 36.9, p < .001, ε = .92, η2p = .59). Greater scores 
(pleasantness) were found for pleasant and neutral scripts compared to unpleasant one 
(pleasant vs. unpleasant: p < .001, Cohen’s d = 2.46; neutral vs. unpleasant: p < .001, 
Cohen’s d = 1.88; pleasant vs. neutral: p = .33, Cohen’s d = 0.27). Specifically, the mean 
(SD) pleasantness ratings for pleasant, neutral and unpleasant scripts were respectively 7.1 
(2.3), 5.8 (2.7), 3.1 (2.4) in group with depression and 7.8 (1.5), 7.9 (1.8), 2.1 (1.3) in group 
without depression. No significant effect for Group (F[1, 26] = 3.28, p = .08, η2p = .11) or 
Group × Condition interaction (F[2, 52] = 3.02, p = .06, ε = .92, η2p = .10) was noted. 
Similarly, in the case of arousal, a significant Condition main effect (F[2, 52] = 
15.46, p < .001, ε = .84, η2p = .37) was noted. Greater scores were observed for pleasant and 
unpleasant scripts compared to neutral one (pleasant vs. unpleasant: p = .10, Cohen’s d = 
0.36; neutral vs. unpleasant: p < .001, Cohen’s d = 1.24; pleasant vs. neutral: p < .001, 
Cohen’s d = 0.91). Specifically, the mean (SD) arousal ratings for pleasant, neutral and 
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unpleasant scripts were respectively 5.6 (2.5), 3.0 (2.5), 6.1 (3.0) in group with depression 
and 4.4 (2.8), 2.4 (2.3), 5.9 (2.9) in group without depression. No significant effect for Group 
(F[1, 26] = 0.82, p = .37, η2p = .03) or Group × Condition interaction (F[2, 52] = 0.45, p = 
.60, ε = .84, η2p = .02) was noted. 
 
Effects of depression on HRV parameters during the emotional imagery task 
The Group × Condition ANCOVA on IBIs did not show a significant effect for 
Group (F[1, 25] = 0.40, p = .53 , η2p = .02), Condition (F[3, 75] = 0.46, p = .63, ε = .65, η
2
p = 
.02) or Group × Condition interaction (F[3, 75] = 1.27, p = .29, ε = .65, η2p = .05). In the case 
of HRV parameters, the Group × Condition ANCOVA on HF n.u. yielded a significant main 
effect for Group (F[1, 25] = 4.67, p < .05, η2p = .16), and a Group × Condition interaction 
effect (F[3, 75] = 3.49, p < .04, ε = .85, η2p = .12). Fisher’s LSD post hoc test revealed that, 
compared to patients without depression, those with depression had significantly lower HF 
n.u. during unpleasant script (p < .01, Cohen’s d = 1.34), but not during baseline (p = .12, 
Cohen’s d = 0.56), pleasant (p = .59, Cohen’s d = 0.20) and neutral (p = .08, Cohen’s d = 
0.67) scripts. Moreover, in patients with depression, a significantly lower HF n.u. for 
unpleasant script compared to pleasant one (p < .03, Cohen’s d = 0.55), but not for other 
contrasts (ps > .21, Cohen’s ds < .28), was noted. In patients without depression, no 
difference among conditions was found (ps > .09, Cohen’s ds < 0.45). The main effect for 
Condition (F[3, 75] = 2.04, p = .13, ε = .85, η2p = .08) was not significant. Similarly, the 
Group × Condition ANCOVA on lnHF yielded a marginally significant Group × Condition 
interaction effect (F[3, 75] = 2.52, p = .08, ε = .82, η2p = .09), showing the same trend 
observed for HF component expressed in n.u. No significant main effect for Group (F[1, 25] 
= 1.78, p = .19 , η2p = .07) or Condition (F[3, 75] = 1.47, p = .24, ε = .82, η
2
p = .06) was 
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noted. Finally, the Group × Condition ANCOVA on lnLF did not show significant effect for 
Group (F[1, 25] = 0.00, p = .99 , η2p = .00), Condition (F[3, 75] = 1.59, p = .20, ε = .87, η
2
p = 
.06), or Group × Condition interaction (F[3, 75] = 0.72, p = .52, ε = .87, η2p = .03). The 
results of IBIs and HRV analyses are shown in Figure 4.1. 
Correlation analyses revealed significant associations between CES-D scores and 
residualized changes in IBIs (r = -.38; p < .05) and HF n.u. (r = -.49; p < .01) from baseline 
to imaging of unpleasant scripts, as shown in Figure 4.2.4 Specifically, greater CES-D scores 
were associated with greater reductions in IBIs (i.e., greater heart rate reactivity) and HF n.u. 
(i.e., greater vagal withdrawal) during the imaging of unpleasant script. By contrast, CES-D 
scores were unrelated to residualized changes in IBIs and HF n.u. from baseline to imaging 
of neutral and pleasant scripts (ps > .08). No significant correlations between CES-D scores 
and changes in lnLF and lnHF were noted (ps > .14). 
 
                                                 
4
 All significant correlation survived the adjustment for QMI score (p < .05). Moreover, the significant 
correlation between CES-D scores and residualized changes in HF n.u. from baseline to imaging of 
unpleasant script survived after the exclusion of two outliers (r = -.75, p < .001) 
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Figure 4.1. Mean (SE) IBIs, lnLF, lnHF, and HF n.u. reactivity as a function of 
emotional Condition (Baseline without script, Pleasant, Neutral and Unpleasant scripts) in 
the group with depression and without depression. Mixed ANCOVAs revealed a significant 
Group × Condition interaction effect (p < .04). Fisher’s LSD post hoc test revealed that 
patients with depression had significantly lower HF n.u. during unpleasant script compared 
to patients without depression (p < .01, Cohen’s d = 1.34). A significantly lower HF n.u. for 
unpleasant script compared to pleasant one (p < .03, Cohen’s d = 0.55) in patients with 
depression was also noted. IBIs = inter-beat intervals in ms; lnLF = log of low frequency 
power (0.04 to 0.15 Hz) in ms2; lnHF = log of high frequency power (0.15 to 0.40 Hz) in 
ms2; HF n.u. = high frequency expressed in normalized units [HF/(total power-VLF)*100]. 
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Figure 4.2. Correlation analyses between scores in the Center for Epidemiological 
Studies of Depression (CES-D) scale and residualized changes in inter-beat intervals (IBIs) 
(r = -.38; p < .05) and high frequency components expressed in normalized units (HF n.u.) (r 
= -.49; p < .01) from baseline to imaging of unpleasant script. 
 
 
 
4.5 Discussion 
The present study investigated the influence of depression on IBIs and HRV 
reactivity during an emotional imagery task in patients after cardiac surgery. We found that 
postoperative depression was directly associated with increased vagal withdrawal during the 
emotional imagery task. Specifically, our findings showed that patients with postoperative 
depression had significantly lower HF n.u., reflecting greater vagal withdrawal, during the 
imaging of unpleasant script compared to nondepressed patients after surgery. Consistent 
with this finding, CES-D scores were inversely associated with residualized changes in HF 
n.u. from baseline to unpleasant script, but not pleasant or neutral one. Moreover, unpleasant 
script elicited greater vagal withdrawal (i.e., reduced HF n.u.) in patients with depression 
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compared to neutral and pleasant scripts, whereas no difference among emotions in 
nondepressed patients was noted. Although not significantly, results obtained for lnHF 
resemble the same pattern of vagal reactivity found for HF n.u during emotional imagery 
task as a function of depression. By contrast, depression was unrelated to IBIs and lnLF 
reactivity during the imagery task. However, correlation analysis revealed that CES-D scores 
were significantly associated with greater reductions in IBIs (i.e., greater heart rate 
reactivity) from baseline to imaging of unpleasant script. 
These novel findings add to the literature of depression-related exaggerated 
cardiovascular reactivity by showing that a depression-increased vagal withdrawal 
relationship extends to patients after cardiac surgery. In particular, these preliminary findings 
complement studies that have documented increased vagal withdrawal during non-emotional 
stressors (e.g., forehead cold pressor or mental arithmetic task) in healthy individuals with 
depressed mood (Hughes & Stoney, 2000) as well as in patients with cardiovascular diseases 
(Kibler & Ma, 2004). Most importantly, the present study suggests that increased vagal 
withdrawal to unpleasant emotions in patients who underwent cardiac surgery may mediate 
the conferral of cardiac risk by depression (Blumenthal et al., 2003; Lespérance & Frasure-
Smith, 2000). 
The main finding – the depression-related increased vagal withdrawal for unpleasant 
script – is in line with previous reports showing that depression is characterized by a mood-
congruent bias toward negative valenced affects or stimuli (Eizenman et al., 2003; Erickson 
et al., 2005; Murphy et al., 1999). In turn, the mood-congruent bias toward negative 
information supports the maladaptive patterns of information that trigger and sustain 
depressed mood (Dalgleish & Watts, 1990; Mathews & MacLeod, 1994; Mogg & Bradley, 
1998). Consistent with this finding, it has been proposed the negative potentiation view, 
which postulates that emotional and physiological reactivity to negative emotional stimuli is 
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potentiated by the pervasive negative mood states that are frequent in patients with 
depression (Golin et al., 1977; Lewinsohn et al., 1973). 
Our results are at odds with a recent study in which depression was associated with 
blunted cardiovascular reactivity in patients with CHD (York et al., 2007). It should be 
noted, however, that the discrepancy between our findings and those of York and coworkers 
(2007) may be accounted for by methodological issues. Specifically, given that York and 
coworkers (2007) analyzed the correlation between depression and the change in 
cardiovascular parameters (i.e., heart rate, systolic and diastolic blood pressure) from the 
baseline (i.e., pre-stress) to recovery period (i.e., post-stress), they actually examined 
cardiovascular recovery after a stressor, but not cardiovascular reactivity to a stressor. 
Conversely, given that we were interested in examining the influence of depression on 
cardiovagal reactivity to emotional stimuli, reactivity of heart rate and HRV parameters was 
analyzed during different emotional conditions – resting baseline, pleasant, neutral and 
unpleasant scripts. 
The relative contribution of the sympathetic and parasympathetic nervous systems to 
depression-related exaggerated cardiac reactivity as a risk factor for cardiovascular diseases 
is still debated (Carney et al., 2005). Nonetheless, the current findings suggest that 
depression is more likely to be associated with reduced cardiac vagal modulation rather than 
excessive sympathetic activity on heart. Indeed, a selective association was found between 
depression and HRV parameters that have been shown to be largely influenced by cardiac 
vagal control (i.e., lnHF and HF n.u.) (Berntson et al., 1997; Taylor et al., 1998). By contrast, 
reactivity of LF components, which are the mirror of both sympathetic and vagal influences 
on cardiac activity (Task Force, 1996), was unrelated to depression after cardiac surgery. A 
possible explanation for this finding is that cardiac sympathetic reactivity was at least 
partially blocked by beta-blockers, which also may explain null finding concerning IBIs 
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reactivity during the imagery task. However, it is important to note that CES-D scores were 
selectively associated with greater reductions in IBIs from baseline to imaging of unpleasant 
script, thus suggesting that depression does increase heart rate reactivity in negative context. 
As far as baseline values are concerned, no significant group differences in cardiac 
vagal regulation (i.e., lnHF power and HF n.u.) between patients with depression and those 
without depression after surgery were noted. This finding is at odds with previous evidence 
that depression is associated with reduced HRV in patients with CHD as well as in those 
individuals who underwent cardiac surgery (Carney et al., 2001; Carney & Freedland, 2003; 
Patron et al., 2012). However, it should be noted that baseline lnHF power and HF n.u. were 
lower, although not significantly, in patients with depression than those without depression in 
the postoperative period. Given that the effect sizes between groups on resting vagally-
mediated parameters were medium (lnHF: Cohen’s d = 0.35; HF n.u.: Cohen’s d = 0.56), the 
low statistical power due to a relatively small sample size may help to explain this null result. 
The current findings should be interpreted in light of a number of possible 
methodological issues. First, this study used a relatively small sample size; therefore, the 
present results need to be replicated to fully understand the relationship between 
postoperative depression and cardiac reactivity during (emotional) stressors in patients after 
cardiac surgery. However, the effect sizes for HF n.u. were medium to large, with the largest 
effect sizes tending to occur between groups during the imaging of unpleasant script 
(Cohen’s d = 1.34) as well as between pleasant and unpleasant scripts within individuals with 
depression (Cohen’s d = 0.55). Second, the current study did not take into account respiration 
rate, even though the HRV may be confounded and exaggerated by respiration without 
reflecting the influence of vagal control on the HR (Grossman & Taylor, 2007). However, 
there is large evidence that even uncontrolled HRV recordings can be an independent 
predictor of adverse outcome in medically ill populations, especially in patients with 
 119 
cardiovascular diseases (Bigger et al., 1993; Kleiger et al., 1987; Rich et al., 1988). 
Moreover, given that imagery task did not require patients to speak or read, it is likely that its 
influence on respiratory rate was minimal. Finally, depression was evaluated by means of 
CES-D questionnaire but not clinically evaluated in the patients enrolled in the study. 
Although CES-D has shown good psychometric properties, it has been validated in a large 
community population and cover the most symptomatic elements of depression such as sleep 
disturbance, poor appetite or fatigue, it cannot replace a psychiatric evaluation using 
structured criteria defined in the fifth edition of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5) (American Psychiatric Association, 2013). Clearly, future 
research is warranted to replicate and extend these findings by selectively studying patients 
with diagnosis of major depressive disorder. 
In conclusion, the present study examine whether and how cardiac reactivity to 
emotional stimuli is modulated by depression in patients after cardiac surgery. Depression 
was associated with greater vagal withdrawal during the imaging of unpleasant emotion. This 
finding therefore suggests that depression-related vagal withdrawal during emotional 
stressors may be implicated as one plausible pathophysiological mechanism linking 
depression and cardiac risk in patients who underwent cardiac surgery. 
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CHAPTER 5 
 
Depression treatments in patients with cardiovascular diseases5 
 
 
5.1 Introduction to respiratory sinus arrhythmia biofeedback 
Bio-behavioral techniques include a wide variety of relaxation training such as 
mindfulness, autogenic training, hypnosis, progressive muscle relaxation and biofeedback. 
While in general, relaxation training has been reported to be effective in reducing 
stress and depressive symptoms, no consistent findings have been reported on relaxation 
training leading to reduced cardiac risk. Particularly, biofeedback Only biofeedback 
trainings, and specifically HRV biofeedback, has been reported to be effective in reducing 
cardiac risk. 
Biofeedback train an individual to modify his bodily physiological activity in order 
to improve either health and/or performance (Gilbert & Moss, 2003; Schwartz & Andrasik, 
2003; Shaffer, 2006). Therefore, the person should increase personal awareness of 
physiological processes and gain voluntary control over body and mind. In order to achieve 
these goals, biofeedback instruments are used to feed-back information about bodily 
physiological activity. Biofeedback instruments can be used to measure a wide range of 
physiological signals, such as, brain electrical activity (neurofeedback), muscle activity 
(EMG biofeedback), skin temperature (thermal feedback), electrodermal activity (SCL 
biofeedback), blood pressure, blood flow, respiration, heart rate, and heart rate variability.  
                                                 
5
 Results from this study have been partially published in:  Patron, E., Messerotti Benvenuti, S., Favretto, 
G., Valfrè, C., Bonfà, C., Gasparotto, R., & Palomba, D (2013). Biofeedback Assisted Control of 
Respiratory Sinus Arrhythmia as a Biobehavioral Intervention for Depressive Symptoms in Patients after 
Cardiac Surgery: A Preliminary Study. Applied Psychophysiology and Biofeedback, 38, 1-9. 
 122
Biofeedback therapy has particularly developed over the last 30 years, and large 
research prospective studies consistently report positive results on the effectiveness of 
biofeedback for a variety of disorders, such as headache (migraine, mixed, and tension) (Bild 
& Adams, 1980; Budzynski, Stoyva, Adler, & Mullaney, 1973), essential hypertension 
(Nakao, Yano, Nomura, & Kuboki, 2003; Yucha et al., 2001), and urinary incontinence 
(Floratos et al., 2002; Theofrastous et al., 2002). In addition, many research findings reported 
that a biofeedback treatment, alone and in combination with other therapies, is effective for 
treating many medical and psychological disorders, including hypertension (Nakao et al., 
2003; Yucha et al., 2001), but also, attentional disorders (Linden, Habib, & Radojevic, 1996; 
Monastra, 2005) and depression (Karavidas et al., 2007). Moreover, several biofeedback 
protocol are available, which address different disorders, including anxiety, depression, and 
chronic pain (Bassman & Uellendahl, 2003; Burke, 2003; Freeman, 2001; Kessler et al., 
2001). 
Biofeedback treatment basis relies on the bidirectional mind-body interaction, so that 
modifications in the mind and emotions affect the body, and, in turn, variation in the body 
activity also influences the mind and emotions. Especially, biofeedback requires training of 
the individuals, in order to achieve awareness, self-regulate, increase control over the body 
and brain, and increase flexibility in physiologic responding.  
Recently, there has been growing interest in the application of bio-behavioral 
treatment, such as biofeedback, for both depression symptoms and cardiac diseases. Durmus 
and colleagues (2005) found that biofeedback was associated not only with improvements in 
pain and physical function scores, but they also demonstrated a significant reduction in 
depression and anxiety symptoms, in 50 women with a diagnosis of knee osteoarthritis. More 
recently, in a study by Karavidas and coworkers (2007) a small group of 11 participants with 
major depressive disorder received a 10 weeks treatments using HRV biofeedback. The 
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findings reported that, after four session, there were significant improvements in depression. 
Furthermore, improvements in depression symptoms persisted for the duration of the study. 
Regarding depressed patients with cardiovascular diseases, in the last two decades, 
some studies have reported that biobehavioral interventions such as biofeedback can be 
effective in reducing cardiovascular risk by enhancing vagal regulation in patients with 
coronary heart disease (for a review, see Wheat & Larkin, 2010). One of the first study, by 
Cowan and colleagues (1990), tested the effectiveness of biofeedback in survivors of out-of-
hospital ventricular fibrillation or asystole. Patients in the active group received psychosocial 
therapy, consisting of biofeedback focused on altering autonomic tone, cognitive behavioral 
therapy, and cardiovascular health education. The authors found that patients in the 
biofeedback group showed a reduced risk of cardiovascular death, and diminished all-cause 
mortality. Specifically, the authors reported that, in six patients, psychosocial treatment 
(including biofeedback) increased HRV and led to a better balance between sympathetic and 
parasympathetic activities (Cowan et al., 1990). Similarly, Del Pozo and coworkers (2004) 
studied the effect of a 6 weeks HRV biofeedback training on patients with coronary heart 
disease. Specifically, 61 patients were randomized to receive either 45 min of HRV 
biofeedback treatment or control condition. HRV biofeedback treatment consists of breath 
training with an emphasis on abdominal breathing. In addition, participants were requested to 
exercise at home for at least 20 min per day. The findings reported that CHD patients in the 
active condition showed increases in HRV, as measured by SDNN and rMSSD, at the end of 
the training. More importantly the results were maintained 18 week after the training ended. 
In addition, Nolan and coworkers (2005) carried out a smaller study on 46 patients with 
coronary heart disease, who were randomized to receive either 5 session of the active or the 
control condition treatment. The active condition includes training in cognitive behavioral 
skills and HRV biofeedback training, while the control condition consists in training in 
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cognitive behavioral skills and autogenic relaxation. The HRV biofeedback was designed to 
increase respiratory sinus arrhythmia and counter vagal inhibition immediately after stress. 
The findings showed that 5 sessions of biofeedback and brief behavioral-cognitive training 
yield enhanced vagal HR regulation during recovery from stress compared to autogenic 
relaxation and brief behavioral-cognitive training. In addition, patients receiving HRV 
biofeedback manifested reduced symptoms of emotional stress and depression. Patients in 
the control condition showed lower symptoms of emotional stress and depression, but these 
modifications were not associated to vagal cardiac control modifications.  
Therefore, cardiorespiratory biofeedback, including HRV biofeedback, may be 
effective and reliable training for cardiac patients with comorbid depressive symptoms, since 
it seems to be effective in increasing vagal regulation, thus reducing cardiac risk in these 
patients, and reduce depressive symptoms, further lowering risk factors linked to depression. 
 
Mechanism by which RSA biofeedback increases vagal tone 
RSA-biofeedback (or HRV biofeedback) is a cardiorespiratory training, which 
stimulate differential systems involved in cardioregulatory aspect, such as respiratory sinus 
arrhythmia and baroreflex (BR) activity. In addition, the cardiovascular system, which is 
stimulated during the training, have resonance characteristics (deBoer, Karemaker, & 
Strackee, 1987; Vaschillo, Lehrer, Rishe, & Konstantinov, 2002). Specifically, three 
cardioregulatory phenomenon such as, HR modification, respiration and blood pressure 
oscillation are associated by one resonant frequency, that is about 0.1 Hz. In fact, Vaschillo 
and colleagues (2002) found that at this particular resonant frequency (0.1 Hz) the phase 
relationship between HR modification and blood pressure oscillations is exactly 180°, and 
the phase relationship between HR oscillations and respiration is exactly 0°(Vaschillo et al., 
2002). What happens, exactly, is that when a person inhale there is an increase in HR 
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(respiration driven—RSA) and decrease in blood pressure. At the same time, the decrease in 
blood pressure stimulates the baroreceptors, resulting in a further increase in HR, and 
maximizing the respiratory induced increases in HR. Successively, during exhalation HR 
decreases (vagus nerve stimulation) and blood pressure increase (see Figure 5.1). 
 
 
 
Figure 5.1 Diagrammatic representation of respiration, HR and blood pressure 
pattern during biofeedback breathing close to the individual’s resonance frequency. The 
graphs show oscillations in HR almost completely in phase (close to 0°) with respiration, 
while blood pressure fluctuation is out of phase (at approximately 180°) with respiration and 
HR. Thus, other sources of variability are minimized. 
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During RSA-biofeedback, the individual is coached to breathe near to or at a 
particular resonant frequency, in order to increase HR oscillations (thus variability) by 
stimulating rhythmically not only the variation in HR, but also, the baroreceptors activity. 
More importantly, RSA-biofeedback near to or at the individual’s particular resonant 
frequency allow to take advantage of the phase relationship between different systems, 
making possible to achieve the highest amplitudes of HR oscillations, thus magnifying HRV. 
In biofeedback, daily practice is very important. In fact, the constant rhythmical 
stimulation of a resonant system increases the amplitude of system oscillations, leading to 
higher total variability. Hence, daily practice of RSA-biofeedback increase the baroreflex 
gain (Lehrer et al., 2003) and improve modulation of various autonomic functions (Lehrer et 
al., 2003). 
So, RSA-biofeedback seems to be reliable and effective intervention to increase 
HRV and, thus, vagal control on the heart. Therefore, biofeedback can be a useful 
intervention in patients with CVDs or after cardiac surgery, in order to reduce cardiac risk 
factors. Furthermore, some studies reported biofeedback effectiveness in reducing perceived 
stress and depressive symptom, in both patients with and without cardiovascular disease. 
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5.2 Abstract 
The current study investigated whether biofeedback training aimed at increasing 
respiratory sinus arrhythmia (RSA), a measure of cardiac vagal modulation, can reduce 
depressive symptoms in patients after cardiac surgery. This randomized controlled study 
enrolled 26 patients after first-time cardiac surgery. The patients were randomly assigned to 
an RSA-biofeedback group (N = 13) or to a standard rehabilitation group (N = 13). The 
biofeedback training consisted of five 45 min sessions designed to increase RSA. The 
outcome was assessed as changes in RSA and in the Centre for Epidemiologic Studies of 
Depression (CES-D) values from pre- to post-training. Both groups were comparable for 
demographic and biomedical characteristics. RSA increased significantly in patients who 
underwent RSA-biofeedback compared to controls. Moreover, the CES-D scores were 
reduced significantly from pre- to post-training in the RSA-biofeedback group compared to 
the controls. Changes in RSA were inversely correlated with changes in CES-D scores from 
pre- to post-training. These findings extend the effectiveness of RSA-biofeedback for 
increasing vagal modulation as well as for reducing depressive symptoms in post-surgical 
patients. Overall, the current study also suggests that this biobehavioral intervention may add 
to the efficacy of postoperative risk reduction programs and rehabilitation protocols in 
cardiac surgery patients. 
 
 
 
 
Keywords: cardiac surgery; depressive symptoms; parasympathetic nervous system; 
respiratory sinus arrhythmia; vagal tone 
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5.3 Introduction 
Undergoing cardiac surgery is a significant life event with a relevant impact on the 
affective status of patients. Among patients undergoing cardiac surgery, high rates of 
depression and anxiety, 25–30%, are reported (Langeluddecke et al., 1989; McKhann et al., 
1997). Specifically, Langeluddecke and colleagues (1989) reported that 36% of patients prior 
to coronary artery bypass surgery (CABG), had a clinically significant score on the Center 
for Epidemiological Study of Depression scale (CES-D) (Radloff, 1977), whereas the 
incidence of anxiety measured with the Spielberger State Anxiety Inventory (STAI) 
(Spielberger et al., 1970) was approximately 30%.  
Importantly, preoperative depression persist after cardiac surgery in up to 20% of 
patients (Vingerhoets, 1998). Several studies have shown that patients with postoperative 
depression are at greater risk for more cardiac morbidity and fatal cardiac events 
(Blumenthal et al., 2003; Connerney et al., 2001). Connerney and coworkers (2001) reported 
that major depressive disorder was an independent predictor of cardiac events one year after 
CABG even after controlling for other biomedical risk factors. In the largest study of 
depression as a risk factor for mortality in patients after cardiac surgery, Blumenthal and 
colleagues (2003) showed that patients with persistent (i.e., before as well as 6 months after 
CABG) mild or moderate to severe depression had a greater likelihood (i.e., more than twice) 
of death than those who were never depressed. 
The psychophysiological mechanisms underlying depression as a risk factor for 
cardiovascular disease, cardiac morbidity, and/or fatal cardiac events after surgery are still 
debated. Both behavioral (i.e., poor adherence to cardiac treatment regimen) and biological 
(i.e., increased platelet aggregation) factors have been proposed as possible explanations. 
However, the strongest evidence implicates reduced autonomic tone on the heart in the 
development of cardiovascular diseases (Carney et al., 1995). Indeed, it is well-established 
 129 
that depression is related to dysregulation of the hypothalamic pituitary-adrenal axis and 
increased sympathetic nervous system activity (Siever & Davis, 1985; Veith, 1994). Elevated 
sympathetic and/or reduced parasympathetic nervous system activities, in turn, have also 
been associated with ventricular fibrillation, ventricular tachycardia, and sudden cardiac 
death in patients with coronary heart disease (Podrid et al., 1990; Pruvot et al., 2000). 
Respiratory sinus arrhythmia (RSA) has been widely used to assess cardiac 
autonomic modulation (Berntson et al., 1997; Grossman & Taylor, 2007). Several lines of 
evidence have documented that reduced RSA may be predictive of morbidity in individuals 
with cardiovascular diseases and may represent an index of poor vagal control as well as a 
marker of cardiovascular risk (Bigger et al., 1992; Hayano et al., 1990). Cross-sectional and 
longitudinal studies have also shown that reduced levels of RSA are linked to depression 
and/or depressive symptoms in nonsurgical populations (Balogh et al., 1993; Carney et al., 
1995). However, discrepant findings have also been reported regarding the relationship 
between RSA and depression (Carney et al., 1988; Khaykin et al., 1998). Possible reasons for 
these inconsistent findings involve the heterogeneity of individuals diagnosed with 
depression (Gotlib & Hammen, 1992), small sample sizes, and the quantification of RSA 
without controlling for possible confounds such as respiration rate and depth (Grossman & 
Taylor, 2007).  
Pharmacological treatments of depression in patients with cardiovascular diseases 
and, to a major extent, in patients after cardiac surgery also represent a challenge. Indeed, 
with the exception of selective serotonin reuptake inhibitors (SSRIs) that are not 
contraindicated in patients with cardiovascular diseases, norepinephrine reuptake inhibitors, 
and tricyclic antidepressants can exert a vagolytic effect (Agelink et al., 2002), yielding to 
reduced heart rate variability (HRV) (Schroeder et al., 2002), or anticholinergic effects 
(Feighner, 1999). Based on these findings, nonpharmacological treatments for depression in 
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patients with coronary heart disease have been developed. There is evidence that cognitive 
behavioral interventions and interpersonal therapy can be effective in reducing depression 
(Lett, Davidson, & Blumenthal, 2005). Interestingly, Carney and coworkers (2000) reported 
that cognitive behavioral therapy can also increase short-term HRV and reduce HR in 
severely depressed patients. However, in the largest study to date, while cognitive behavioral 
therapy was effective in lowering depression and increasing social support in patients after 
the onset of acute myocardial infarction, it failed to reduce cardiac morbidity and mortality 
(Berkman et al., 2003). Conversely, it is important to note that, although not mediated by 
change in depression, pharmacological therapy with SSRIs was associated with a reduction 
in risk of myocardial infarction, reinfarction and/or mortality. Specifically, the inhibitory 
effects of SSRIs on platelets have been implicated in reducing risk of myocardial infarction 
and/or mortality (Serebruany et al., 2001).  
Although the effectiveness of psychological interventions for reducing risk factors 
related to coronary heart diseases is still debated (Lett, Davidson, et al., 2005), in the last two 
decades, several studies have reported that biobehavioral interventions such as biofeedback 
can be effective in reducing cardiovascular risk by enhancing vagal regulation in patients 
with coronary heart disease (for a review, see Wheat & Larkin, 2010). Specifically, Cowan 
and coworkers (1990) first reported that RSA-biofeedback training increased HRV and led to 
a better balance between sympathetic and parasympathetic activities in six cardiac patients. 
Del Pozo and coworkers (2004) extended this finding by showing that, compared to controls, 
RSA-biofeedback intervention increased HRV in patients with coronary heart disease six as 
well as 18 weeks after RSA training. More importantly, Nolan and coworkers (2005) 
reported that patients with coronary heart disease who had received five sessions of RSA-
biofeedback showed increased parasympathetic HR modulation as well as reduced symptoms 
of depression compared to controls (i.e., without RSA-biofeedback).  
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Though there is increasing evidence that biofeedback interventions can enhance 
vagal modulation and, in turn, reduce symptoms of depression and cardiovascular outcome in 
patients with cardiovascular diseases, research has yet to investigate the potential 
effectiveness of RSA-biofeedback for increasing vagal control for treating depressive 
symptoms in the context of rehabilitation after cardiac surgery. Accordingly, the aims of the 
present study were two-fold. First, we examined whether, compared to the treatment as usual 
(TAU), RSA-biofeedback plus TAU (RSA-biofeedback + TAU) increases vagal regulation, 
as measured by RSA, in patients after first-time cardiac surgery. Second, we investigated 
whether increased vagal control was related to reduced depressive and anxiety symptoms in 
patients who had undergone cardiac surgery.  
 
 
5.4 Methods 
 
Participants 
Thirty-three consecutive patients (mean age = 60.7, SD = 8.1) who underwent first-
time cardiac surgery were sequentially enrolled in the study. All the patients had undergone 
cardiac surgery at a regional highly specialized hospital and were admitted for rehabilitation 
between November 2010 and July 2011. Informed consent was obtained. Age greater than 
75, an inability to read or understand Italian, visual or auditory impairments, the use of 
psychotropic drugs, other life-threatening medical illness, and prior cerebrovascular and/or 
neurological diseases were the exclusion criteria. Seven patients declined to participate 
because of scheduling for other rehabilitation protocols or unavailability. The remaining 
patients (N = 26) received information on the entire procedure of the study. All patients were 
also provided with information on physiological measures (i.e., HR, abdominal and thoracic 
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respiration, RSA) recorded during pre- and post-training assessments as well as during RSA-
biofeedback intervention. They were told that learning to increase the size of HR changes in 
phase with abdominal breathing (i.e., RSA) would help them to exercise important responses 
that regulate the autonomic nervous system. Increased autonomic regulation, in turn, would 
improve patients’ ability to cope with everyday stress (Lehrer, Vaschillo, & Vaschillo, 2000). 
Then, each patient was randomly assigned to the RSA-biofeedback + TAU group (N = 13) or 
to the TAU group (N = 13). All the patients were treated with beta-blocker and/or 
angiotensin-converting enzyme inhibitor medications. All the study procedures received 
local ethics committee approval.  
The descriptive statistics for each group are reported in Table 5.1. 
 
Psychological Measures 
The psychological evaluation included a short clinical interview and three self-report 
questionnaires aimed at assessing depressive and anxiety symptoms. The depressive and 
anxiety symptoms questionnaires included: 
1- CES-D (Fava, 1982; Radloff, 1977). The Cronbach’s alpha of CES-D scale in the 
present study was 0.88. 
2- STAI Y1/Y2 (Spielberger et al., 1970; Spielberger, 1996). The Cronbach’s alpha of 
STAI Y1 and Y2 was 0.92 and 0.84, respectively. 
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Table 5.1. A Comparison of the Demographic and Biomedical Characteristics of the Groups 
Notes: Data are M (SD) of continuous and N (%) of categorical variables. RSA = respiratory 
sinus arrhythmia; TAU = treatment as usual; CABG = coronary artery bypass graft; PTCA = 
percutaneous transluminal coronary angioplasty; HR = heart rate; bpm = beats per minute; 
RR = inter-beat intervals; SBP = systolic blood pressure; DBP = diastolic blood pressure 
 
 
Variable 
RSA-biofeedback +TAU 
(N = 13) 
TAU 
(N = 13) 
p 
Age (years) 61.3 (8.1) 58.3 (9.0) .38 
Education (years) 10.9 (3.8) 9.7 (2.7) .38 
Male Gender (N, %) 11 (85) 12 (92) .99 
Surgical Procedure   .39 
   CABG (N, %) 4 (31) 8 (61)  
   Heart Valve (N, %) 4 (31) 1 (8)  
   Combined (N, %) 5 (38) 4 (31)  
Diabetes (N, %) 2 (16) 3 (23) .99 
Hypertension (N, %) 7 (54) 8 (61) .99 
Myocardial Infarction (N, %) 1 (8) 2 (16) .99 
Dyslipidemia (N, %) 5 (38) 9 (69) .24 
PTCA 1 (8) 3 (23) .59 
Smoking   .77 
   Actual (N, %) 2 (16) 3 (23)  
   Past (N, %) 3 (23) 4 (31)  
   No (N, %) 8 (61) 6 (46)  
HR (bpm) 72.7 (10.8) 75.5 (13.8) .57 
RR (ms) 845 (145) 836 (254) .91 
SBP (mmHg) 101.3 (7.4) 105.8 (9.1) .18 
DBP (mmHg) 65.4 (8.3) 64.0 (5.2) .61 
Abdominal Respiration (cycles/min) 16.4 (1.8) 15.0 (3.5) .20 
Log Thoracic Respiration (cycles/min) 3.0 (0.0) 2.9 (0.1) .08 
 134
Physiological Recording 
Physiological measures were recorded in a standardized way using a computerized 
recording system (ProComp Infiniti, Thought Technology; Montreal, Canada). Blood volume 
pulse (BVP) was recorded by means of a photoplethysmographic detection sensor attached to 
the left ring finger. The HR signal derived from the analog output of the BVP amplifier was 
processed via a 12-bit analog-to-digital converter with a sampling rate of 256 Hz and stored 
sequentially for spectral analysis. All the HR data were exported in the Kubios-HRV 2.0 
(Kuopio, Finland) software to correct artifacts with a piecewise cubic spline interpolation 
method that generates missing or corrupted values into the RR series. Respiration was 
recorded with two strain gauges/tube filled with conduction fluid the respiration belt 
recorded thoracic and abdominal respiration, respectively. 
RSA was employed as a reasonable and reliable measure of cardiac vagal regulation 
(Grossman & Taylor, 2007), during both the assessment and the training phases. The 
mechanisms that produce RSA comprehend the interaction between the cardiac and 
respiratory responses (Grossman, 1983), hence, respiration can confound the relationship 
between cardiac vagal control and RSA (Grossman & Taylor, 2007; Lehrer et al., 2006). 
Accordingly, in order to correct RSA calculation for respiration rate, the respiratory 
frequency range was calculated for each patient (i.e., maximum minus minimum respiratory 
frequency, expressed in cycles/min) and converted in Hz (i.e., from cycles/min to 
cycles/sec). Then, a fast Fourier transformation was applied to the variation of RR intervals 
occurring within the specific respiratory frequency range for each patient. Successively, RSA 
epochs were averaged for each assessment phase (i.e., pre-training and post-training 
assessments, see below). RSA values were expressed in ms2. 
According to the European Society of Hypertension international protocol (De 
Greeff, Arora, Hervey, Liu, & Shennan, 2008), pre-training resting left arm blood pressure 
 135 
was measured by means of a Tensoval Duo Control machine (Hartmann; Heidenheim, 
Deutschland). Three readings were taken at 1 minute intervals, and averaged, according to 
the American Heart Association (Pickering et al., 2005) recommendations for blood pressure 
measurement. 
 
Assessment 
The day after admission for rehabilitation(i.e., pre-training, approximately 10 days 
after cardiac surgery), and at discharge from the hospital (i.e., post-training, approximately 
25 days after cardiac surgery), all patients underwent the same assessment protocol. The 
assessment protocol consisted of a psychological evaluation assessing psychological 
disorders, particularly depression and anxiety symptoms. Self-report questionnaires for 
depressive and anxiety symptoms were administered individually before and after the 
training by a trained psychologist blind to the patient’s group assignment (RSA-biofeedback 
+ TAU or TAU only group). After the psychological evaluation, blood pressure was 
measured and HR and respiration were recorded over a 4-minute baseline to obtain the basal 
RSA. All physiological recordings were taken with the patients sitting on a semireclined 
armchair at a 70° angle after adaptation to the laboratory. No support for the legs was 
employed in order to avoid possible confound effect of body position on cardiovascular 
activity. The light was dimmed to provide a relaxing atmosphere and the temperature in the 
room was approximately 21ºC. During the basal physiological recordings, all patients were 
asked not to close their eyes to avoid differences in the procedure used during the assessment 
and biofeedback training phases. After the pre-training assessment, the patients were 
randomly assigned to the RSA-biofeedback + TAU group or to the TAU only group. 
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Intervention Protocol 
Patients were randomized to receive either five sessions of RSA-biofeedback + TAU 
or the TAU protocol.  
RSA-biofeedback was designed to increase RSA and, therefore, to counter vagal 
inhibition associated with depressive symptoms (Lehrer, Vaschillo, & Vaschillo, 2000). The 
RSA-biofeedback training was scheduled approximately once a day within a two-week 
period, and each session lasted about 45 minutes. The RSA-feedback was presented through 
a 15-inch monitor connected to a Biograph Infiniti biofeedback machine (Thought 
Technology; Montreal, Canada). Before starting the first biofeedback training session, the 
patients were informed about the feedback system and about the physiological measures 
being monitored (i.e., HR, abdominal and thoracic respiration). Further, they were informed 
about RSA measure and introduced to RSA-biofeedback procedure. After BVP sensor and 
respiration strain gauge attachment, the patients were trained to recognize the signals on the 
screen, specifically thoracic (white line) and abdominal (blue line) breathing and heart rate 
tachogram (red line). After they familiarize with the signals, two six min RSA trainings were 
performed. Physiological feedback was monitored visually showing a concurrent HR beat-to-
beat tachogram (i.e., beats/min) (red line) as well as thoracic (white line) and abdominal 
(blue line) breath respiration (i.e. cycles/min) (see Figure 5.2). The beat-to-beat tachogram 
and abdominal respiration were superimposed on the same axes and the on-line moving 
feedback display was updated at successive 30-second periods.  
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Figure 5.2 Screenshot from a session of Biofeedback. On the screen (duration 1 
minute) are represented thoracic (white line) and abdominal (blue line) breathing and heart 
rate tachogram (red line). The task asked to the patient was: ―Try to sincronize heart rate (the 
red line) with abdominal breating (the blue line)‖. 
 
During RSA-biofeedback training session, patients were instructed to maximize RSA 
using the tachogram display (red line) and abdominal respiration (blue line). Specifically, the 
RSA-biofeedback training goal was to synchronize the HR (red line) with abdominal 
breathing (blue line). Patients were told to breathe approximately in phase with HR 
fluctuations, in order to maximize the increases and decreases in HR that accompany 
breathing and, therefore, to increase RSA amplitude (Lehrer et al., 2000). To facilitate 
HR/breathing synchronization and to maximize RSA amplitude, all the patients were 
instructed to breathe abdominally and regularly at a decreased rate (i.e., 6 cycles/min) (Del 
 138
Pozo et al., 2004; Nolan et al., 2005); for the specific instructions given in the current study 
to use biofeedback without pacing stimulus and to breathe abdominally, see (Lehrer et al., 
2000, pp. 186-187). Each patient was reminded not to breathe too deeply to avoid 
hyperventilation symptoms. No pacing stimulus was provided during the first training 
session. After the completion of each session, patients were also encouraged to practice 
abdominal breathing for 15 minutes per day. All RSA-biofeedback sessions were conducted 
in the same setting used during the pre- and post-training assessment. 
Both groups (RSA-biofeedback + TAU or the TAU) received standard treatment. 
TAU consisted of daily counseling sessions such as dietary and smoking cessation 
counseling, weight management, and stress management according to the guidelines of the 
American Heart Association and the American Association of Cardiovascular and Pulmonary 
Rehabilitation (Balady et al., 2000; Task Force, 1996). 
 
Statistical Analysis 
Analysis of variance (ANOVA), with the group (RSA-biofeedback + TAU, TAU) as 
the between-subjects factor, was applied to compare age, education, resting HR, inter-beat 
intervals (IBI), abdominal and thoracic respiration rate, and blood pressure of the two groups.  
Fisher’s exact test or chi-square analyses were conducted to compare the two groups 
in terms of demographic, biomedical, and behavioral variables.  
Separate mixed analyses of covariance (ANCOVAs) with group (RSA-biofeedback + 
TAU, TAU) as a between-subject factor, time (pre-training assessment, post-training 
assessment) as a within-subject factor, and age and gender as covariates were conducted on 
the physiological measures, namely HR, IBI, abdominal and thoracic respiration rate and 
RSA, as well as on the psychological measures, namely the STAI Y1/Y2, and CES-D scores. 
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Age and gender were entered as covariates a priori because of their influence on RSA (Craft 
& Schwartz, 1995).  
Kolmogorov-Smirnov-test for normal distribution was performed for each dependent 
variable, showing that all data were normally distributed (p > .11) except for thoracic 
respiration. This latter measure was normalized using logarithmic transformation.  
Partial eta-squared (ηp
2) was reported as a measure of the effect size. The ηp
2 values 
considered to represent small, medium, and large effects are .01, .06, and .14, respectively 
(Cohen, 1977). Fisher’s LSD test was used for post-hoc analyses.  
Moreover, hierarchical linear regression analyses were used to test if changes in RSA 
from pre- to post-training periods can predict changes in psychological questionnaires scores 
(i.e., CES-D, STAI Y1 and Y2) from pre- to post-training periods, while controlling for 
abdominal respiration rate.  
A p value of < .05 was considered statistically significant. All statistical analyses 
were performed using STATISTICA 6.1 (StatSoft Inc., Tulsa, OK, USA).  
 
5.5 Results 
 
Characteristics of Patients Who Underwent RSA-biofeedback plus TAU and TAU 
Fisher’s exact test and the chi-square analysis revealed no group differences for 
gender, surgical procedure, diabetes, hypertension, myocardial infarction, dyslipidemia, 
PTCA, and smoking. Similarly, ANOVA yielded no group differences for age (F(1, 24) = 
0.80, ηp
2 = .03), education (F(1, 24) = 0.80, ηp
2 = .03), RR (F(1, 24) = 0.01, ηp
2 = .0005), HR 
(F(1, 24) = 0.32, ηp
2 = .01), abdominal (F(1, 24) = 1.71, ηp
2 = .07) and log thoracic 
respiration (F(1, 24) = 3.33, ηp
2 = .12), systolic, blood pressure (F(1, 24) = 1.90, ηp
2 = .07), 
and diastolic blood pressure (F(1, 24) = 0.26, ηp
2 = .01). 
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Effects of Biofeedback on Physiological Measures 
The group by time ANCOVA on RSA yielded a main effect for the group (F(1, 22) = 
11.26, p < .01, ηp
2= .34), and a group × time interaction effect (F(1, 22) = 14.6, p < .001, ηp
2 
= .40). This interaction is depicted in Figure 5.3. Post-hoc Fisher’s LSD comparisons showed 
a significant increase in RSA from pre- to post-training in the RSA-biofeedback + TAU 
group (p < .001), whereas no significant difference in RSA from pre- to post-training was 
found in the TAU group (p = .85). Also, compared to the patients who received TAU, the 
patients who underwent RSA-biofeedback + TAU had significantly greater RSA in the post-
training (p < .0001). ANCOVA analyses did not show any main effect for group and time on 
RR (all p’s > .70), HR (all p’s > .61), abdominal (all p’s > .12) and log thoracic respiration 
(all p’s > .24). Moreover, no group × time interaction effects were found for RR (F(1, 22) = 
0.06, p = .81, ηp
2 = .003), HR (F(1, 22) = 0.05, p = .82, ηp
2 = .002), abdominal (F(1, 22) = 
2.54, p = .13, ηp
2 = .10) and log thoracic respiration (F(1, 22) = 1.86, p = .19, ηp
2 = .08). 
 
Effects of RSA-biofeedback on Symptoms of Depression and Anxiety 
The group by time ANCOVA on CES-D scores yielded a significant group × time 
interaction effect (F(1, 22) = 4.31, p < .05, ηp
2 = .16). Post-hoc Fisher’s LSD comparisons 
showed a significant decrease in CES-D scores from pre-training to post-training in the RSA-
biofeedback + TAU group (p < .02), whereas no significant difference in the CES-D scores 
from pre- to post-training was found in the control group (p = .95). No significant differences 
between groups in the pre- (p = .27) and post-training (p = .37) in the CES-D scores were 
noted. 
In the case of STAI Y1, the group by time ANCOVA did not reveal a significant 
main effect for the group (F(1, 22) = 0.55, p =.47, ηp
2 = .02), time (F(1, 22) = 1.16, p = .29, 
ηp
2 = .05), or group × time (F(1, 22) = 1.28, p =.27, ηp
2 = .05). Similarly, the group by time 
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ANCOVA on the STAI Y2 scores failed to show a significant main effect for the group (F(1, 
22) =1.22, p = .28, ηp
2 = .05), time (F(1, 22) = 0.31, p = .58, ηp
2 = .01), or group × time (F(1, 
22) = 2.51, p = .13, ηp
2 = .10). All means (SD) and statistical details are reported in Table 5.2. 
 
 
 
Figure 5.3. Pre- and post-training respiratory sinus arrhythmia (RSA) values (ms2) in 
RSA-biofeedback group and controls. ANCOVA revealed a significant Group × Time 
interaction effect (p < .001). *Post-hoc Fisher’s LSD comparisons, p < .001; **Post-hoc 
Fisher’s LSD comparisons, p < .0001 
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Table 5.2. ANCOVA on Depression, State and Trait Anxiety Scores from Pre- to Post-
training in Patients Who Underwent RSA-biofeedback + TAU and TAU 
Variable Pre-training Post-training p ηp
2 
CES-D  < .05 .16 
      RSA-biofeedback + TAU 15.3 (11.2) 8.9 (4.5) .02  
      TAU 11.8 (6.9) 11.7 (7.8) .95  
STAI Y1  .27 .05 
      RSA-biofeedback + TAU 46.0 (8.9) 42.2 (6.5)   
      TAU 45.2 (7.6) 43.8 (8.0)   
STAI Y2  .13 .10 
      RSA-biofeedback + TAU 43.9 (6.3) 43.6 (4.9)   
      TAU 47.6 (7.8) 43.7 (5.7)   
Notes: Data are M (SD). ANCOVA = analysis of covariance; RSA = respiratory sinus 
arrhythmia; TAU = treatment as usual; CES-D = Center for Epidemiological Study 
Depression; STAI Y1-Y2 = State and Trait Anxiety Inventory 
 
 
Relationship between RSA, CES-D, and STAI Y1/Y2 Scores 
Hierarchical linear regression analyses showed that changes in CES-D scores were 
predicted by changes in RSA from pre- to post-training periods (β = -.50, p = .03). In 
contrast, changes in RSA were not related to changes in STAI Y1 (β = .15, p = .55) and Y2 
(β = .06, p = .81) scores. It is worth noting that changes in abdominal respiratory frequency 
did not predict changes in any psychological scores (all p’s > .26). 
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5.6 Discussion 
The present study examined the potential effectiveness of RSA-biofeedback training 
for increasing RSA, as a measure of vagal modulation, in patients who underwent first-time 
cardiac surgery. It also aimed to elucidate whether an increase in vagal control would reduce 
depressive and/or anxiety symptoms. We found that, compared to the patients who received 
TAU, RSA significantly increased from pre- to post-training in patients who underwent 
RSA-biofeedback + TAU training. Moreover, the patients who underwent RSA-biofeedback 
+ TAU were characterized by a reduction in depressive symptoms from pre- to post-training 
compared to patients who underwent the standard rehabilitation protocol only (i.e., TAU 
group). Although not significant, patients who underwent RSA-biofeedback + TAU had 
more depressive symptoms than patients who received TAU in the pre-training period. While 
the mean (SD) score on CES-D was 11.8 (6.9) in TAU group, in RSA-biofeedback +TAU 
group it was 15.3 (11.2) that falls close to the CES-D cut-off value for mild depressive 
symptoms (i.e., 16). It is important to note that RSA-biofeedback group showed a significant 
reduction in the CES-D scores from pre- to post-training (from 15.3 to 8.9), whereas CES-D 
scores did not change in TAU group (pre-training = 11.8, post-training = 11.7). Consistent 
with these findings, linear regression analyses showed that changes in RSA were selectively 
associated with changes in CES-D scores but not in STAI Y1 and Y2 scores from pre- to 
post-training. Moreover, it is worth noting that this association between changes in RSA and 
CES-D scores was independent of abdominal respiration rate. 
These novel findings add to the literature on the biobehavioral treatment of 
cardiovascular disease by showing that the effectiveness of RSA-biofeedback intervention 
for increasing vagal modulation extends to patients after cardiac surgery, even under beta-
blocker medication. More importantly, our study suggests the effectiveness of RSA 
biofeedback in treating depressive symptoms as revealed by the association between changes 
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in RSA and CES-D scores from pre- to post-training. These preliminary findings 
complement recent studies that have documented RSA-biofeedback effectiveness in 
enhancing vagal control (Cowan et al., 1990; Del Pozo et al., 2004; Nolan et al., 2005), as 
well as for reducing depressive symptoms in patients with coronary heart disease (Nolan et 
al., 2005). The current results are also in line with previous findings showing the 
effectiveness of RSA-biofeedback in several clinical populations such as patients with 
asthma (Lehrer et al., 1997; Lehrer et al., 2004), chronic obstructive pulmonary disease 
(Giardino, Chan, & Borson, 2004), fibromyalgia (Hassett et al., 2007), or in healthy 
individuals (Lehrer et al., 2003). 
RSA-biofeedback training may add to the efficacy of cognitive behavioral 
psychotherapy designed to treat depressive symptoms in patients who have undergone first 
time cardiac surgery. Indeed, cognitive behavioral interventions are aimed at treating 
depression by enhancing the cognitive priming of positive emotion, relaxation, and 
pleasurable social activities as well as by inhibiting cognitive rumination on negative events 
and negative self-talk. However, the psychophysiological networks and autonomic nervous 
system pathways that mediate the influence of cognitive behavioral therapy on depression 
and/or anxiety are still partially unknown. In contrast, our preliminary findings suggest that 
RSA-biofeedback training may independently enhance HR vagal modulation and reduce 
depressive symptoms with beneficial effects on postoperative patients’ functional and 
clinical outcome. Although the crucial mechanisms underlying the effectiveness of RSA-
biofeedback in enhancing vagal modulation are still debated (Wheat & Larkin, 2010), it is 
plausible that RSA-biofeedback may increase peripheral HR modulation by making the 
baroreceptors more efficient (Lehrer et al., 2000; Lehrer et al., 2003). However, given that 
the baroreflex gain was not recorded in the current study, the likelihood of that possibility is 
indeterminable. 
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Although not directly investigated in the present study, RSA-biofeedback may reduce 
postoperative cardiac events by acting on pathophysiological mechanisms underlying the 
influence of depression on cardiovascular diseases morbidity and/or mortality, especially the 
altered autonomic nervous system activity (Carney et al., 2000). Additional research is 
needed to compare the efficacy of RSA-biofeedback and pharmacological therapy with 
SSRIs in reducing depressive symptoms as well as risk of cardiac mortality and morbidity in 
patients with cardiovascular diseases and/or in those individuals who underwent cardiac 
surgery (Berkman et al., 2003; Lespérance et al., 2007). 
Another speculative explanation for the current findings may lie in the relationship 
among RSA-biofeedback, medullary neurons in the cardiorespiratory network, and cortical 
frontal-limbic circuits (Benarroch, 1997; Thayer & Lane, 2000). Given that, during RSA-
biofeedback, patients are engaged in maintaining concentration in a targeted physiological 
index (i.e., RSA), biofeedback may increase vagal regulation by evoking concurrently 
generalized emotional self-control and focused attention. This psychological response may 
be associated with a brain network that involves the prefrontal and anterior cingulated cortex, 
which, in turn, are neural substrates of goal-directed behavior and emotion, respectively 
(Thayer & Lane, 2000). The prefrontal and anterior cingulate cortex are, in turn, connected 
with the amygdala, insula, parabrachial nucleus, lateral hypothalamus, and medullary 
neurons involved in the parasympathetic and sympathetic modulation of the heart and, 
therefore, have been linked to neurocardiac regulation (Benarroch, 1997; Thayer & Lane, 
2000). Interestingly, Kubota and colleagues (2001) reported that a meditation procedure can 
increase vagal modulation as well as prefrontal cortex activity. Although there is evidence 
for an interface between cardiac regulation and cognitive-emotional functioning, future 
research on the effectiveness of biofeedback training is warranted to examine this potential 
relationship. 
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The current findings should be interpreted in light of a number of possible 
methodological issues. First, this study used a relatively small sample size; therefore, the 
present results need to be replicated to fully understand the effectiveness of RSA-
biofeedback in treating depressive symptoms in patients after cardiac surgery. Nonetheless, 
the effect size, which indicates the proportion of the variance in the dependent variable that is 
related to the independent variable(s), showed large group × time effects on RSA (ηp
2 = .40) 
and CES-D scores (ηp
2 = .16). Second, although the pre-training mean score of RSA-
biofeedback group on CES-D was close to the cut-off value for mild depressive symptoms 
(i.e., 16), cardiac surgery patients enrolled in the present study were not diagnosed as 
depressed. Moreover, given that CES-D is considered a screening measure for depressive 
symptoms, it is not definitive for supporting a diagnosis of depression. To overcome this 
limitation, future studies should extend the present findings by including patients who met 
the diagnostic criteria for major and minor depression according to the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV, Association American 
Psychiatric, 1994). Third, all the patients were treated in the hospital with a beta-blocker 
and/or angiotensin-converting enzyme inhibitor medication which, in turn, influenced 
cardiovascular physiology and, therefore, the blood pressure, HR, and RSA values. However, 
the pharmacological treatment was a part of these cardiac patients’ standard clinical care in 
this post-surgical context and was the same between the RSA-biofeedback + TAU group and 
the TAU group. Fourth, we employed photoplethysmography instead of electrocardiogram, 
which, in turn, is the gold-standard method to measure HR, HRV, and RSA. Nonetheless, 
several studies have reported that the parameters of photoplethysmographic variability are 
highly correlated with HRV and RSA extracted from electrocardiogram (Lu et al., 2008). 
Fifth, the lack of a non-contingent RSA biofeedback group makes it somewhat difficult to 
understand whether the results observed in the present study may be fully attributable RSA 
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biofeedback intervention or to incidental factors. Therefore, future investigations should 
include a non-contingent RSA feedback group to test more rigorously the efficacy of RSA 
biofeedback against such a genuine placebo controls. Finally, although the current study 
showed that RSA is modifiable through biofeedback in an acute timeframe, we did not 
conduct follow up evaluations, so we do not know whether the current results on RSA and 
depressive symptoms will be long-lasting (Wheat & Larkin, 2010). This latter limitation 
makes it somewhat difficult to evaluate the real effectiveness of RSA-biofeedback for 
reducing depressive (and anxiety) symptoms in cardiac surgery patients. The questionnaires 
used in the current study, especially the STAI Y2 that evaluates persistent anxiety, imply 
ratings that should be performed over an extended period of time. Clearly, future research is 
warranted to replicate and extend the present findings by conducting long-term follow-up 
studies to demonstrate the longevity of the improvements in RSA and depressive 
symptomatology in postsurgical patients. Future studies should also investigate the 
effectiveness of RSA-biofeedback on trait anxiety over a longer period than two weeks. 
The current study, investigate, in addition to the standard cardiac rehabilitation 
program, the effectiveness of RSA-biofeedback training for increasing vagal modulation as 
well as for reducing depressive symptoms in patients after cardiac surgery. Our preliminary 
findings may extend the potential effectiveness of RSA-biofeedback to the post-surgical 
period and suggest that this novel biobehavioral training may add to the efficacy of 
postoperative risk reduction programs and cardiac rehabilitation protocols. 
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CHAPTER 6 
GENERAL DISCUSSION 
 
 
6.1 A summary of main findings 
In this thesis four studies have been described that were primarily meant to 
investigate the psychophysiological mechanisms underlying the relationship between 
depression and increased cardiac risk in patients after first time cardiac surgery, and, 
secondarily, to test the effectiveness of a biofeedback training in reducing cardiac risk in 
these patients.  
Results of the first study that examined the association between depression and 
altered autonomic control on the heart, confirmed and extended previous data on depressed 
patients with CVDs. Specifically, the findings yielded that also depressed patients after first 
time cardiac surgery had reduced HRV and, particularly, lowered vagal control on the heart, 
compared to patients without depression. In addition, a sympathovagal dysfunction, 
characterized by increased LF/HF ratio, mainly influenced by reduced vagal control on the 
heart, was seen in depressed patients compared to those without depression. These findings 
suggest that the depression-reduced HRV relationship extends to patients after cardiac 
surgery, and that depression may be selectively related to impaired parasympathetic activity 
in these patients, independently of anxiety. These findings add to the well-known role of 
increased sympathetic cardiac control, as one possible physiological mechanisms linking 
depression to cardiovascular diseases (Carney et al., 2001; Carney et al., 2005) providing the 
evidence that support the relationship between depression and reduced vagal cardiac 
modulation. 
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As discussed across the thesis, other physiological mechanisms that may link 
depression to increased cardiac risk have been reported. Specifically, inflammation response 
and platelet activation process received consistent support. Even though, reduced HRV and 
inflammation response markers or platelet activation process have been generally described 
as independent pathways, recently Carney and Freedland (2009) proposed that a low HRV, 
that reflect reduced vagal control on the heart, may be associated with higher levels of 
inflammation response and platelet activation markers. These markers, commonly reported in 
depressed patients with CVDs, may contribute to the increased morbidity and mortality 
associated with depression.  
The present results provide further support to the importance of carefully assess 
depression in patients after cardiac surgery in order to control for autonomic dysfunction 
related to cardiac morbidity or mortality. 
One further issue was the identification of which emotional regulation strategies may 
be impaired in cardiac patients with depression. Accordingly, in the second study, the 
relationship between depression and emotion regulation strategies in patients after cardiac 
surgery, was investigated. The findings showed that depressed patients reported using 
significantly more suppression of emotion, but not cognitive reappraisal, compared to 
nondepressed individuals. Gross and John (2003) reported that individuals who frequently 
use suppression of emotion, show a tendency to experience more negative mood. In fact, 
individuals who suppress emotions deal with stressful situations by masking their feelings 
and suppressing external displays of both positive and negative emotions. This, in turn, leads 
to unsuccessful mood regulation, reduced positive emotion experience and expression, 
increased negative emotions, including feelings of inadequacy and inauthenticity and 
negative thought about emotions. In this context, cognitive theories of depression postulate 
that negative or maladaptive cognitive styles such as the negativity biases (the tendency for 
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negative interpretation to predominate over positive) play a role in the etiology and 
maintenance of depression disorders (Shook, Fazio, & Vasey, 2007).  
Findings from the present thesis add to the literature on negativity biases by showing 
that suppression of emotions, a negative style to face emotions, was partially responsible for 
the observed diminished vagal control in depressed patients who underwent first time cardiac 
surgery. Suppression of emotions may leads to increased morbidity and mortality risk linked 
to depression. Therefore, increased trait levels of emotion suppression should be addressed, 
in order to reduce the effect of depression on sympathovagal imbalance in cardiac surgery 
patients. 
While the first and second study were mainly focused on effects of depression or 
emotion regulation strategies on HRV at rest, the third study was designed to examine 
whether postoperative depression would be associated with altered autonomic changes 
during emotional stressors, in patients after cardiac surgery. Altered stress response, 
especially to emotional stressors, have been associated to the development of depression 
through different behavioral and psychophysiological pathways. By assessing cardiac vagal 
modification during three emotional imagery tasks (e.g., pleasant, neutral and unpleasant), 
finding of the third study yield a direct association between postoperative depression and 
vagal withdrawal during emotional stressors. Patients with postoperative depression had 
significantly greater emotional response, characterized by disproportionate vagal withdrawal, 
specifically during unpleasant imagery, compared to nondepressed patients after surgery. 
Therefore, the findings suggest that the vagal withdrawal, other than sympathetic activation, 
during unpleasant emotional stressors, in patients who underwent cardiac surgery, may 
mediate the conferral of cardiac risk by depression. These results add to the well-known role 
of pure sympathetic response during emotional stressors. In fact, many studies have reported 
increased sympathetic reactivity during emotional stressors in depressed patients (Matthews, 
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Nelesen, & Dimsdale, 2005; Thornton & Hallas, 1999). In addition, cardiac hyper-reactivity 
during emotional stressors have been shown to increase the risk of developing hypertension 
(Carroll et al., 2001; Treiber, Turner, Davis, & Strong, 1997), coronary heart disease and 
congestive heart failure (Phillips, 2011). Conversely, some studies have found a reduction in 
parasympathetic response during emotional stressors in depressed patients (Salomon, Clift, 
Karlsdóttir, & Rottenberg, 2009). The attenuated vagal response seen in depressed patients 
may reflect a compensatory response, caused by incessant activation of hypothalamic-
pituitary-adrenal axis (Barton et al., 2007; Weber et al., 2000), and may lead to increased 
cardiac risk through reduced variability of heart rate both at rest and in response to emotional 
stressors. 
In this context, Henry and colleagues (2007) recently proposed a dimensional model 
of mixed state and depression, that includes both emotional hypo- and hyper-reactivity. 
According to this model, individuals with emotional hyper-reactivity are characterized by 
feeling emotions of unusual intensity, and higher instability of the tonality of mood. 
Conversely, individuals with emotional hypo-reactivity are characterized by a general 
emotional inhibition in all dimensions. The distinction between hypo- and hyper-reactive 
depression may be useful to understand differences in cardiovascular reactivity. It can be 
hypothesized that specific depression types may be selectively associated not only with 
opposite patterns of emotional reactivity, but also with different patterns of cardiovascular 
reactivity to stressors. Either cardiac hyper- or hypo-reactivity may be pathophysiological 
mechanisms leading to increased cardiac risk in depressed patients. Therefore, the present 
results underline the need to identify the mechanisms by which depression types are 
specifically associated with peculiar reactivity pattern and to identify particular interventions 
focused at improving specific emotional and cardiovascular reactivity patterns in depressed 
patients.  
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Finally, the research was focused on potential non pharmacological treatment of 
depression in cardiac patients. Common cardiac rehabilitation programs include 
psychotherapeutic intervention (interpersonal therapy and cognitive behavioral therapy), life 
style modification and bio-behavioral intervention (relaxation training). These interventions, 
whether generally effective in improving mood disorders, were found ineffective in cardiac 
risk reduction. Rather, there is increasing evidence that cardiorespiratory biofeedback, 
namely, RSA-biofeedback, can enhance vagal control on the heart, reduce symptoms of 
depression and, in turn, improve cardiovascular outcome in patients with cardiovascular 
diseases (Cowan et al., 1990; Del Pozo et al., 2004; Nolan et al., 2005). The fourth study was 
designed to investigate whether a short RSA-biofeedback training could increase vagal 
control on the heart (as measured by RSA) at rest, and reduce depressive symptoms in 
patients after first time cardiac surgery. The findings showed that compared to the patients 
who received standard rehabilitation protocol, vagal control on the heart significantly 
increased from pre to post-training in patients who underwent both RSA-biofeedback 
training plus standard rehabilitation. Furthermore, the patients who underwent RSA-
biofeedback showed a significant reduction in depressive symptoms from pre to post-training 
compared to patients who underwent the standard rehabilitation protocol only.  
These results are of particular importance, in light of the fact that depression 
treatment in cardiac patients is a challenge. In fact, many pharmacological treatment (such as 
tricyclics, MAOIs, lithium, barbiturates and second-generation antidepressants) are not 
recommended or even contraindicated in these patients (Carney et al., 2002; Cohen et al., 
2000; Glassman et al., 2002). In addition, psychotherapeutic interventions (i.e., cognitive 
behavioral therapy and interpersonal therapy) and bio-behavioral intervention (i.e., stress 
management, progressive muscle relaxation, autogenic training) while effective in reducing 
depression, have been found to be ineffective in reducing cardiac risk (Lett, Davidson, et al., 
 154
2005; van Dixhoorn & White, 2005). Conversely, RSA-biofeedback was found to be 
effective in increasing cardiac vagal control, that in turn, has been associated with a 
reduction of the cardiac risk profile (Thayer & Lane, 2007). Furthermore, the reduction in 
depressive symptoms may lead to additional reduction in cardiac risk.  
In conclusion, the present findings support the hypothesis that a short training of 
RSA-biofeedback can be efficiently added to cardiac rehabilitation programs as a substitute 
of pharmacological treatment in depressed patients after cardiac surgery. 
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6.2 Limitations of the research  
The current findings should be interpreted in light of a number of possible 
limitations. First, in the studies investigating the psychophysiological mechanisms 
underlying the relationship between depression and cardiac risk, HRV has been recorded 
without accounting for respiration rate. Yet, HRV indexes may be influenced and 
confounded by respiration without reflecting only the influence of vagal control on the HR 
(Grossman & Taylor, 2007). However, since the respiratory frequency band, in the human 
adult, usually range from about 9 to 24 breath per minute (0.15 - 0.4 Hz) HRV indexes 
associated with vagal regulation (i.e., HF band) is thought to be mediated mainly by 
fluctuations of vagal-cardiac nerve activity and can provide a reliable index of vagal activity 
(Berntson et al., 1997; Eckberg, 2003; Grossman & Taylor, 2007; Hedman et al., 1995). In 
addition, there is large evidence that even HRV recordings uncontrolled for respiration rate 
can be an independent predictor of a negative outcome in medically ill populations, 
especially in patients with cardiovascular diseases (Bigger et al., 1993; Kleiger et al., 1987; 
Rich et al., 1988). HRV recording uncontrolled for respiration rate can show reduced HRV in 
depressed patients with coronary heart disease (Carney et al., 1995; Stein et al., 2000) or 
after myocardial infarction (Carney et al., 2001) compared to nondepressed individuals. 
Therefore, even if HRV recording uncontrolled for respiration represents a reliable index of 
vagal influence on the heart, controlling for respiration rate would provide more precise 
information on the pathophysiological mechanism leading to increased cardiac risk. 
Second, the studies reported in this thesis did not include patients with a diagnosis of 
major depression disorder, but enrolled patients with clinically relevant depressive 
symptoms, as measured by the CES-D questionnaire (Radloff, 1977). Although CES-D has 
shown good psychometric properties, it has been validated in a large community population 
and covers the most symptomatic elements of depression such as sleep disturbance, poor 
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appetite or fatigue, it cannot replace a psychiatric evaluation using structured criteria defined 
in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; 
American Psychiatric Association, 2013). Although, depressive conditions include 
subclinical symptoms that are milder or briefer compared to diagnose of major depression. 
Even though mild and short-lasting symptoms may have moderate to little impact on a 
person’s life, mild but persistent symptoms may be detrimental to a person’s adjustment. In 
fact, research has shown, that subclinical depression may predict the development of major 
depression or other emotional problems, and may result in significant impairment in affective 
and social functioning (Gotlib, Lewinsohn, & Seeley, 1995; Horwath, Johnson, Klerman, & 
Weissman, 1992; Wells et al., 1989; Zonderman, Herbst, Schmidt, Costa, & McCrae, 1993). 
Furthermore, many studies have reported an association between subclinical depressive 
symptoms and not only major depression, with reduced HRV (Agelink, Boz, et al., 2002; 
Carney et al., 2000; Yeragani et al., 1995). More importantly, it has been recently shown that 
there is a dose-response relationship between depression severity and cardiac events, 
specifically, more severe depression resulted to be associated with earlier and more severe 
cardiac events (Lichtman et al., 2008). Therefore it seems important, especially in cardiac 
surgery patients, to accurately monitor not only patients with major depression but also 
patients with subclinical depressive symptoms. 
Finally, in the biofeedback study, the lack of adequate control condition (i.e., heart 
rate biofeedback or relaxation training), makes it somewhat difficult to understand whether 
the findings may be specifically attributable to RSA-biofeedback training effects, or more 
generally to the biofeedback intervention. In fact, the biofeedback training may involve a 
top-down mechanism, activated by focused attention and concentration. During a 
biofeedback training, patients are engaged in maintaining concentration and focused 
attention on the feedback signal (whether visual or acoustic) and/or on the targeted 
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physiological index (i.e., HR, RSA). Focused attention has been linked with the activation of 
the prefrontal and anterior cingulate cortex that in turn, are part of a wide brain network that 
have been associated with cardiovascular control of the heart (Thayer & Lane, 2000). 
Interestingly, Kubota and colleagues (2001) reported that a meditation procedure, that 
produce an increased prefrontal cortex activity can in turn, improve vagal modulation on the 
heart. 
Some studies reported the effectiveness of EMG and thermal biofeedback (McGinnis, 
McGrady, Cox, & Grower-Dowling, 2005) and neurofeedback (Hammond, 2005), in 
reducing depressive symptoms, but no results have been reported on the effectiveness of 
these biofeedback intervention in improving vagal control of heart function. Therefore it 
seems important, to compare the influence on parasympathetic activity on the heart of both 
an RSA-biofeedback and an adequate biofeedback control condition. 
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6.3 Directions for future research  
In order to overcome the above-mentioned limitations and to extend the current 
findings, future research should further investigate alteration of the ANS as the potential 
psychophysiological mechanisms linking depression to increased cardiac risks. In order to 
better understand the psychophysiological mechanisms that underlie the depression-increased 
cardiac risk relationship, future research should examine the neural mechanisms that regulate 
the autonomic nervous system control.  
Depression, as a disorder of the regulation of mood and emotion, has been shown to 
be associated with abnormalities in the morphometry and activity of different cerebral 
structures, including the prefrontal cortex, the anterior cingulate cortex, the hippocampus and 
the amygdala [see Drevets (1998) for comprehensive review]. Reduced mean gray matter 
volume of the left subgenual prefrontal cortex have been found in familial bipolar and 
unipolar depressed (Drevets et al., 1997). In addition, decreased metabolism of the 
dorsolateral and dorsomedial prefrontal cortex and the anterior cingulate gyrus have been 
reported in depressed patients, compared to controls (Mayberg et al., 1997).  
Interestingly, all these structures modulate, through tonic inhibition, the neural 
structures implicated in emotional behaviors, such as the amygdala, the mediodorsal nucleus 
of the thalamus, and the ventral striatum (the ventromedial caudate and the nucleus 
accumbens). Depressed patients have been reported to have abnormally increased 
metabolism in the amygdala and the medial thalamus (Greicius et al., 2007).  
More importantly, many lines of evidence suggested that the structures involved in 
emotion regulation circuit (i.e., prefrontal cortex, amygdala and hippocampus), are involved 
in the modulation of the cardiovascular function. Nevertheless, the neural control of 
cardiovascular activity is not clear. Benarroch (1993, 1997) described the central autonomic 
network, that affect heart rhythms through vagus nerve influence on the sinoatrial node. The 
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central autonomic network includes prefrontal cortical areas, such as the orbitofrontal cortex 
and medial prefrontal cortex, the amygdala, the insula and the hypothalamus. Specifically, 
the prefrontal cortex, the anterior cingulate cortex, and the amygdala all have projections to 
the hypothalamic and medullary neurons involved in the modulation of parasympathetic and 
sympathetic branches of the ANS (see Figure 6.1) (Balaban & Thayer, 2001; Matthews, 
Paulus, Simmons, Nelesen, & Dimsdale, 2004; Thayer & Lane, 2000; Wong, Massé, 
Kimmerly, Menon, & Shoemaker, 2007).  
Hypoactivation of the prefrontal cortex that have been reported in depressed patients 
would lead to activation (decreased inhibition) of the central nucleus of the amygdala, this, in 
turn, may activate specific pathways leading to increase in the sympathetic outflow and/or 
reduced parasympathetic influence on the heart. First, the amygdala activation may increase 
sympathetic activity on heart, by decreasing inhibition on neurons in the caudal ventrolateral 
medulla (CVLM), that, in turn, cause activation of neurons in the rostral ventrolateral 
medulla (RVLM). RVLM neurons specifically control sympathetic activity. Second, the 
amygdala activation may reduce parasympathetic activity, by inhibition of neurons in the 
nucleus of the solitary tract, that, in turn produce the inhibition of neurons of the nucleus 
ambiguus (NA) and neurons of the dorsal vagal motor nucleus (DVN), causing a reduction of 
parasympathetic activity. These effects would produce a sympathovagal imbalance on the 
heart, characterized by increased HR and decrease HRV (Thayer & Lane, 2009). This wide 
central autonomic network have been proposed to control the interplay of parasympathetic 
and sympathetic outputs on the sinoatrial node variability of the heart rate time series (i.e., 
the HRV) (Benarroch, 1993; Benarroch, 1997; Thayer, Ahs, Fredrikson, Sollers, & Wager, 
2012; Thayer & Lane, 2009). 
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Figure 6.1. Schematic diagram representing the pathways by which the prefrontal 
cortex might influence parasympathetic and sympathetic control of heart rate. The prefrontal, 
cingulate, and insula cortices form an interconnected network with bi-directional 
communication with the amygdala. The amygdala is under tonic inhibitory control from the 
prefrontal cortex. The activation of the central nucleus of the amygdala inhibits the nucleus 
of the solitary tract (NTS) which in turn inhibits inhibitory caudal ventrolateral medullary 
(CVLM) inputs to the rostral ventrolateral medullary (RVLM) sympathoexcitatory neurons, 
and inhibits vagal motor neurons in the nucleus ambiguous (NA) and the dorsal vagal motor 
nucleus (DVN). In addition, the central nucleus of the amygdala activate sympathoexcitatory 
neurons in the RVLM (Thayer & Lane, 2009). 
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Arnsten and Goldman-Rakic (1998) proposed that, during emotional stressor, the 
prefrontal cortex is inhibited in order to allow more automatic processes, mediated by 
subcortical structures such as the amygdala, to control behavioral responses (Arnsten & 
Goldman-Rakic, 1998). This selective prefrontal inactivation helps to organize fast adaptive 
responses to threat, but may often be maladaptive in human society. In fact, in modern 
human society, cognitive and emotional flexibility are necessary for self-regulation and 
adaptation to environmental demands. Prolonged prefrontal inactivity may lead to 
hypervigilance, defensiveness, and perseveration, thus contributing to the vulnerability 
associated with many psychiatric disorders, including depression. 
To verify if both the pathways involved in the central autonomic control of the heart 
(i.e., central control of either sympathetic or parasympathetic cardiac influence) are altered in 
depressed patients, future research should include functional and/or structural cerebral 
measurement recorded simultaneously with cardiovascular activity. Useful evidence may 
also come from connectivity analysis that may provide further information on the neural 
pathways linking central structures to both parasympathetic and sympathetic control on the 
heart. In addition, both indexes of parasympathetic (i.e., HF of HRV, RSA) and sympathetic 
activity (pre ejection period time) should be included to obtain a more accurate information 
on both the branches of ANS activity on the heart in depressed patients. 
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6.4 Conclusions  
Taken together, these findings provide steps for understanding the psychological and 
psychobiological mechanisms underlying the relationship between depression and increased 
cardiac risk. The present findings confirm previous results on the association between 
depression and impaired vagal control on the heart. This relationship have also been shown 
to be partially mediated by altered emotion regulation strategies, specifically, by excessive 
suppression of emotions. In addition, depressed cardiac patients have been found to show 
altered vagal response to emotional stressors. These findings add to the literature on stress 
response in depressed patients by showing that depression is not only related with increased 
sympathetic activation to stressors, but result, as well, to be associated with vagal withdrawal 
during unpleasant stressors. 
Therefore, postoperative depression should be accurately monitored, in order to 
improve cardiac outcomes in patients after cardiac surgery. In addition, these results suggest 
the need for emotion regulation training which may be useful to reduce the risk associated 
with altered emotional regulation both at rest and in response to emotional stressors. 
More importantly, these findings provide new evidence supporting the usefulness of 
a short RSA-biofeedback intervention, in increasing vagal control on the heart and improving 
depressive symptoms. This biofeedback training should be usefully added to standard cardiac 
rehabilitation protocols in order to reduce the depression-related cardiac risk factors. 
In conclusion, the present thesis provides further information to explain the 
psychophysiological mechanisms underlying the relationship between depression and 
increased cardiac risk, and more importantly, yields evidence in support of the effectiveness 
of biofeedback training in patients after cardiac surgery. 
 
 163 
 
  
 164
References 
Agelink, M. W., Boz, C., Ullrich, H., & Andrich, J. (2002). Relationship between major 
depression and heart rate variability. Clinical consequences and implications for 
antidepressive treatment. Psychiatry Research, 113(1-2), 139–49. 
Agelink, M. W., Majewski, T. B., Andrich, J., & Mueck-Weymann, M. (2002). Short-term 
effects of intravenous benzodiazepines on autonomic neurocardiac regulation in 
humans: a comparison between midazolam, diazepam, and lorazepam. Critical Care 
Medicine, 30(5), 997–1006. 
Agenzia Italiana del Farmaco. (2012). L ’uso dei Farmaci in Italia. Rapporto Nazionale 
giugno-settembre 2012. (Agenzia Italiana del Farmaco, Ed.). Roma. 
Akselrod, S., Gordon, D., Ubel, F. A., Shannon, D. C., Berger, A. C., & Cohen, R. J. (1981). 
Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat 
cardiovascular control. Science, 213(4504), 220–2. 
American Psychiatric Association. (2000). Treatment Works for Major Depressive Disorder: 
A Patient and Family Guide. 
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition. (American Psychiatric Association, Ed.). Arlington, VA. 
Anda, R., Williamson, D., Jones, D., Macera, C., Eaker, E., Glassman, A., & Marks, J. 
(1993). Depressed affect, hopelessness, and the risk of ischemic heart disease in a 
cohort of U.S. adults. Epidemiology (Cambridge, Mass.), 4(4), 285–94. 
Andrade, L., Caraveo-anduaga, J. J., Berglund, P., Bijl, R. V., Graaf, R. De, Vollebergh, W., 
… Wittchen, H.-U. (2003). The epidemiology of major depressive episodes: results 
from the International Consortium of Psychiatric Epidemiology (ICPE) surveys. 
International Journal of Methods in Psychiatric Research, 12(1), 3–21. 
Anisman, H., Hayley, S., Turrin, N., & Merali, Z. (2002). Cytokines as a stressor: 
implications for depressive illness. The International Journal of 
Neuropsychopharmacology, 5(4), 357–73. 
Anrep, G. V, Pascual, W., & R ssler, R. (1936). Respiratory Variations of the Heart Rate. II-
-The Central Mechanism of the Respiratory Arrhythmia and the Inter-Relations 
between the Central and the Reflex Mechanisms. Proceedings of the Royal Society of 
London. Series B, Biological Sciences, 119(813), 218–230. 
 165 
Appelhans, B. M., & Luecken, L. J. (2006). Heart Rate Variability as an Index of Regulated 
Emotional Responding. Review of General Psychology, 10(3), 229–240. 
Appels, A., & Mulder, P. (1988). Excess fatigue as a precursor of myocardial infarction. 
European Heart Journal, 9(7), 758–64. 
Ariyo, A. A., Haan, M., Tangen, C. M., Rutledge, J. C., Cushman, M., Dobs, A., & Furberg, 
C. D. (2000). Depressive Symptoms and Risks of Coronary Heart Disease and 
Mortality in Elderly Americans. Circulation, 102(15), 1773–1779. 
Arnsten, A. F., & Goldman-Rakic, P. S. (1998). Noise stress impairs prefrontal cortical 
cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. Archives 
of General Psychiatry, 55(4), 362–8. 
Arrowsmith, J. E., Grocott, H. P., Reves, J. G., & Newman, M. F. (2000). Central nervous 
system complications of cardiac surgery. British Journal of Anaesthesia, 84(3), 378–93. 
Asnis, G. M., Halbreich, U., Ryan, N. D., Rabinowicz, H., Puig-Antich, J., Nelson, B., … 
Friedman, J. H. (1987). The relationship of the dexamethasone suppression test (1 mg 
and 2 mg) to basal plasma cortisol levels in endogenous depression. 
Psychoneuroendocrinology, 12(4), 295–301. 
Association American Psychiatric. (1994). Diagnostic and Statistical Manual of Mental 
Disorders. (A. P. Association, Ed.) (4th ed.). Washington, DC. 
Baker, R. A., Andrew, M. J., Schrader, G., & Knight, J. L. (2001). Preoperative Depression 
and Mortality in Coronary Artery Bypass Surgery: Preliminary Findings. ANZ Journal 
of Surgery, 71, 139–142. 
Balaban, C. D., & Thayer, J. F. (2001). Neurological bases for balance-anxiety links. Journal 
of Anxiety Disorders, 15(1-2), 53–79. 
Balady, G. J., Ades, P. A., Comoss, P., Limacher, M., Pina, I. L., Southard, D., … Bazzarre, 
T. (2000). Core Components of Cardiac Rehabilitation/Secondary Prevention 
Programs : A Statement for Healthcare Professionals From the American Heart 
Association and the American Association of Cardiovascular and Pulmonary 
Rehabilitation Writing Group. Circulation, 102(9), 1069–1073. 
Balogh, S., Fitzpatrick, D. F., Hendricks, S. E., & Paige, S. R. (1993). Increases in heart rate 
variability with successful treatment in patients with major depressive disorder. 
Psychopharmacology Bulletin, 29(2), 201–6. 
 166
Balzarotti, S., John, O. P., & Gross, J. J. (2010). An Italian Adaptation of the Emotion 
Regulation Questionnaire. European Journal of Psychological Assessment, 26(1), 61–7. 
Barefoot, J. C., & Schroll, M. (1996). Symptoms of depression, acute myocardial infarction, 
and total mortality in a community sample. Circulation, 93(11), 1976–80. 
Barnes, R. F., Veith, R. C., Borson, S., Verhey, J., Raskind, M. A., & Halter, J. B. (1983). 
High levels of plasma catecholamines in dexamethasone-resistant depressed patients. 
The American Journal of Psychiatry, 140(12), 1623–5. 
Barth, J., Schumacher, M., & Herrmann-Lingen, C. (2004). Depression as a risk factor for 
mortality in patients with coronary heart disease: a meta-analysis. Psychosomatic 
Medicine, 66(6), 802–13. 
Barton, D. A., Dawood, T., Lambert, E. A., Esler, M. D., Haikerwal, D., Brenchley, C., … 
Lambert, G. W. (2007). Sympathetic activity in major depressive disorder: identifying 
those at increased cardiac risk? Journal of Hypertension, 25(10), 2117–24. 
Bassman, L. E., & Uellendahl, G. (2003). Complementary/alternative medicine: Ethical, 
professional, and practical challenges for psychologists. Professional Psychology: 
Research and Practice, 34(3), 264. 
Benarroch, E. (1997). Central autonomic network: functional organization and clinical 
correlations. (Futura Publishing Company, Ed.). 
Benarroch, E. E. (1993). The central autonomic network: functional organization, 
dysfunction, and perspective. Mayo Clinic Proceedings, 68(10), 988–1001. 
Berkman, L. F., Blumenthal, J., Burg, M., Carney, R. M., Catellier, D., Cowan, M. J., … 
Contribution, O. (2003). Effects of Treating Depression and Low Perceived Social 
Support on clinical events after myocardial infarction: the Enhancing Recovery in 
Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA, 289(23), 
3106–16. 
Berntson, G. G., Bigger, J. T., Eckberg, D. L., Grossman, P., Kaufmann, P. G., Malik, M., … 
Van Der Molen, M. W. (1997). Heart rate variability: Origins, methods, and interpretive 
caveats. Psychophysiology, 34(6), 623–648. 
Berntson, G. G., Cacioppo, J. T., Binkley, P. F., Uchino, B. N., Quigley, K. S., & Fieldstone, 
A. (1994). Autonomic cardiac control. III. Psychological stress and cardiac response in 
autonomic space as revealed by pharmacological blockades. Psychophysiology, 31(6), 
599–608. 
 167 
Berntson, G. G., Cacioppo, J. T., & Quigley, K. S. (1993). Respiratory sinus arrhythmia: 
autonomic origins, physiological mechanisms, and psychophysiological implications. 
Psychophysiology, 30(2), 183–196. 
Bigger, J. T., Fleiss, J. L., Rolnitzky, L. M., & Steinman, R. C. (1993). The ability of several 
short-term measures of RR variability to predict mortality after myocardial infarction. 
Circulation, 88(3), 927–34. 
Bigger, J. T., Fleiss, J. L., Steinman, R. C., Rolnitzky, L. M., Kleiger, R. E., & Rottman, J. 
N. (1992). Frequency domain measures of heart period variability and mortality after 
myocardial infarction. Circulation, 85(1), 164–71. 
Bild, R., & Adams, H. E. (1980). Modification of migraine headaches by cephalic blood 
volume pulse and EMG biofeedback. Journal of Consulting and Clinical Psychology, 
48(1), 51–7. 
Billman, G. E., Schwartz, P. J., & Stone, H. L. (1982). Baroreceptor reflex control of heart 
rate: a predictor of sudden cardiac death. Circulation, 66(4), 874–80. 
Björntorp, P., Holm, G., & Rosmond, R. (1999). Hypothalamic arousal, insulin resistance 
and Type 2 diabetes mellitus. Diabetic Medicine : A Journal of the British Diabetic 
Association, 16(5), 373–83. 
Blachly, P. H., & Blachly, B. J. (1968). Vocational and Emotional Status of 263 Patients 
After Heart Surgery. Circulation, 38(3), 524–32. 
Blazer, D. G., Kessler, R. C., McGonagle, K. A., & Swartz, M. S. (1994). The prevalence 
and distribution of major depression in a national community sample: the National 
Comorbidity Survey. The American Journal of Psychiatry, 151(7), 979–86. 
Blumenthal, J. A., Lett, H. S., Babyak, M. A., White, W., Smith, P. K., Mark, D. B., … 
Newman, M. F. (2003). Depression as a risk factor for mortality after coronary artery 
bypass surgery. Lancet, 362(9384), 604–9. 
Blumenthal, J. A., Sherwood, A., Babyak, M. A., Watkins, L. L., Waugh, R., Georgiades, A., 
… Hinderliter, A. (2005). Effects of exercise and stress management training on 
markers of cardiovascular risk in patients with ischemic heart disease: a randomized 
controlled trial. JAMA, 293(13), 1626–34. 
Bolanos, M., Nazeran, H., & Haltiwanger, E. (2006). Comparison of heart rate variability 
signal features derived from electrocardiography and photoplethysmography in healthy 
individuals. In Engineering in Medicine and Biology Society, 2006. EMBS’06. 28th 
Annual International Conference of the IEEE (pp. 4289–4294). 
 168
Bollini, P., Pampallona, S., Kupelnick, B., Tibaldi, G., & Munizza, C. (2006). Improving 
compliance in depression: a systematic review of narrative reviews. Journal of Clinical 
Pharmacy and Therapeutics, 31(3), 253–60. 
Bradley, M. M., & Lang, P. J. (2007). Affective Norms for English Text (ANET): Affective 
ratings of text and instruction manual. Techical Report. D-1, University of Florida, 
Gainesville, FL. 
Brown, A. D. H., Barton, D. A., & Lambert, G. W. (2009). Cardiovascular abnormalities in 
patients with major depressive disorder: autonomic mechanisms and implications for 
treatment. CNS Drugs, 23(7), 583–602. 
Budzynski, T. H., Stoyva, J. M., Adler, C. S., & Mullaney, D. J. (1973). EMG biofeedback 
and tension headache: a controlled outcome study. Psychosomatic Medicine, 35(6), 
484–96. 
Burg, M. M. (2003a). Depressive Symptoms and Mortality Two Years After Coronary 
Artery Bypass Graft Surgery (CABG) in Men. Psychosomatic Medicine, 65(4), 508–10. 
Burg, M. M. (2003b). Presurgical Depression Predicts Medical Morbidity 6 Months After 
Coronary Artery Bypass Graft Surgery. Psychosomatic Medicine, 65(1), 111–8. 
Burke, A. (2003). Biofeedback and the CAM consumer. Biofeedback Magazine, 31(3). 
Butler, E. A., Wilhelm, F. H., & Gross, J. J. (2006). Respiratory sinus arrhythmia, emotion, 
and emotion regulation during social interaction. Psychophysiology, 43(6), 612–22. 
Cacioppo, J. T. (1994). Social neuroscience: autonomic, neuroendocrine, and immune 
responses to stress. Psychophysiology, 31(2), 113–28. 
Camm, A. J., Malik, M., Bigger, J. T., Breithardt, G., Cerutti, S., Cohen, R. J., … Task Force 
of The European Society of Cardiology and the North American Society for Pacing and 
Electrophysiology. (1996). Heart Rate Variability : Standards of Measurement , 
Physiological Interpretation , and Clinical Use. Circulation, 93(44), 1043–65. 
Campbell-Sills, L., Barlow, D. H., Brown, T. A., & Hofmann, S. G. (2006a). Acceptability 
and suppression of negative emotion in anxiety and mood disorders. Emotion, 6(4), 
587–95. 
Campbell-Sills, L., Barlow, D. H., Brown, T. A., & Hofmann, S. G. (2006b). Effects of 
suppression and acceptance on emotional responses of individuals with anxiety and 
mood disorders. Behaviour Research and Therapy, 44(9), 1251–63. 
 169 
Carney, R. M., Blumenthal, J. a, Freedland, K. E., Stein, P. K., Howells, W. B., Berkman, L. 
F., … Jaffe, A. S. (2005). Low heart rate variability and the effect of depression on 
post-myocardial infarction mortality. Archives of Internal Medicine, 165(13), 1486–91. 
Carney, R. M., Blumenthal, J. A., Stein, P. K., Watkins, L., Catellier, D., Berkman, L. F., … 
Freedland, K. E. (2001). Depression, heart rate variability, and acute myocardial 
infarction. Circulation, 104(17), 2024–8. 
Carney, R. M., & Freedland, K. E. (2003). Depression, mortality, and medical morbidity in 
patients with coronary heart disease. Biological Psychiatry, 54(3), 241–7. 
Carney, R. M., & Freedland, K. E. (2009). Depression and heart rate variability in patients 
with coronary heart disease. Cleveland Clinic Journal of Medicine, 76 Suppl 2, S13–7. 
Carney, R. M., Freedland, K. E., Miller, G. E., & Jaffe, A. S. (2002). Depression as a risk 
factor for cardiac mortality and morbidity: a review of potential mechanisms. Journal of 
Psychosomatic Research, 53(4), 897–902. 
Carney, R. M., Freedland, K. E., Rich, M. W., & Jaffe, A. S. (1995). Depression as a risk 
factor for cardiac events in established coronary heart disease: a review of possible 
mechanisms. Annals of Behavioral Medicine : A Publication of the Society of 
Behavioral Medicine, 17(2), 142–9. 
Carney, R. M., Freedland, K. E., Rich, M. W., Smith, L. J., & Jaffe, A. S. (1993). Ventricular 
tachycardia and psychiatric depression in patients with coronary artery disease. The 
American Journal of Medicine, 95(1), 23–8. 
Carney, R. M., Freedland, K. E., Stein, P. K., Skala, J. A., Hoffman, P., & Jaffe, A. S. 
(2000). Change in Heart Rate and Heart Rate Variability During Treatment for 
Depression in Patients With Coronary Heart Disease. Psychosomatic Medicine, 62(5), 
639–47. 
Carney, R. M., Rich, M. W., TeVelde, A., Saini, J., Clark, K., & Freedland, K. E. (1988). 
The relationship between heart rate, heart rate variability and depression in patients with 
coronary artery disease. Journal of Psychosomatic Research, 32(2), 159–64. 
Carney, R. M., Saunders, R. D., Freedland, K. E., Stein, P., Rich, M. W., & Jaffe, A. S. 
(1995). Association of depression witk reduced heart rate variability in coronary artery 
disease. The American Journal of Cardiology, 76(8), 562–564. 
 170
Carroll, D., Smith, G. D., Shipley, M. J., Steptoe, A., Brunner, E. J., & Marmot, M. G. 
(2001). Blood pressure reactions to acute psychological stress and future blood pressure 
status: a 10-year follow-up of men in the Whitehall II study. Psychosomatic Medicine, 
63(5), 737–43. 
Casey, E., Hughes, J. W., Waechter, D., Josephson, R., & Rosneck, J. (2008). Depression 
predicts failure to complete phase-II cardiac rehabilitation. Journal of Behavioral 
Medicine, 31(5), 421–31. 
Cay, E. L., & O’Rourke, A. (1992). Quality of Life after Open Heart Surgery. In Quality of 
Life after Open Heart Surgery (Vol. 132, pp. 177–83). Dordrecht: Springer 
Netherlands. 
Chang-Quan, H., Bi-Rong, D., Zhen-Chan, L., Yuan, Z., Yu-Sheng, P., & Qing-Xiu, L. 
(2009). Collaborative Care Interventions for Depression in the Elderly : A Systematic 
Review of Randomized controlled trials. Journal of Investigative Medicine, 57(2), 446–
55. 
Chen, Y.-H., Tsai, S.-Y., Lee, H.-C., & Lin, H.-C. (2009). Increased risk of acute myocardial 
infarction for patients with panic disorder: a nationwide population-based study. 
Psychosomatic Medicine, 71(7), 798–804. 
Clark, D. C., & Fawcett, J. (1992). An empirically based model of suicide risk assessment for 
patients with affective disorder. In American Psychiatric Association (Ed.), Suicide and 
clinical practice. Clinical practice (p. 189). Arlington, VA, US. 
Cohen, H. W., Gibson, G., & Alderman, M. H. (2000). Excess risk of myocardial infarction 
in patients treated with antidepressant medications: association with use of tricyclic 
agents. The American Journal of Medicine, 108(1), 2–8. 
Cohen, J. (1988). Statistical power analysis for the behavioral sciencies. (A. Press, Ed.). 
New York, NY: Routledge. 
Cohen, P., Cohen, J., West, S., & Aiken, L. (2003). Applied Multiple Regression/Correlation 
Analysis for the Behavioral Sciences. (Lawrence Erlbaum, Ed.) (3rd ed.). London, UK. 
Connerney, I., Shapiro, P. a, McLaughlin, J. S., Bagiella, E., & Sloan, R. P. (2001). Relation 
between depression after coronary artery bypass surgery and 12-month outcome: a 
prospective study. Lancet, 358(9295), 1766–71. 
Connor, T. J., & Leonard, B. E. (1998). Depression, stress and immunological activation: the 
role of cytokines in depressive disorders. Life Sciences, 62(7), 583–606. 
 171 
Cooper, D. C., Milic, M. S., Tafur, J. R., Mills, P. J., Bardwell, W. A., Ziegler, M. G., & 
Dimsdale, J. E. (2010). Adverse impact of mood on flow-mediated dilation. 
Psychosomatic Medicine, 72(2), 122–7. 
Cowan, M. J., Kogan, H., Burr, R., Hendershot, S., & Buchanan, L. (1990). Power spectral 
analysis of heart rate variability after biofeedback training. Journal of 
Electrocardiology, 23 Suppl, 85–94. 
Craft, N., & Schwartz, J. B. (1995). Effects of age on intrinsic heart rate, heart rate 
variability, and AV conduction in healthy humans. The American Journal of 
Physiology, 268(4), H1441–52. 
Dahlöf, B. (2010). Cardiovascular disease risk factors: epidemiology and risk assessment. 
The American Journal of Cardiology, 105(S1), A3–9. 
Dalgleish, T., & Watts, F. N. (1990). Biases of attention and memory in disorders of anxiety 
and depression. Clinical Psychology Review, 10(5), 589–604. 
Dantzer, R. (2006). Cytokine, sickness behavior, and depression. Neurologic Clinics, 24(3), 
441–60. 
Das, U. N. (2000). Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why 
and how? Prostaglandins, Leukotrienes, and Essential Fatty Acids, 63(6), 351–62. 
Davidson, K. W., Rieckmann, N., Clemow, L., Schwartz, J. E., & Shimbo, D. (2010). 
Enhanced Depression Care for Patients With Acute Coronary Syndrome and Persistent 
Depressive Symptoms. Archives of Internal Medicine, 170, 600–8. 
Dawood, T., Lambert, E. A., Barton, D. A., Laude, D., Elghozi, J.-L., Esler, M. D., … 
Lambert, G. W. (2007). Specific serotonin reuptake inhibition in major depressive 
disorder adversely affects novel markers of cardiac risk. Hypertension Research, 30(4), 
285–93. 
De Greeff, A., Arora, J., Hervey, S., Liu, B., & Shennan, A. H. (2008). Accuracy assessment 
of the Tensoval duo control according to the British and European Hypertension 
Societies’ standards. Blood Pressure Monitoring, 13(2), 111–6. 
deBoer, R. W., Karemaker, J. M., & Strackee, J. (1987). Hemodynamic fluctuations and 
baroreflex sensitivity in humans: a beat-to-beat model. The American Journal of 
Physiology, 253(3), H680–9. 
 172
Del Pozo, J. M., Gevirtz, R. N., Scher, B., & Guarneri, E. (2004). Biofeedback treatment 
increases heart rate variability in patients with known coronary artery disease. American 
Heart Journal, 147(3), E11–7. 
Demirel, S., Akkaya, V., Oflaz, H., Tükek, T., & Erk, O. (2002). Heart rate variability after 
coronary artery bypass graft surgery: a prospective 3-year follow-up study. Annals of 
Noninvasive Electrocardiology : The Official Journal of the International Society for 
Holter and Noninvasive Electrocardiology, Inc, 7(3), 247–50. 
Dickens, C., Cherrington, A., & McGowan, L. (2012). Depression and health-related quality 
of life in people with coronary heart disease: a systematic review. European Journal of 
Cardiovascular Nursing, 11(3), 265–75. 
Drevets, W. C. (1998). Functional neuroimaging studies of depression: the anatomy of 
melancholia. Annual Review of Medicine, 49, 341–61. 
Drevets, W. C., Price, J. L., Simpson, J. R., Todd, R. D., Reich, T., Vannier, M., & Raichle, 
M. E. (1997). Subgenual prefrontal cortex abnormalities in mood disorders. Nature, 
386(6627), 824–7. 
Dunn, A. J., Swiergiel, A. H., & de Beaurepaire, R. (2005). Cytokines as mediators of 
depression: what can we learn from animal studies? Neuroscience and Biobehavioral 
Reviews, 29(4-5), 891–909. 
Durel, L. A., Kus, L. A., Anderson, N. B., McNeilly, M., Llabre, M. M., Spitzer, S., … 
Schneiderman, N. (1993). Patterns and stability of cardiovascular responses to 
variations of the cold pressor test. Psychophysiology, 30(1), 39–46. 
Durmus, D., Alayli, G., & Canturk, F. (2005). Effects of biofeedback-assisted isometric 
exercise and electrical stimulation on pain, anxiety, and depression scores in knee 
osteoarthritis. Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi, 51(4), 142–5. 
Dyer, A. R., Persky, V., Stamler, J., Paul, O., Shekelle, R. B., Berkson, D. M., … Lindberg, 
H. A. (1980). Heart rate as a prognostic factor for coronary heart disease and mortality: 
findings in three Chicago epidemiologic studies. American Journal of Epidemiology, 
112(6), 736–49. 
Eagle, K. A., Guyton, R. A., Davidoff, R., Ewy, G. A., Fonger, J., Gardner, T. J., … Smith, 
S. C. (1999). ACC/AHA guidelines for coronary artery bypass graft surgery: executive 
summary and recommendations : A report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines. 
Circulation, 100(13), 1464–80. 
 173 
Eaker, E. D., Sullivan, L. M., Kelly-Hayes, M., D’Agostino, R. B., & Benjamin, E. J. (2007). 
Marital status, marital strain, and risk of coronary heart disease or total mortality: the 
Framingham Offspring Study. Psychosomatic Medicine, 69(6), 509–13. 
Eckberg, D. L. (1983). Human sinus arrhythmia as an index of vagal cardiac outflow. 
Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology, 
54(4), 961–6. 
Eckberg, D. L. (2000). Physiological basis for human autonomic rhythms. Annals of 
Medicine, 32(5), 341–9. 
Eckberg, D. L. (2003). The human respiratory gate. The Journal of Physiology, 548(2), 339–
52. 
Eckberg, D. L., & Eckberg, M. J. (1982). Human sinus node responses to repetitive, ramped 
carotid baroreceptor stimuli. The American Journal of Physiology, 242(4), H638–44. 
Ehring, T., Tuschen-Caffier, B., Schnülle, J., Fischer, S., & Gross, J. J. (2010). Emotion 
regulation and vulnerability to depression: spontaneous versus instructed use of emotion 
suppression and reappraisal. Emotion, 10(4), 563–72. 
Eizenman, M., Yu, L. H., Grupp, L., Eizenman, E., Ellenbogen, M., Gemar, M., & Levitan, 
R. D. (2003). A naturalistic visual scanning approach to assess selective attention in 
major depressive disorder. Psychiatry Research, 118(2), 117–28. 
Elkin, I., Shea, M. T., Watkins, J. T., Imber, S. D., Sotsky, S. M., Collins, J. F., … Parloff, 
M. B. (1989). National Institute of Mental Health Treatment of Depression 
Collaborative Research Program General Effectiveness of Treatments. Archives of 
General Psychiatry, 46, 971–82. 
Ell, K., Xie, B., Quon, B., Quinn, D. I., Dwight-Johnson, M., & Lee, P. (2008). Randomized 
Controlled Trial of Collaborative Care Management of Depression Among Low-Income 
Patients With Cancer. Journal of Clinical Oncology, 26, 4488–96. 
Ellis, R. J., & Thayer, J. F. (2010). Music and autonomic nervous system (dys) function. 
Music Perception, 27(4), 317. 
Emanuele, E., Geroldi, D., Minoretti, P., Coen, E., & Politi, P. (2005). Increased plasma 
aldosterone in patients with clinical depression. Archives of Medical Research, 36(5), 
544–8. 
 174
Empana, J. P., Sykes, D. H., Luc, G., Juhan-Vague, I., Arveiler, D., Ferrieres, J., … 
Ducimetiere, P. (2005). Contributions of depressive mood and circulating inflammatory 
markers to coronary heart disease in healthy European men: the Prospective 
Epidemiological Study of Myocardial Infarction (PRIME). Circulation, 111(18), 2299–
305. 
Erickson, K., Drevets, W. C., Clark, L., Cannon, D. M., Bain, E. E., Zarate, C. A., … 
Sahakian, B. J. (2005). Mood-congruent bias in affective go/no-go performance of 
unmedicated patients with major depressive disorder. The American Journal of 
Psychiatry, 162(11), 2171–3. 
Esler, M. (1982). The Peripheral Kinetics of Norepinephrine in Depressive Illness. Archives 
of General Psychiatry, 39(3), 295. 
Esler, M., & Kaye, D. (2000). Sympathetic nervous system activation in essential 
hypertension, cardiac failure and psychosomatic heart disease. Journal of 
Cardiovascular Pharmacology, 35(7), S1–7. 
Everson, S. A., Goldberg, D. E., Kaplan, G. A., Cohen, R. D., Pukkala, E., Tuomilehto, J., & 
Salonen, J. T. (1996). Hopelessness and risk of mortality and incidence of myocardial 
infarction and cancer. Psychosomatic Medicine, 58(2), 113–21. 
Everson-Rose, S. A., Meyer, P. M., Powell, L. H., Pandey, D., Torréns, J. I., Kravitz, H. M., 
… Matthews, K. A. (2004). Depressive symptoms, insulin resistance, and risk of 
diabetes in women at midlife. Diabetes Care, 27(12), 2856–62. 
Farrell, T. G., Bashir, Y., Cripps, T., Malik, M., Poloniecki, J., Bennett, E. D., … Camm, A. 
J. (1991). Risk stratification for arrhythmic events in postinfarction patients based on 
heart rate variability, ambulatory electrocardiographic variables and the signal-averaged 
electrocardiogram. Journal of the American College of Cardiology, 18(3), 687–97. 
Fava, G. (1982). Versione italiana del CES-D per la valutazione degli stati depressivi. In 
Organizzazioni Speciali (Ed.), Nuovi Metodi in Psicometria. Firenze. 
Feighner, J. P. (1999). Overview of antidepressants currently used to treat anxiety disorders. 
The Journal of Clinical Psychiatry, 60 Suppl 2, 18–22. 
Felder, R. B., Francis, J., Weiss, R. M., Zhang, Z. H., Wei, S. G., & Johnson, A. K. (2001). 
Neurohumoral regulation in ischemia-induced heart failure. Role of the forebrain. 
Annals of the New York Academy of Sciences, 940, 444–53. 
Fenton, W. S., & Stover, E. S. (2006). Mood disorders: cardiovascular and diabetes 
comorbidity. Current Opinion in Psychiatry, 19(4), 421–7. 
 175 
Ferrari, R., Censi, S., Mestrorilli, F., & Boraso, A. (2003). Prognostic benefits of heart rate 
reduction in cardiovascular disease. European Heart Journal, S5, G10–14. 
Floratos, D. L., Sonke, G. S., Rapidou, C. A., Alivizatos, G. J., Deliveliotis, C., 
Constantinides, C. A., & Theodorou, C. (2002). Biofeedback vs verbal feedback as 
learning tools for pelvic muscle exercises in the early management of urinary 
incontinence after radical prostatectomy. BJU International, 89(7), 714–9. 
Forbes, L. M., & Chaney, R. H. (1980). Cardiovascular changes during acute depression. 
Psychosomatics, 21(6), 472–7. 
Ford, D. E., Mead, L. A., Chang, P. P., Cooper-Patrick, L., Wang, N.-Y., & Klag, M. J. 
(1998). Depression Is a Risk Factor for Coronary Artery Disease in Men. Archives of 
Internal Medicine, 158, 1422–1426. 
Fráguas, R. J., Ramadan, Z. B., Pereira, A. N., & Wajngarten, M. (2000). Depression with 
irritability in patients undergoing coronary artery bypass graft surgery: the 
cardiologist’s role. General Hospital Psychiatry, 22(5), 365–74. 
Frasure-Smith, N., & Lespérance, F. (2003). Depression and other psychological risks 
following myocardial infarction. Archives of General Psychiatry, 60(6), 627–36. 
Frasure-Smith, N., Lespérance, F., & Talajic, M. (1995). Depression and 18-month prognosis 
after myocardial infarction. Circulation, 91(4), 999–1005. 
Freedland, K. E., Rich, M. W., Skala, J. A., Carney, R. M., Davila-Roman, V. G., & Jaffe, A. 
S. (2003). Prevalence of Depression in Hospitalized Patients With Congestive Heart 
Failure. Psychosomatic Medicine, 65(1), 119–28. 
Freedland, K. E., Skala, J. A., Carney, R. M., Rubin, E. H., Lustman, P. J., Davila-Roman, 
V. G., … Hogue, C. W. (2009). Treatment of Depression After Coronary Artery Bypass 
Surgery: A Randomized Controlled Trial. Archives of General Psychiatry, 66(4), 387–
96. 
Freeman, L. (2001). Mosby’s Complementary & Alternative Medicine a Research-based 
Approach. 
Friedman, B. H. (2007). An autonomic flexibility--neurovisceral integration model of anxiety 
and cardiac vagal tone. Biological Psychology, 74(2), 185–199. 
Frijda, N. H. (1988). The laws of emotion. The American Psychologist, 43(5), 349–58. 
 176
Gallagher, R., McKinley, S., & Dracup, K. (2004). Post discharge problems in women 
recovering from coronary artery bypass graft surgery. Australian Critical Care : 
Official Journal of the Confederation of Australian Critical Care Nurses, 17(4), 160–5. 
Gehi, A., Mangano, D., Pipkin, S., Browner, W. S., & Whooley, M. A. (2005). Depression 
and heart rate variability in patients with stable coronary heart disease: findings from 
the Heart and Soul Study. Archives of General Psychiatry, 62(6), 661–6. 
Giardino, N. D., Chan, L., & Borson, S. (2004). Combined heart rate variability and pulse 
oximetry biofeedback for chronic obstructive pulmonary disease: preliminary findings. 
Applied Psychophysiology and Biofeedback, 29(2), 121–33. 
Giardino, N., Lehrer, P., & Feldman, J. (2000). The role of oscillations in self-regulation: 
Their contribution to homeostasis. In Harwood (Ed.), Stress and health: Research and 
clinical applications (pp. 27–52). Newark. 
Gilbert, C., & Moss, D. (2003). Biofeedhack and biological monito ring. Handbook of mind-
body medicine for primary care (Vol. 109). 
Glassman, A. H., Connor, C. M. O., Califf, R. M., Swedberg, K., Schwartz, P., Swenson, J. 
R., … Harrison, W. M. (2002). Sertraline Treatment of Major Depression in Patients 
With Acute MI or Unstable Angina. JAMA, 288(6), 701–710. 
Glassman, A. H., Roose, S. P., & Bigger, J. T. (1993). The safety of tricyclic antidepressants 
in cardiac patients. Risk-benefit reconsidered. JAMA, 269(20), 2673–5. 
Glassman, A. H., & Shapiro, P. A. (1998). Depression and the course of coronary artery 
disease. The American Journal of Psychiatry, 155(1), 4–11. 
Gold, P. W., Wong, M.-L., Goldstein, D. S., Gold, H. K., Ronsaville, D. S., Esler, M., … 
Kling, M. A. (2005). Cardiac implications of increased arterial entry and reversible 24-h 
central and peripheral norepinephrine levels in melancholia. Proceedings of the 
National Academy of Sciences of the United States of America, 102(23), 8303–8. 
Goldberger, A. L. (1991). Is the normal heartbeat chaotic or homeostatic? Physiology, 6(2), 
87–91. 
Goldberger, A. L., Rigney, D. R., Mietus, J., Antman, E. M., & Greenwald, S. (1988). 
Nonlinear dynamics in sudden cardiac death syndrome: heartrate oscillations and 
bifurcations. Experientia, 44(11-12), 983–7. 
 177 
Golin, S., Hartman, S. A., Klatt, E. N., Munz, K., & Wolfgang, G. L. (1977). Effects of self-
esteem manipulation on arousal and reactions to sad models in depressed and 
nondepressed college students. Journal of Abnormal Psychology, 86(4), 435–9. 
Gonzales, R. (2001). ABC relaxation training as a treatment for depression for Puerto Rican 
elderly. Advances in ABC Relaxation: Applications and Inventories, 209–11. 
Gorman, J. M. (1997). Comorbid depression and anxiety spectrum disorders. Depression and 
Anxiety, 4(4), 160–8. 
Gorman, J. M., & Sloan, R. P. (2000). Heart rate variability in depressive and anxiety 
disorders. American Heart Journal, 140(S4), 77–83. 
Gotlib, I. H., & Hammen, C. L. (1992). Psychological aspects of depression: Toward a 
cognitive-interpersonal integration. (John Wiley & Sons, Ed.). Chichester, UK. 
Gotlib, I. H., Lewinsohn, P. M., & Seeley, J. R. (1995). Symptoms versus a diagnosis of 
depression: differences in psychosocial functioning. Journal of Consulting and Clinical 
Psychology, 63(1), 90–100. 
Goyal, T. M., Idler, E. L., Krause, T. J., & Contrada, R. J. (2005). Quality of life following 
cardiac surgery: impact of the severity and course of depressive symptoms. 
Psychosomatic Medicine, 67(5), 759–65. 
Greicius, M. D., Flores, B. H., Menon, V., Glover, G. H., Solvason, H. B., Kenna, H., … 
Schatzberg, A. F. (2007). Resting-state functional connectivity in major depression: 
abnormally increased contributions from subgenual cingulate cortex and thalamus. 
Biological Psychiatry, 62(5), 429–37. 
Griffiths, J., Ravindran, A. V, Merali, Z., & Anisman, H. (2000). Dysthymia: a review of 
pharmacological and behavioral factors. Molecular Psychiatry, 5(3), 242–61. 
Gross, J. J. (1998). The emerging field of emotion regulation: An integrative review. Review 
of General Psychology, 2(3), 271–99. 
Gross, J. J. (2002). Emotion regulation: affective, cognitive, and social consequences. 
Psychophysiology, 39(3), 281–91. 
Gross, J. J. J., & John, O. P. (2003). Individual differences in two emotion regulation 
processes: implications for affect, relationships, and well-being. Journal of Personality 
and Social Psychology, 85(2), 348–62. 
 178
Gross, J. J., & Levenson, R. W. (1997). Hiding feelings: the acute effects of inhibiting 
negative and positive emotion. Journal of Abnormal Psychology, 106(1), 95–103. 
Gross, J. J., & Muñoz, R. F. R. (1995). Emotion Regulation and Mental Health. Clinical 
Psychology: Science and Practice, 2(2), 151–64. 
Grossman, P. (1983). Respiration, stress, and cardiovascular function. Psychophysiology, 
20(3), 284–300. 
Grossman, P., & Taylor, E. W. (2007). Toward understanding respiratory sinus arrhythmia: 
Relations to cardiac vagal tone, evolution and biobehavioral functions. Biological 
Psychology, 74, 263–285. 
Hammond, D. C. (2005). Neurofeedback treatment of depression and anxiety. Journal of 
Adult Development, 12(2), 131–7. 
Hannan, E. L., Racz, M. J., Walford, G., Ryan, T. J., Isom, O. W., Bennett, E., & Jones, R. 
H. (2003). Predictors of readmission for complications of coronary artery bypass graft 
surgery. JAMA, 290(6), 773–80. 
Harris, C. R. (2001). Cardiovascular responses of embarrassment and effects of emotional 
suppression in a social setting. Journal of Personality and Social Psychology, 81(5), 
886–97. 
Hassett, A. L., Radvanski, D. C., Vaschillo, E. G., Vaschillo, B., Sigal, L. H., Karavidas, M. 
K., … Lehrer, P. M. (2007). A pilot study of the efficacy of heart rate variability (HRV) 
biofeedback in patients with fibromyalgia. Applied Psychophysiology and Biofeedback, 
32(1), 1–10. 
Hathaway, S., & McKinley, J. (1967). MMPI manual (rev. ed.). (Psychological Corporation, 
Ed.). New York, NY. 
Hausberg, M., Hillebrand, U., & Kisters, K. (2007). Addressing sympathetic overactivity in 
major depressive disorder. Journal of Hypertension, 25(10), 2004–5. 
Hawkley, L., Bosch, J., & Engeland, C. (2007). Loneliness, dysphoria, stress and immunity: 
A role for cytokines. In CRC Press (Ed.), Cytokines: Stress and Immunity, Second 
Edition (2nd ed.). Bocan Raton, LA. 
Hayano, J., Sakakibara, Y., Yamada, M., Ohte, N., Fujinami, T., Yokoyama, K., … Takata, 
K. (1990). Decreased magnitude of heart rate spectral components in coronary artery 
disease. Its relation to angiographic severity. Circulation, 81(4), 1217–24. 
 179 
Hedelin, R., Wiklund, U., Bjerle, P., & Henriksson-Larsén, K. (2000). Pre- and post-season 
heart rate variability in adolescent cross-country skiers. Scandinavian Journal of 
Medicine & Science in Sports, 10(5), 298–303. 
Hedman, A. E., Tahvanainen, K. U., Hartikainen, J. E., & Hakumäki, M. O. (1995). Effect of 
sympathetic modulation and sympatho-vagal interaction on heart rate variability in 
anaesthetized dogs. Acta Physiologica Scandinavica, 155(2), 205–14. 
Hemingway, H., & Marmot, M. (1999). Psychosocial factors in the aethiology and prognosis 
of coronary heart disease: systematic review of prospective cohort studies. British 
Medical Journal, 318, 1460–7. 
Henry, C., M’Baïlara, K., Desage, A., Gard, S., Misdrahi, D., & Vieta, E. (2007). Towards a 
reconceptualization of mixed states, based on an emotional-reactivity dimensional 
model. Journal of Affective Disorders, 101(1-3), 35–41. 
Hill, M. R., Wallick, D. W., Martin, P. J., & Levy, M. N. (1995). Effects of repetitive vagal 
stimulation on heart rate and on cardiac vasoactive intestinal polypeptide efflux. The 
American Journal of Physiology, 268(5), H1939–46. 
Hirsch, J. A., & Bishop, B. (1981). Respiratory sinus arrhythmia (RSA) in man: altered 
inspired 02 and C02. Advances in Physiological Science, 9, 305–312. 
Ho, P. M., Arciniegas, D. B., Grigsby, J., McCarthy, M., McDonald, G. O., Moritz, T. E., … 
Hammermeister, K. E. (2004). Predictors of cognitive decline following coronary artery 
bypass graft surgery. The Annals of Thoracic Surgery, 77(2), 597–603. 
Ho, P. M., Masoudi, F. a, Spertus, J. a, Peterson, P. N., Shroyer, a L., McCarthy, M., … 
Rumsfeld, J. S. (2005). Depression predicts mortality following cardiac valve surgery. 
The Annals of Thoracic Surgery, 79(4), 1255–9. 
Honig, A., Kuyper, A. M., Schene, Aa. H., Van Melle, J. P., de Jonge, P., Tulner, D. M., … 
Ormel, J. (2007). Treatment of Post-Myocardial Infarction Depressive Disorder : A 
Randomized, Placebo-Controlled Trial With Mirtazapine. Psychosomatic Medicine, 69, 
606–13. 
Horwath, E., Johnson, J., Klerman, G. L., & Weissman, M. M. (1992). Depressive symptoms 
as relative and attributable risk factors for first-onset major depression. Archives of 
General Psychiatry, 49(10), 817–23. 
Howren, M. B., Lamkin, D. M., & Suls, J. (2009). Associations of depression with C-
reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine, 71(2), 171–
86. 
 180
Hoyle, R. H., & Robinson, J. C. (2004). Mediated and Moderated Effects in Social 
Psychological Research: Measurement, Design, and Analysis Issues. In Sage (Ed.), The 
Sage Handbook of Methods in Social Psychology. Thousand Oaks, CA. 
Huffman, J. C., Mastromauro, C. A., Sowden, G., Fricchione, G. L., Healy, B. C., & Januzzi, 
J. L. (2011). Impact of a Depression Care Management Program for Hospitalized 
Cardiac Patients, 198–205. 
Hughes, J. W., & Stoney, C. M. (2000). Depressed mood is related to high-frequency heart 
rate variability during stressors. Psychosomatic Medicine, 62(6), 796–803. 
Huikuri, H. V, & Mäkikallio, T. H. (2001). Heart rate variability in ischemic heart disease. 
Autonomic Neuroscience : Basic & Clinical, 90(1-2), 95–101. 
Izrailtyan, I., Kresh, J. Y., Morris, R. J., Brozena, S. C., Kutalek, S. P., & Wechsler, A. S. 
(2000). Early detection of acute allograft rejection by linear and nonlinear analysis of 
heart rate variability. The Journal of Thoracic and Cardiovascular Surgery, 120(4), 
737–45. 
Kamath, M. V, Ghista, D. N., Fallen, E. L., Fitchett, D., Miller, D., & McKelvie, R. (1987). 
Heart rate variability power spectrogram as a potential noninvasive signature of cardiac 
regulatory system response, mechanisms, and disorders. Heart and Vessels, 3(1), 33–
41. 
Kannel, W. B., Anderson, K., McGee, D. L., Degatano, L. S., & Stampfer, M. J. (1987). 
Nonspecific electrocardiographic abnormality as a predictor of coronary heart disease: 
the Framingham Study. American Heart Journal, 113(2), 370–6. 
Karavidas, M. K., Lehrer, P. M., Vaschillo, E., Vaschillo, B., Marin, H., Buyske, S., … 
Hassett, A. (2007). Preliminary results of an open label study of heart rate variability 
biofeedback for the treatment of major depression. Applied Psychophysiology and 
Biofeedback, 32(1), 19–30. 
Katon, W., Korff, M. Von, Lin, E., Simon, G., Walker, E., Unutzer, J., … Ludman, E. 
(1999). Stepped Collaborative Care for Primary Care Patients With Persistent 
Symptoms of Depression. Archives of General Psychiatry, 56, 1109–15. 
Katon, W., Von Korff, M., Lin, E., Simon, G., Ludman, E., Russo, J., … Bush, T. (2004). 
The Pathways Study: A Randomized Trial of Collaborative Care in Patients With 
Diabetes and Depression. Archives of General Psychiatry2, 61, 1042–9. 
 181 
Kawachi, I., Sparrow, D., Vokonas, P. S., & Weiss, S. T. (1995). Decreased heart rate 
variability in men with phobic anxiety (data from the Normative Aging Study). The 
American Journal of Cardiology, 75(14), 882–5. 
Kemp, A. H., Quintana, D. S., Gray, M. a, Felmingham, K. L., Brown, K., & Gatt, J. M. 
(2010). Impact of depression and antidepressant treatment on heart rate variability: a 
review and meta-analysis. Biological Psychiatry, 67(11), 1067–74. 
Kessler, R. C., McGonagle, K. A., Nelson, C. B., Hughes, M., Swartz, M., & Blazer, D. G. 
(1994). Sex and depression in the National Comorbidity Survey. II: Cohort effects. 
Journal of Affective Disorders, 30(1), 15–26. 
Kessler, R. C., Soukup, J., Davis, R. B., Foster, D. F., Wilkey, S. A., Van Rompay, M. I., & 
Eisenberg, D. M. (2001). The use of complementary and alternative therapies to treat 
anxiety and depression in the United States. The American Journal of Psychiatry, 
158(2), 289–94. 
Keyes, C. L. M., & Lopez, S. J. (2012). Toward a science of mental health: Positive 
directions in diagnosis and interventions. In Handbook of positive psychology. New 
York, NY. 
Khaykin, Y., Dorian, P., Baker, B., Shapiro, C., Sandor, P., Mironov, D., … Newman, D. 
(1998). Autonomic correlates of antidepressant treatment using heart-rate variability 
analysis. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 43(2), 
183–6. 
Khurana, R. K., Watabiki, S., Hebel, J. R., Toro, R., & Nelson, E. (1980). Cold face test in 
the assessment of trigeminal-brainstem-vagal function in humans. Annals of Neurology, 
7(2), 144–9. 
Kibler, J. L., & Ma, M. (2004). Depressive symptoms and cardiovascular reactivity to 
laboratory behavioral stress. International Journal of Behavioral Medicine, 11(2), 81–7. 
Kikuchi, M., Hanaoka, A., Kidani, T., Remijn, G. B., Minabe, Y., Munesue, T., & Koshino, 
Y. (2009). Heart rate variability in drug-naïve patients with panic disorder and major 
depressive disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 
33(8), 1474–8. 
Kimball, C. P. (1969). A predictive study of adjustment to cardiac surgery. The Journal of 
Thoracic and Cardiovascular Surgery, 58(6), 891–6. 
 182
Kleiger, R. E., Miller, J. P., Bigger, J. T., & Moss, A. J. (1987). Decreased heart rate 
variability and its association with increased mortality after acute myocardial infarction. 
The American Journal of Cardiology, 59(4), 256–62. 
Kop, W. J. (1999). Chronic and acute psychological risk factors for clinical manifestations of 
coronary artery disease. Psychosomatic Medicine, 61(4), 476–87. 
Kop, W. J., Kuhl, E. A., Barasch, E., Jenny, N. S., Gottlieb, S. S., & Gottdiener, J. S. (2010). 
Association between depressive symptoms and fibrosis markers: the Cardiovascular 
Health Study. Brain, Behavior, and Immunity, 24(2), 229–35. 
Kristal-Boneh, E., Raifel, M., Froom, P., & Ribak, J. (1995). Heart rate variability in health 
and disease. Scandinavian Journal of Work, Environment & Health, 21(2), 85–95. 
Krittayaphong, R., Cascio, W. E., Light, K. C., Sheffield, D., Golden, R. N., Finkel, J. B., … 
Sheps, D. S. (1997). Heart rate variability in patients with coronary artery disease: 
differences in patients with higher and lower depression scores. Psychosomatic 
Medicine, 59(3), 231–5. 
Kubota, Y., Sato, W., Toichi, M., Murai, T., Okada, T., Hayashi, A., & Sengoku, A. (2001). 
Frontal midline theta rhythm is correlated with cardiac autonomic activities during the 
performance of an attention demanding meditation procedure. Brain Research. 
Cognitive Brain Research, 11(2), 281–7. 
Kubzansky, L. D., & Adler, G. K. (2010). Aldosterone: a forgotten mediator of the 
relationship between psychological stress and heart disease. Neuroscience and 
Biobehavioral Reviews, 34(1), 80–6. 
La Rovere, M. T., Bigger, J. T., Marcus, F. I., Mortara, A., & Schwartz, P. J. (1998). 
Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality 
after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial 
Infarction) Investigators. Lancet, 351(9101), 478–84. 
Langeluddecke, P., Fulcher, G., Baird, D., Hughes, C., & Tennant, C. (1989). A prospective 
evaluation of the psychosocial effects of coronary artery bypass surgery. Journal of 
Psychosomatic Research, 33(1), 37–45. 
Langosch, W., & Schmoll-Flockerzie, H. (1992). Psychological reactions to open heart 
surgery: results of a quantitative and qualitative analysis of the recovery process. In 
Quality of Life after Open Heart Surgery. Dordrecht: Springer Netherlands. 
 183 
Lavie, C. J., & Milani, R. V. (2006). Adverse psychological and coronary risk profiles in 
young patients with coronary artery disease and benefits of formal cardiac 
rehabilitation. Archives of Internal Medicine, 166(17), 1878–83. 
Lavie, C. J., & Milani, R. V. (2004). Cardiac rehabilitation and depression. The American 
Journal of Cardiology, 93(8), 1080. 
Lechin, F., van der Dijs, B., Orozco, B., Lechin, M. E., Báez, S., Lechin, A. E., … Jiménez, 
V. (1995). Plasma neurotransmitters, blood pressure, and heart rate during supine-
resting, orthostasis, and moderate exercise conditions in major depressed patients. 
Biological Psychiatry, 38(3), 166–73. 
Lehrer, P. M., Carr, R. E., Smetankine, A., Vaschillo, E., Peper, E., Porges, S., … Hochron, 
S. (1997). Respiratory sinus arrhythmia versus neck/trapezius EMG and incentive 
inspirometry biofeedback for asthma: a pilot study. Applied Psychophysiology and 
Biofeedback, 22(2), 95–109. 
Lehrer, P. M., Vaschillo, E., Lu, S.-E., Eckberg, D., Vaschillo, B., Scardella, A., & Habib, R. 
(2006). Heart rate variability biofeedback: effects of age on heart rate variability, 
baroreflex gain, and asthma. Chest, 129(2), 278–84. 
Lehrer, P. M., Vaschillo, E., & Vaschillo, B. (2000). Resonant frequency biofeedback 
training to increase cardiac variability: rationale and manual for training. Applied 
Psychophysiology and Biofeedback, 25(3), 177–91. 
Lehrer, P. M., Vaschillo, E., Vaschillo, B., Lu, S.-E., Eckberg, D. L., Edelberg, R., … 
Hamer, R. M. (2003). Heart rate variability biofeedback increases baroreflex gain and 
peak expiratory flow. Psychosomatic Medicine, 65(5), 796–805. 
Lehrer, P. M., Vaschillo, E., Vaschillo, B., Lu, S.-E., Scardella, A., Siddique, M., & Habib, 
R. H. (2004). Biofeedback treatment for asthma. Chest, 126(2), 352–61. 
Leichsenring, F., Hiller, W., Weissberg, M., & Leibing, E. (2006). Cognitive-Behavioral 
Therapy and Psychodynamic Psychotherapy : Techniques , Efficacy , and Indications. 
American Journal of Psychotherapy, 60(3), 233–260. 
Lespérance, F., & Frasure-Smith, N. (2000). Depression and 1-year prognosis in unstable 
angina. Archives of Internal …, 160(9), 1354. 
 184
Lespérance, F., Frasure-Smith, N., Koszycki, D., Laliberté, M.-A., van Zyl, L. T., Baker, B., 
… Guertin, M.-C. (2007). Effects of citalopram and interpersonal psychotherapy on 
depression in patients with coronary artery disease: the Canadian Cardiac Randomized 
Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA, 
297(4), 367–79. 
Lett, H. S., Blumenthal, J. a, Babyak, M. a, Strauman, T. J., Robins, C., & Sherwood, A. 
(2005). Social support and coronary heart disease: epidemiologic evidence and 
implications for treatment. Psychosomatic Medicine, 67(6), 869–78. 
Lett, H. S., Davidson, J., & Blumenthal, J. A. (2005). Nonpharmacologic treatments for 
depression in patients with coronary heart disease. Psychosomatic Medicine, 67(S1), 
S58–62. 
Lewinsohn, P. M., Lobitz, W. C., & Wilson, S. (1973). ―Sensitivity‖ of depressed individuals 
to aversive stimuli. Journal of Abnormal Psychology, 81(3), 259–63. 
Liao, D., Barnes, R. W., Chambless, L. E., Simpson, R. J., Sorlie, P., & Heiss, G. (1995). 
Age, race, and sex differences in autonomic cardiac function measured by spectral 
analysis of heart rate variability--the ARIC study. Atherosclerosis Risk in Communities. 
The American Journal of Cardiology, 76(12), 906–12. 
Lichtman, J. H., Bigger, J. T., Blumenthal, J. A., Frasure-Smith, N., Kaufmann, P. G., 
Lespérance, F., … Froelicher, E. S. (2008). Depression and coronary heart disease: 
recommendations for screening, referral, and treatment: a science advisory from the 
American Heart Association. Circulation, 118(17), 1768–75. 
Linden, M., Habib, T., & Radojevic, V. (1996). A controlled study of the effects of EEG 
biofeedback on cognition and behavior of children with attention deficit disorder and 
learning disabilities. Biofeedback and Self-Regulation, 21(1), 35–49. 
Linden, W., Stossel, C., & Maurice, J. (1996). Psychosocial interventions for patients with 
coronary artery disease: a meta-analysis. Archives of Internal Medicine, 156(7), 745–
52. 
Liu, G.-Z., Wu, D., Zhao, G.-R., Huang, B.-Y., Mei, Z.-Y., Guo, Y.-W., & Wang, L. (2010). 
Use of refined sample entropy and heart rate variability to assess the effects of wearable 
respiratory biofeedback. In Biomedical Engineering and Informatics (BMEI), 2010 3rd 
International Conference on (Vol. 5, pp. 1915–1919). 
Lown, B., & Verrier, R. L. (1976). Neural activity and ventricular fibrillation. The New 
England Journal of Medicine, 294(21), 1165–70. 
 185 
Lu, S., Zhao, H., Ju, K., Shin, K., Lee, M., Shelley, K., & Chon, K. H. (2008). Can 
photoplethysmography variability serve as an alternative approach to obtain heart rate 
variability information? Journal of Clinical Monitoring and Computing, 22(1), 23–9. 
Maes, M., De Ruyter, M., Claes, R., & Suy, E. (1998). Sex-related differences in the 
relationships between self-rated depression and biological markers. Journal of Affective 
Disorders, 15(2), 119–25. 
Magni, G., Unger, H. P., Valfrè, C., Polesel, E., Cesari, F., Rizzardo, R., … Gallucci, V. 
(1987). Psychosocial outcome one year after heart surgery. A prospective study. 
Archives of Internal Medicine, 147(3), 473–7. 
Malliani, A. (2000). Principles of Cardiovascular Neural Regulation in Health and Disease 
(Vol. 6). Boston, MA: Springer US. 
Malliani, A., Lombardi, F., & Pagani, M. (1994). Power spectrum analysis of heart rate 
variability: a tool to explore neural regulatory mechanisms. British Heart Journal, 
71(1), 1–2. 
Malliani, A., Pagani, M., Lombardi, F., & Cerutti, S. (1991). Cardiovascular neural 
regulation explored in the frequency domain. Circulation, 84(2), 482–492. 
Mancia, G., Ludbrook, J., Ferrari, A., Gregorini, L., & Zanchetti, A. (1978). Baroreceptor 
reflexes in human hypertension. Circulation Research, 43(2), 170–7. 
Martens, E. J., Nyklícek, I., Szabó, B. M., & Kupper, N. (2008). Depression and anxiety as 
predictors of heart rate variability after myocardial infarction. Psychological Medicine, 
38(3), 375–83. 
Mathers, C. D., & Loncar, D. (2006). Projections of global mortality and burden of disease 
from 2002 to 2030. PLoS Medicine, 3(11), e442. 
Mathew, J. P., Fontes, M. L., Tudor, I. C., Ramsay, J., Duke, P., Mazer, C. D., … Mangano, 
D. T. (2004). A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA, 
291(14), 1720–9. 
Mathews, A., & MacLeod, C. (1994). Cognitive approaches to emotion and emotional 
disorders. Annual Review of Psychology, 45, 25–50. 
Matthews, S. C., Nelesen, R. A., & Dimsdale, J. E. (2005). Depressive symptoms are 
associated with increased systemic vascular resistance to stress. Psychosomatic 
Medicine, 67(4), 509–13. 
 186
Matthews, S. C., Paulus, M. P., Simmons, A. N., Nelesen, R. A., & Dimsdale, J. E. (2004). 
Functional subdivisions within anterior cingulate cortex and their relationship to 
autonomic nervous system function. NeuroImage, 22(3), 1151–6. 
Matveev, M., & Prokopova, R. (2002). Diagnostic value of the RR-variability indicators for 
mild hypertension. Physiological Measurement, 23(4), 671–82. 
May, H. T., Sheng, X., Catinella, A. P., Horne, B. D., Carlquist, J. F., & Joy, E. (2010). 
Antilipidemic adherence post-coronary artery disease diagnosis among those with and 
without an ICD-9 diagnosis of depression. Journal of Psychosomatic Research, 69(2), 
169–74. 
Mayberg, H. S., Brannan, S. K., Mahurin, R. K., Jerabek, P. A., Brickman, J. S., Tekell, J. L., 
… Fox, P. T. (1997). Cingulate function in depression: a potential predictor of 
treatment response. Neuroreport, 8(4), 1057–61. 
McGinnis, R. A., McGrady, A., Cox, S. A., & Grower-Dowling, K. A. (2005). Biofeedback-
Assisted Relaxation in Type 2 Diabetes. Diabetes Care, 28(9), 2145–9. 
McGrady, A., McGinnis, R., Badenhop, D., Bentle, M., & Rajput, M. (2009). Effects of 
depression and anxiety on adherence to cardiac rehabilitation. Journal of 
Cardiopulmonary Rehabilitation and Prevention, 29(6), 358–64. 
McKenzie, L. H., Simpson, J., & Stewart, M. (2010). A systematic review of pre-operative 
predictors of post-operative depression and anxiety in individuals who have undergone 
coronary artery bypass graft surgery. Psychology Health & Medicine, 15(1), 74–93. 
McKhann, G. M., Borowicz, L. M., Goldsborough, M. a, Enger, C., & Selnes, O. a. (1997). 
Depression and cognitive decline after coronary artery bypass grafting. Lancet, 349, 
1282–4. 
Melzig, C. A., Weike, A. I., Hamm, A. O., & Thayer, J. F. (2009). Individual differences in 
fear-potentiated startle as a function of resting heart rate variability: implications for 
panic disorder. International Journal of Psychophysiology, 71(2), 109–17. 
Mendes de Leon, C. F. (1998). Depression and Risk of Coronary Heart Disease in Elderly 
Men and Women: New Haven EPESE, 1982-1991. Archives of Internal Medicine, 
158(21), 2341–8. 
Meyer, T., Buss, U., & Herrmann-Lingen, C. (2010). Role of cardiac disease severity in the 
predictive value of anxiety for all-cause mortality. Psychosomatic Medicine, 72(1), 9–
15. 
 187 
Milani, R. V, & Lavie, C. J. (2007). Impact of cardiac rehabilitation on depression and its 
associated mortality. The American Journal of Medicine, 120(9), 799–806. 
Miller, A. H., Maletic, V., & Raison, C. L. (2009). Inflammation and its discontents: the role 
of cytokines in the pathophysiology of major depression. Biological Psychiatry, 65(9), 
732–41. 
Miller, G. E., Stetler, C. A., Carney, R. M., Freedland, K. E., & Banks, W. A. (2002). 
Clinical depression and inflammatory risk markers for coronary heart disease. The 
American Journal of Cardiology, 90(12), 1279–83. 
Miyata, K., Shimokawa, H., Higo, T., Yamawaki, T., Katsumata, N., Kandabashi, T., … 
Takeshita, A. (2000). Sarpogrelate, a selective 5-HT2A serotonergic receptor 
antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. 
Journal of Cardiovascular Pharmacology, 35(2), 294–301. 
Mogg, K., & Bradley, B. P. (1998). A cognitive-motivational analysis of anxiety. Behaviour 
Research and Therapy, 36(9), 809–48. 
Mols, F., Martens, E. J., & Denollet, J. (2010). Type D personality and depressive symptoms 
are independent predictors of impaired health status following acute myocardial 
infarction. Heart, 96(1), 30–5. 
Monastra, V. J. (2005). Overcoming the barriers to effective treatment for attention-
deficit/hyperactivity disorder: a neuro-educational approach. International Journal of 
Psychophysiology, 58(1), 71–80. 
Mookadam, F., & Arthur, H. M. (2004). Social support and its relationship to morbidity and 
mortality after acute myocardial infarction: systematic overview. Archives of Internal 
Medicine, 164(14), 1514–8. 
Moore, S. A., Zoellner, L. A., & Mollenholt, N. (2008). Are expressive suppression and 
cognitive reappraisal associated with stress-related symptoms? Behaviour Research and 
Therapy, 46(9), 993–1000. 
Mortara, A., La Rovere, M. T., Pinna, G. D., Prpa, A., Maestri, R., Febo, O., … Tavazzi, L. 
(1997). Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and 
hemodynamic correlates and prognostic implications. Circulation, 96(10), 3450–8. 
Moser, D. K., McKinley, S., Riegel, B., Doering, L. V, Meischke, H., Pelter, M., … Dracup, 
K. (2011). Relationship of persistent symptoms of anxiety to morbidity and mortality 
outcomes in patients with coronary heart disease. Psychosomatic Medicine, 73(9), 803–
9. 
 188
Moyer, C. F., Sajuthi, D., Tulli, H., & Williams, J. K. (1991). Synthesis of IL-1 alpha and IL-
1 beta by arterial cells in atherosclerosis. The American Journal of Pathology, 138(4), 
951–60. 
Murck, H., Schüssler, P., & Steiger, A. (2012). Renin-angiotensin-aldosterone system: the 
forgotten stress hormone system: relationship to depression and sleep. 
Pharmacopsychiatry, 45(3), 83–95. 
Murphy, F. C., Sahakian, B. J., Rubinsztein, J. S., Michael, A., Rogers, R. D., Robbins, T. 
W., & Paykel, E. S. (1999). Emotional bias and inhibitory control processes in mania 
and depression. Psychological Medicine, 29(6), 1307–21. 
Murray, C. J., & Lopez, a D. (1997). Alternative projections of mortality and disability by 
cause 1990-2020: Global Burden of Disease Study. Lancet, 349(9064), 1498–504. 
Musselman, D. L., Evans, D. L., & Nemeroff, C. B. (1998). The Relationship of Depression 
to Cardiovascular Disease. Archives of General Psychiatry, 55, 580–92. 
Myers, C. W., Cohen, M. A., Eckberg, D. L., & Taylor, J. A. (2001). A model for the genesis 
of arterial pressure Mayer waves from heart rate and sympathetic activity. Autonomic 
Neuroscience : Basic & Clinical, 91, 62–75. 
Nakao, M., Yano, E., Nomura, S., & Kuboki, T. (2003). Blood pressure-lowering effects of 
biofeedback treatment in hypertension: a meta-analysis of randomized controlled trials. 
Hypertension Research, 26(1), 37–46. 
Nashef, S. A., Roques, F., Michel, P., Gauducheau, E., Lemeshow, S., & Salamon, R. 
(1999). European system for cardiac operative risk evaluation (EuroSCORE). European 
Journal of Cardio-Thoracic Surgery, 16(1), 9–13. 
Nemeroff, C. B., Musselman, D. L., & Evans, D. L. (1998). Depression and cardiac disease. 
Depression and Anxiety, 8(S1), 71–9. 
Nolan, R. P., Kamath, M. V, Floras, J. S., Stanley, J., Pang, C., Picton, P., & Young, Q. R. 
(2005). Heart rate variability biofeedback as a behavioral neurocardiac intervention to 
enhance vagal heart rate control. American Heart Journal, 149(6), 1137. 
Orth-gome, K., Wamala, S. P., Horsten, M., Schneiderman, N., & Mittleman, M. A. (2000). 
Marital Stress Worsens Prognosis in Women With Coronary Heart Disease. JAMA, 
284(23), 3008–14. 
Palatini, P., & Julius, S. (1997). Heart rate and the cardiovascular risk. Journal of 
Hypertension, 15(1), 3–17. 
 189 
Pardo, Y., Merz, C. N., Velasquez, I., Paul-Labrador, M., Agarwala, A., & Peter, C. T. 
(2000). Exercise conditioning and heart rate variability: evidence of a threshold effect. 
Clinical Cardiology, 23(8), 615–20. 
Patron, E., Messerotti Benvenuti, S., Favretto, G., Gasparotto, R., & Palomba, D. (2014). 
Depression and reduced heart rate variability after cardiac surgery: The mediating role 
of emotion regulation. Autonomic Neuroscience : Basic & Clinical, 180, 53–58. 
Patron, E., Messerotti Benvenuti, S., Favretto, G., Valfrè, C., Bonfà, C., Gasparotto, R., & 
Palomba, D. (2012). Association between depression and heart rate variability in 
patients after cardiac surgery: a pilot study. Journal of Psychosomatic Research, 73(1), 
42–6. 
Patron, E., Messerotti Benvenuti, S., Favretto, G., Valfrè, C., Bonfà, C., Gasparotto, R., & 
Palomba, D. (2013). Biofeedback assisted control of respiratory sinus arrhythmia as a 
biobehavioral intervention for depressive symptoms in patients after cardiac surgery: a 
preliminary study. Applied Psychophysiology and Biofeedback, 38(1), 1–9. 
Patron, E., Messerotti Benvenuti, S., & Palomba, D. (in press). Preoperative and 
perioperative predictors of reactive and persistent depression after cardiac surgery: A 
three-month follow-up study. Psychosomatics. 
Penninx, B. W. J. H., Beekman, A. T. F., Honig, A., Deeg, D. J. H., Schoevers, R. A., van 
Eijk, J. T. M., & van Tilburg, W. (2001). Depression and Cardiac Mortality. Archives of 
General Psychiatry, 58, 221–7. 
Penninx, B. W. J. H., Kritchevsky, S. B., Yaffe, K., Newman, A. B., Simonsick, E. M., 
Rubin, S., … Pahor, M. (2003). Inflammatory markers and depressed mood in older 
persons: results from the Health, Aging and Body Composition study. Biological 
Psychiatry, 54(5), 566–72. 
Perski, A., Feleke, E., Anderson, G., Samad, B. A., Westerlund, H., Ericsson, C.-G. G., & 
Rehnqvist, N. (1998). Emotional distress before coronary bypass grafting limits the 
benefits of surgery. American Heart Journal, 136(3), 510–7. 
Phillips, A. C. (2011). Blunted cardiovascular reactivity relates to depression, obesity, and 
self-reported health. Biological Psychology, 86(2), 106–13. 
Pickering, T. G., Hall, J. E., Appel, L. J., Falkner, B. E., Graves, J., Hill, M. N., … Roccella, 
E. J. (2005). Recommendations for blood pressure measurement in humans and 
experimental animals: part 1: blood pressure measurement in humans: a statement for 
professionals from the Subcommittee of Professional and Public Education of the 
American Heart Association. Circulation, 111(5), 697–716. 
 190
Pimm, J., Foole, F., & Feist, J. (1986). Depression in coronary artery bypass patients. In 
Proceedings of the 15th European Conference on Psychosomatic Research (pp. 229–
236). London, UK. 
Pirraglia, P. A., Peterson, J. C., William-Russo, P., Gorkin, L., & Charlson, M. E. (1999). 
Depressive Symptomatology In Coronary Artery Bypass Graft Surgery Patients. 
Internationa Journal of Geriatric Psychiatry, 14(March), 668–80. 
Pitzalis, M. V, Iacoviello, M., Massari, F., Guida, P., Romito, R., Forleo, C., … Rizzon, P. 
(2001). Influence of gender and family history of hypertension on autonomic control of 
heart rate, diastolic function and brain natriuretic peptide. Journal of Hypertension, 
19(1), 143–8. 
Pizzi, C., Mancini, S., Angeloni, L., Fontana, F., Manzoli, L., & Costa, G. M. (2009). Effects 
of selective serotonin reuptake inhibitor therapy on endothelial function and 
inflammatory markers in patients with coronary heart disease. Clinical Pharmacology 
and Therapeutics, 86(5), 527–32. 
Pizzi, C., Manzoli, L., Mancini, S., & Costa, G. M. (2008). Analysis of potential predictors 
of depression among coronary heart disease risk factors including heart rate variability, 
markers of inflammation, and endothelial function. European Heart Journal, 29(9), 
1110–7. 
Podrid, P. J. (1990). Potassium and ventricular arrhythmias. The American Journal of 
Cardiology, 65(10), 33E–44. 
Podrid, P. J., Fuchs, T., & Candinas, R. (1990). Role of the sympathetic nervous system in 
the genesis of ventricular arrhythmia. Circulation, 82(S2), I103–13. 
Pollak, Y., & Yirmiya, R. (2002). Cytokine-induced changes in mood and behaviour: 
implications for ―depression due to a general medical condition‖, immunotherapy and 
antidepressive treatment. The International Journal of Neuropsychopharmacology, 
5(4), 389–99. 
Porges, S. W. (2007). A phylogenetic journey through the vague and ambiguous Xth cranial 
nerve: A commentary on contemporary heart rate variability research. Biological 
Psychology, 74(2), 301–307. 
Pratt, L. A., Ford, D. E., Crum, R. M., Armenian, H. K., Gallo, J. J., & Eaton, W. W. (1996). 
Depression, Psychotropic Medication, and Risk of Myocardial Infarction: Prospective 
Data From the Baltimore ECA Follow-up. Circulation, 94(12), 3123–9. 
 191 
Pruvot, E., Thonet, G., Vesin, J. M., Van-Melle, G., Seidl, K., Schmidinger, H., … Fromer, 
M. (2000). Heart rate dynamics at the onset of ventricular tachyarrhythmias as retrieved 
from implantable cardioverter-defibrillators in patients with coronary artery disease. 
Circulation, 101(20), 2398–404. 
Radloff, L. S. (1977). The CES-D Scale: A self-report depression scale for research in the 
general population. Applied Psychological Measurement, 1(3), 385–401. 
Randall, W. (1994). Efferent sympathetic innervation of the heart. (Oxford University Press, 
Ed.)Oxford University Press, New York. New York, NY. 
Rechlin, T. (1994). The effect of amitriptyline, doxepin, fluvoxamine, and paroxetine 
treatment on heart rate variability. Journal of Clinical Psychopharmacology, 14(6), 
392–5. 
Rechlin, T., Claus, D., & Weis, M. (1994). Heart rate analysis in 24 patients treated with 150 
mg amitriptyline per day. Psychopharmacology, 116(1), 110–4. 
Rich, M. W., Saini, J. S., Kleiger, R. E., Carney, R. M., TeVelde, A., & Freedland, K. E. 
(1988). Correlation of heart rate variability with clinical and angiographic variables and 
late mortality after coronary angiography. The American Journal of Cardiology, 62, 
714–7. 
Rieckmann, N., Gerin, W., Kronish, I. M., Burg, M. M., Chaplin, W. F., Kong, G., … 
Davidson, K. W. (2006). Course of depressive symptoms and medication adherence 
after acute coronary syndromes: an electronic medication monitoring study. Journal of 
the American College of Cardiology, 48(11), 2218–22. 
Roest, A. M., Martens, E. J., de Jonge, P., & Denollet, J. (2010). Anxiety and risk of incident 
coronary heart disease: a meta-analysis. Journal of the American College of Cardiology, 
56(1), 38–46. 
Roest, A. M., Martens, E. J., Denollet, J., & de Jonge, P. (2010). Prognostic association of 
anxiety post myocardial infarction with mortality and new cardiac events: a meta-
analysis. Psychosomatic Medicine, 72(6), 563–9. 
Rollman, B. L., & Belnap, B. H. (2011). The Bypassing the Blues trial: collaborative care for 
post-CABG depression and implications for future research. Cleveland Clinic Journal 
of Medicine, 78(S1), S4–12. 
Roose, S. P., Laghrissi-thode, F., Kennedy, J. S., Nelson, J. C., Bigger, J. T., Pollock, B. G., 
… Gergel, I. (1998). Comparison of Paroxetine and Nortriptyline in Depressed Patients 
With Ischemic Heart Disease. JAMA, 279(4), 287–91. 
 192
Roose, S. P., & Miyazaki, M. (1998). Pharmacologic treatment of depression in patients with 
heart disease. Psychosomatic Medicine, 67(S1), S54–7. 
Ross, R. (1999). Atherosclerosis--an inflammatory disease. The New England Journal of 
Medicine, 340(2), 115–26. 
Ruiz-Padial, E., Sollers, J. J., Vila, J., & Thayer, J. F. (2003). The rhythm of the heart in the 
blink of an eye: emotion-modulated startle magnitude covaries with heart rate 
variability. Psychophysiology, 40(2), 306–13. 
Rymaszewska, J., Kiejna, A., & Hadryś, T. (2003). Depression and anxiety in coronary 
artery bypass grafting patients. European Psychiatry, 18(4), 155–160. 
Salomon, K., Clift, A., Karlsdóttir, M., & Rottenberg, J. (2009). Major depressive disorder is 
associated with attenuated cardiovascular reactivity and impaired recovery among those 
free of cardiovascular disease. Health Psychology, 28(2), 157–65. 
Sargunaraj, D., Lehrer, P. M., Hochron, S. M., Rausch, L., Edelberg, R., & Porges, S. W. 
(1996). Cardiac rhythm effects of .125-Hz paced breathing through a resistive load: 
implications for paced breathing therapy and the polyvagal theory. Biofeedback and 
Self-Regulation, 21(2), 131–47. 
Saul, J. P. (1990). Beat-to-beat variations of heart rate reflect modulation of cardiac 
autonomic outflow. Physiology, 5(1), 32–37. 
Saur, C. D., Granger, B. B., Muhlbaier, L. H., Forman, L. M., McKenzie, R. J., Taylor, M. 
C., & Smith, P. K. (2001). Depressive symptoms and outcome of coronary artery 
bypass grafting. American Journal of Critical Care, 10(1), 4–10. 
Scheier, M. F. (1999). Optimism and Rehospitalization After Coronary Artery Bypass Graft 
Surgery. Archives of Internal Medicine, 159(8), 829–835. 
Schleifer, S. J., Macari-Hinson, M. M., Coyle, D. A., Slater, W. R., Kahn, M., Gorlin, R., & 
Zucker, H. D. (1989). The nature and course of depression following myocardial 
infarction. Archives of Internal Medicine, 149(8), 1785–9. 
Schroeder, C., Tank, J., Boschmann, M., Diedrich, A., Sharma, A. M., Biaggioni, I., … 
Jordan, J. (2002). Selective norepinephrine reuptake inhibition as a human model of 
orthostatic intolerance. Circulation, 105(3), 347–53. 
 193 
Schwartz, A. R., Gerin, W., Davidson, K. W., Pickering, T. G., Brosschot, J. F., Thayer, J. 
F., … Linden, W. (2003). Toward a Causal Model of Cardiovascular Responses to 
Stress and the Development of Cardiovascular Disease. Psychosomatic Medicine, 65(1), 
22–35. 
Schwartz, M. S., & Andrasik, F. E. (2003). Biofeedback: A practitioner’s guide . Guilford 
Press. 
Schwartz, P. J., Vanoli, E., Stramba-Badiale, M., De Ferrari, G. M., Billman, G. E., & 
Foreman, R. D. (1988). Autonomic mechanisms and sudden death. New insights from 
analysis of baroreceptor reflexes in conscious dogs with and without a myocardial 
infarction. Circulation, 78(4), 969–79. 
Selvaraj, N., Jaryal, A., Santhosh, J., Deepak, K. K., & Anand, S. (2008). Assessment of 
heart rate variability derived from finger-tip photoplethysmography as compared to 
electrocardiography. Journal of Medical Engineering & Technology, 32(6), 479–84. 
Serebruany, V., Gurbel, P., & O’Connor, C. (2001). Platelet inhibition by sertraline and N-
desmethylsertraline: a possible missing link between depression, coronary events, and 
mortality benefits of selective serotonin reuptake inhibitors. Pharmacological Research, 
43(5), 453–62. 
Serebruany, V. L., Suckow, R. F., Cooper, T. B., O’Connor, C. M., Malinin, A. I., Krishnan, 
K. R. R., … Glassman, A. H. (2005). Relationship between release of 
platelet/endothelial biomarkers and plasma levels of sertraline and N-
desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for 
depression. The American Journal of Psychiatry, 162(6), 1165–70. 
Shaffer, F. (2006). Biofeedback Certification Institute of America: The University Initiative. 
Biofeedback (Vol. 34). 
Shan, L., Saxena, A., McMahon, R., Wilson, A., & Newcomb, A. (2013). A systematic 
review on the quality of life benefits after aortic valve replacement in the elderly. The 
Journal of Thoracic and Cardiovascular Surgery, 145(5), 1173–89. 
Shapiro, P. A., Lespérance, F., Frasure-smith, N., Connor, C. M. O., Jiang, J. W., Dorian, P., 
… Glassman, A. H. (1999). An open-label preliminary trial of sertraline for treatment of 
major depression after acute myocardial infarction (the SADHAT trial). American 
Heart Journal, 137(6), 1100–6. 
Sheehan, P. W. (1967). A shortened form of Betts’ questionnaire upon mental imagery. 
Journal of Clinical Psychology, 23(3), 386–9. 
 194
Sheffield, D., Krittayaphong, R., Cascio, W. E., Light, K. C., Golden, R. N., Finkel, J. B., … 
Sheps, D. S. (1998). Heart rate variability at rest and during mental stress in patients 
with coronary artery disease: differences in patients with high and low depression 
scores. International Journal of Behavioral Medicine, 5(1), 31–47. 
Sherwood, A., Hinderliter, A. L., Watkins, L. L., Waugh, R. A., & Blumenthal, J. A. (2005). 
Impaired endothelial function in coronary heart disease patients with depressive 
symptomatology. Journal of the American College of Cardiology, 46(4), 656–9. 
Shibeshi, W. a, Young-Xu, Y., & Blatt, C. M. (2007). Anxiety worsens prognosis in patients 
with coronary artery disease. Journal of the American College of Cardiology, 49(20), 
2021–7. 
Shimbo, D., Child, J., Davidson, K., Geer, E., Osende, J. I., Reddy, S., … Badimon, J. J. 
(2002). Exaggerated serotonin-mediated platelet reactivity as a possible link in 
depression and acute coronary syndromes. The American Journal of Cardiology, 89(3), 
331–3. 
Shook, N. J., Fazio, R. H., & Vasey, M. W. (2007). Negativity bias in attitude learning: a 
possible indicator of vulnerability to emotional disorders? Journal of Behavior Therapy 
and Experimental Psychiatry, 38(2), 144–55. 
Shrestha, S., Hirvonen, J., Hines, C. S., Henter, I. D., Svenningsson, P., Pike, V. W., & Innis, 
R. B. (2012). Serotonin-1A receptors in major depression quantified using PET: 
Controversies, confounds, and recommendations. NeuroImage, 59(4), 3243–51. 
Siever, L. J., & Davis, K. L. (1985). Overview: toward a dysregulation hypothesis of 
depression. The American Journal of Psychiatry, 142(9), 1017–31. 
Skop, B. P., & Brown, T. M. (1996). Potential vascular and bleeding complications of 
treatment with selective serotonin reuptake inhibitors. Psychosomatics, 37(1), 12–6. 
Soares, P. P. S., Moreno, A. M., Cravo, S. L. D., & Nóbrega, A. C. L. (2005). Coronary 
artery bypass surgery and longitudinal evaluation of the autonomic cardiovascular 
function. Critical Care, 9(2), 124–31. 
Spielberger, C. (1996). STAI: state-trait anxiety inventory: forma Y: manuale. 
Spielberger, C., Gorsuch, R., & Lushene, R. (1970). Manual for the State-Trait Anxiety 
Inventory. (Consulting Psychologists Press, Ed.). Palo Alto, CA. 
Spyer, K. M. (1990). The Central Nervous Organization of Reflex Circulatory Control. 
Central Regulation of Autonomic Functions. New York: Oxford University Press. 
 195 
Stein, P. K., Carney, R. M., Freedland, K. E., Skala, J. A., Jaffe, A. S., Kleiger, R. E., & 
Rottman, J. N. (2000). Severe depression is associated with markedly reduced heart rate 
variability in patients with stable coronary heart disease. Journal of Psychosomatic 
Research, 48(4-5), 493–500. 
Stein, P. K., Domitrovich, P. P., Kleiger, R. E., Schechtman, K. B., & Rottman, J. N. (2000). 
Clinical and demographic determinants of heart rate variability in patients post 
myocardial infarction: insights from the cardiac arrhythmia suppression trial (CAST). 
Clinical Cardiology, 23(3), 187–94. 
Stern, T., Rosenbaum, J., & Fava, M. (2008). Massachusetts general hospital comprehensive 
clinical psychiatry. (Elsevier Health Sciences, Ed.). 
Stier, C. T., Chander, P. N., & Rocha, R. (2002). Aldosterone as a mediator in cardiovascular 
injury. Cardiology in Review, 10(2), 97–107. 
Strik, J., Honig, A., Lousberg, R., Lousberga, A., Cheriex, E., Tuynman-Qua, H., … Van 
Praag, H. (2000). Efficacy and Safety of Fluoxetine in the Treatment of Patients With 
Major Depression After First Myocardial Infarction : Findings From a Double-Blind , 
Placebo-Controlled Trial. Psychosomatic Medicine, 62, 783–789. 
Székely, A., Balog, P., Benk , E., Breuer, T., Székely, J., Kertai, M. D., … Thayer, J. F. 
(2007). Anxiety predicts mortality and morbidity after coronary artery and valve 
surgery--a 4-year follow-up study. Psychosomatic Medicine, 69(7), 625–631. 
Tapanainen, J. M., Thomsen, P. E. B., Køber, L., Torp-Pedersen, C., Mäkikallio, T. H., Still, 
A.-M., … Huikuri, H. V. (2002). Fractal analysis of heart rate variability and mortality 
after an acute myocardial infarction. The American Journal of Cardiology, 90(4), 347–
352. 
Taylor, J. A., Carr, D. L., Myers, C. W., & Eckberg, D. L. (1998). Mechanisms underlying 
very-low-frequency RR-interval oscillations in humans. Circulation, 98(6), 547–55. 
Taylor, J. A., Myers, C. W., Halliwill, J. R., Seidel, H., & Eckberg, D. L. (2001). 
Sympathetic restraint of respiratory sinus arrhythmia: implications for vagal-cardiac 
tone assessment in humans. American Journal of Physiology. Heart and Circulatory 
Physiology, 280(6), H2804–14. 
Thaler, M. S. (2010). The only EKG book you’ll ever need (Vol. 365). Wolters Kluwer 
Health. 
 196
Thayer, J. F., Ahs, F., Fredrikson, M., Sollers, J. J., & Wager, T. D. (2012). A meta-analysis 
of heart rate variability and neuroimaging studies: implications for heart rate variability 
as a marker of stress and health. Neuroscience and Biobehavioral Reviews, 36(2), 747–
56. 
Thayer, J. F., & Brosschot, J. F. (2005). Psychosomatics and psychopathology: looking up 
and down from the brain. Psychoneuroendocrinology, 30(10), 1050–8. 
Thayer, J. F., & Lane, R. D. (2000). A model of neurovisceral integration in emotion 
regulation and dysregulation. Journal of Affective Disorders, 61(3), 201–16. 
Thayer, J. F., & Lane, R. D. (2007). The role of vagal function in the risk for cardiovascular 
disease and mortality. Biological Psychology, 74(2), 224–42. 
Thayer, J. F., & Lane, R. D. (2009). Claude Bernard and the heart-brain connection: further 
elaboration of a model of neurovisceral integration. Neuroscience and Biobehavioral 
Reviews, 33(2), 81–8. 
Thayer, J. F., & Sternberg, E. (2006). Beyond heart rate variability. Annals of the New York 
Academy of Sciences, 1088(1), 361–372. 
Theofrastous, J. P., Wyman, J. F., Bump, R. C., McClish, D. K., Elser, D. M., Bland, D. R., 
& Fantl, J. A. (2002). Effects of pelvic floor muscle training on strength and predictors 
of response in the treatment of urinary incontinence. Neurourology and Urodynamics, 
21(5), 486–90. 
Thornton, E. W., & Hallas, C. N. (1999). Affective status following myocardial infarction 
can predict long-term heart rate variability and blood pressure reactivity. British 
Journal of Health Psychology, 4(3), 231–245. 
Timberlake, N., Klinger, L., Smith, P., Venn, G., Treasure, T., Harrison, M., & Newman, S. 
P. (1997). Incidence and Patterns of Depression Following Coronary Artery Bypass 
Graft Surgery. Journal of Psychosomatic Research, 43(2), 197–207. 
Treiber, F. A., Turner, J. R., Davis, H., & Strong, W. B. (1997). Prediction of resting 
cardiovascular functioning in youth with family histories of essential hypertension: a 5-
year follow-up. International Journal of Behavioral Medicine, 4(4), 278–91. 
Udupa, K., Sathyaprabha, T. N., Thirthalli, J., Kishore, K. R., Lavekar, G. S., Raju, T. R., & 
Gangadhar, B. N. (2007). Alteration of cardiac autonomic functions in patients with 
major depression: a study using heart rate variability measures. Journal of Affective 
Disorders, 100(1-3), 137–41. 
 197 
Vaccarino, V., Johnson, B. D., Sheps, D. S., Reis, S. E., Kelsey, S. F., Bittner, V., … Bairey 
Merz, C. N. (2007). Depression, inflammation, and incident cardiovascular disease in 
women with suspected coronary ischemia: the National Heart, Lung, and Blood 
Institute-sponsored WISE study. Journal of the American College of Cardiology, 
50(21), 2044–50. 
Van Dixhoorn, J. J., & Duivenvoorden, H. J. (1999). Effect of relaxation therapy on cardiac 
events after myocardial infarction: a 5-year follow-up study. Journal of 
Cardiopulmonary Rehabilitation, 19(3), 178–85. 
Van Dixhoorn, J., & White, A. (2005). Relaxation therapy for rehabilitation and prevention 
in ischaemic heart disease: a systematic review and meta-analysis. European Journal of 
Cardiovascular Prevention and Rehabilitation, 12(3), 193–202. 
Van Melle, J. P., de Jonge, P., Honig, A., Schene, A. H., Kuyper, A. M., Crijns, H. J., … 
Ormel, J. (2007). Effects of antidepressant treatment following myocardial infarction. 
Brithis Journal of Psychiatry, 190, 4600–466. 
Vaschillo, E., Lehrer, P., Rishe, N., & Konstantinov, M. (2002). Heart rate variability 
biofeedback as a method for assessing baroreflex function: a preliminary study of 
resonance in the cardiovascular system. Applied Psychophysiology and Biofeedback, 
27(1), 1–27. 
Veith, R. C. (1994). Sympathetic Nervous System Activity in Major Depression: Basal and 
Desipramine-Induced Alterations in Plasma Norepinephrine Kinetics. Archives of 
General Psychiatry, 51(5), 411. 
Vingerhoets, G. (1998). Perioperative anxiety and depression in open-heart surgery. 
Psychosomatics, 39(1), 30–7. 
Watkins, A. (2011). The electrical heart: Energy in cardiac health and disease. In Energy 
medicine east and west: A natural history of qi. New York, NY: Elsevier. 
Watkins, L. L., Blumenthal, J. A., & Carney, R. M. (2002). Association of anxiety with 
reduced baroreflex cardiac control in patients after acute myocardial infarction. 
American Heart Journal, 143(3), 460–6. 
Watkins, L. L., Grossman, P., Krishnan, R., & Blumenthal, J. A. (1999). Anxiety reduces 
baroreflex cardiac control in older adults with major depression. Psychosomatic 
Medicine, 61(3), 334–40. 
Watkins, L. L., Grossman, P., Krishnan, R., & Sherwood, A. (1998). Anxiety and vagal 
control of heart rate. Psychosomatic Medicine, 60(4), 498–502. 
 198
Weber, B., Lewicka, S., Deuschle, M., Colla, M., & Heuser, I. (2000). Testosterone, 
androstenedione and dihydrotestosterone concentrations are elevated in female patients 
with major depression. Psychoneuroendocrinology, 25(8), 765–71. 
Wells, K. B., Stewart, A., Hays, R. D., Burnam, M. A., Rogers, W., Daniels, M., … Ware, J. 
(1989). The functioning and well-being of depressed patients. Results from the Medical 
Outcomes Study. JAMA, 262(7), 914–9. 
Wheat, A. L., & Larkin, K. T. (2010). Biofeedback of heart rate variability and related 
physiology: a critical review. Applied Psychophysiology and Biofeedback, 35(3), 229–
42. 
Whooley, M. A., de Jonge, P., Vittinghoff, E., Otte, C., Moos, R., Carney, R. M., … 
Browner, W. S. (2008). Depressive symptoms, health behaviors, and risk of 
cardiovascular events in patients with coronary heart disease. JAMA, 300(20), 2379–88. 
Wolk, R., Kulakowski, P., & Ceremuzynski, L. (1996). Nifedipine and captopril exert 
divergent effects on heart rate variability in patients with acute episodes of 
hypertension. Journal of Human Hypertension, 10(5), 327–332. 
Wong, S. W., Massé, N., Kimmerly, D. S., Menon, R. S., & Shoemaker, J. K. (2007). 
Ventral medial prefrontal cortex and cardiovagal control in conscious humans. 
NeuroImage, 35(2), 698–708. 
Wulsin, L. R., & Singal, B. M. (2003). Do Depressive Symptoms Increase the Risk for the 
Onset of Coronary Disease? A Systematic Quantitative Review. Psychosomatic 
Medicine, 65(2), 201–210. 
Yasuma, F. (2004). Respiratory Sinus Arrhythmia: Why Does the Heartbeat Synchronize 
With Respiratory Rhythm?. Chest, 125(2), 683. 
Yeragani, V. K., Balon, R., Pohl, R., & Ramesh, C. (1995). Depression and heart rate 
variability. Biological Psychiatry, 38(11), 768–70. 
York, K. M., Hassan, M., Li, Q., Li, H., Fillingim, R. B., & Sheps, D. S. (2007). Coronary 
artery disease and depression: patients with more depressive symptoms have lower 
cardiovascular reactivity during laboratory-induced mental stress. Psychosomatic 
Medicine, 69(6), 521–8. 
Yucha, C. B., Clark, L., Smith, M., Uris, P., LaFleur, B., & Duval, S. (2001). The effect of 
biofeedback in hypertension. Applied Nursing Research, 14(1), 29–35. 
 199 
Ziegelstein, R. C. (2000). Patients With Depression Are Less Likely to Follow 
Recommendations to Reduce Cardiac Risk During Recovery From a Myocardial 
Infarction. Archives of Internal Medicine, 160(12), 1818–23. 
Zonderman, A. B., Herbst, J. H., Schmidt, C., Costa, P. T., & McCrae, R. R. (1993). 
Depressive symptoms as a nonspecific, graded risk for psychiatric diagnoses. Journal of 
Abnormal Psychology, 102(4), 544–52. 
Zorrilla, E. P., Luborsky, L., McKay, J. R., Rosenthal, R., Houldin, A., Tax, A., … Schmidt, 
K. (2001). The relationship of depression and stressors to immunological assays: a 
meta-analytic review. Brain, Behavior, and Immunity, 15(3), 199–226. 
 
